Modification of mammalian cells using artificial microRNAs to alter their properties and the composition of their products
By integrating interfering RNA genes into transposons in mammalian cells and utilizing multi-hairpin amiRNA sequences, the problems of inefficient transfection and instability of RNA interference are solved, and stable suppression of gene expression and improved cell functional changes are achieved.
Patent Information
- Application Number
- CN202080046816.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-04
- Filing Date
- 2020-05-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-05-11
AI Technical Summary
The prior art has problems with low transfection efficiency, high cytotoxicity, high cost and limited expression duration when introducing heterologous nucleic acids into mammalian cells, and RNA interference methods are difficult to suppress gene expression stably for a long time.
Using polynucleotides designed to inhibit gene expression in mammalian cells, the interfering RNA gene is integrated into the transposon and introduced into the cell using a transposon or viral vector, combining a multi-hairpin amiRNA sequence to improve RNA interference reliability and stability.
It has achieved stable inhibition of gene expression in mammalian cells, improved the efficiency and durability of RNA interference, and enhanced the tolerance and functional changes of cells to stress.
Smart Images

Figure CN114127083B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of 62 / 846847, filed May 13, 2019, 62 / 870321, filed July 3, 2019, 62 / 981417, filed February 25, 2020, and 63 / 019733, filed May 4, 2020, which are incorporated by reference in their entireties for all purposes.
[0003] Reference to a sequence listing
[0004] This application relates to the sequence disclosed in the txt file named SEQ_DN20200502_ST25, which is 1,070,000 bytes, created on May 2, 2020, and incorporated by reference. 2. Background technology
[0006] The introduction of heterologous nucleic acids into mammalian cells can be used to alter their properties, as well as the properties of the molecules they produce. Genetically modifiable properties of cultured mammalian cells include glycosylation of proteins secreted by cultured mammalian cells, proteolytic processing of proteins produced by cultured mammalian cells, intracellular trafficking of proteins produced by cells, cell growth properties including which nutrients must be provided to cells externally, and the survival rate and sensitivity of cells to apoptosis under various stresses including high levels of heterologous protein expression. Genetically modifiable properties of immune cells include molecules recognized by immune cells, cellular responses within immune cells, the ability of immune cells to survive and perform immune functions under certain environmental conditions (including conditions that normally lead to cell death, anergy, or exhaustion), and proteins produced by immune cells.
[0007] Stable genetic modification of mammalian cells can be performed by integrating heterologous polynucleotides into the genome of cultured mammalian cells. Heterologous DNA can be introduced into cells in different ways: by transfection with naked plasmid DNA, by packaging the DNA into viral particles for infection of cultured mammalian cells, or by transfecting cells with transposons and their corresponding transposases.
[0008] Non-viral vector systems, including plasmid DNA, often suffer from low cellular delivery efficiency, cytotoxicity, and limited duration of transgene expression due to lack of genomic insertion and resulting degradation and / or dilution of the vector in the transfected cell population. Transgenes delivered by non-viral methods often form long, repetitive arrays (concatemers) that are targets for transcriptional silencing by heterochromatin formation.
[0009] Viral packaging often imposes restrictions on the size of DNA that can be inserted. There are also safety issues regarding viral integration sites, as well as the cost and complexity of viral manufacturing.
[0010] The expression level of the gene encoded on the polynucleotide integrated into the cell genome depends on the configuration of the sequence elements in the polynucleotide. Integration efficiency, the number of polynucleotide copies integrated into each genome, and the genomic locus where integration occurs also affect the expression level of the gene encoded on the polynucleotide. By placing the polynucleotide in a transposon, the efficiency of the polynucleotide integration into the target cell genome can usually be improved. The transposon comprises two ends recognized by a transposase. The transposase acts on the transposon, excises it from a DNA molecule and integrates it into another molecule. The DNA between the two transposon ends is transposed by the transposase together with the transposon ends. The flank is a pair of transposon ends so that the heterologous DNA recognized and transposed by the transposase is referred to as a synthetic transposon in this article. Synthetic transposons and corresponding transposases are introduced into the nucleus of eukaryotic cells and may cause the transposon to transpose into the genome of the cell. The transposon / transposase gene delivery platform is likely to overcome the limitations of naked DNA and viral delivery. PiggyBac-like transposons are attractive because of their unlimited gene cargo capacity, but Mariner transposons (such as Sleeping Beauty) or hAT transposons (such as TcBuster) also provide efficient methods for integrating heterologous DNA into the genome of mammalian cells.
[0011] By inhibiting endogenous genes of mammalian cells, the properties of mammalian cells can be favorably altered. RNA interference methods can be used to inhibit endogenous mammalian cell genes to favorably alter the properties of mammalian cells. RNA interference is a promising technology for inhibiting endogenous genes in mammalian cells. Currently used technologies are limited and cannot reliably inhibit gene expression for a long time. One widely used technique is to treat immune cells with siRNA, either by siRNA transfection or by chemically modified siRNA treatment. This can be used as an experimental technique to determine the phenotypic effects of gene inhibition or gene knockout. However, RNA is unstable, so any effects of siRNA administered as RNA are temporary. A second technique is to transfect a gene encoding shRNA that is operably linked to a promoter transcribed by RNA polymerase III. This technique is often limited by the variable potency of individual shRNA molecules and the highly variable rates of random integration. The use of lentiviral vectors can solve the variable rate of random integration, but the variability of shRNA efficacy remains a big problem (Anastasov et al., 2009. J. Hematop 2, 9-19. "Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer").
[0012] MicroRNAs (miRNAs) are naturally occurring RNAs that are transcribed from their genes by RNA polymerase II. MicroRNAs include intramolecular double-stranded RNA hairpins that are processed by cellular enzymes to produce "guide strands" that are complementary to one or more mRNA targets. The guide strands are physically associated with the RISC complex, through which they inhibit the expression of target mRNAs. Artificial miRNAs (amiRNAs) can be designed by using natural scaffolds and adjusting them to produce guide strands that inhibit targets other than natural targets. Artificial miRNAs can also be transcribed by RNA polymerase III (Snyder et.al., 2009. Nucl. Acids Res. 37 e127 doi:10.1093 / nar / gkp657. "RNA polymerase III candrive polycistronic expression of functional interfering RNAs designed toresemble microRNAs"). The use of miRNA scaffolds can improve the processing of interfering RNAs, but variability in effectiveness remains a challenge. Therefore, there is a need in the art for a robust RNA interference method to inhibit endogenous genes in mammalian cells to change the properties of mammalian cells or proteins or other compounds produced by mammalian cells.
[0013] To achieve favorable phenotypic changes, disclosed herein are methods and compositions for introducing polynucleotides including artificial microRNAs into mammalian cells to suppress endogenous genes in mammalian cells. 3. Summary of the invention
[0015] Methods for modifying the genome of mammalian cells to inhibit endogenous gene expression are described. Mammalian cells can include mammalian cells cultured for the production of expressed proteins. They can also include immune cells, including lymphocytes, such as T cells and B cells and natural killer cells (NK cells), T helper cells, antigen presenting cells, dendritic cells, neutrophils and macrophages.
[0016] RNA interference methods can be used to inhibit the expression of endogenous mammalian cell genes to favorably alter the properties of mammalian cells. Here, we describe methods for improving the efficiency of RNA interference: (i) a gene expressing an interfering RNA (e.g., a shRNA or amiRNA gene) can be integrated into a transposon, wherein one or more copies of the transposon are integrated into a transcriptionally active region of the mammalian cell genome, and (ii) the interfering RNA comprises two or more different guide strands complementary to two or more different sequences within the same mRNA target. Providing two or more guide strands complementary to different sequences within the same mRNA target in a lentiviral vector or a transposon vector greatly improves the reliability of RNA interference.
[0017] Methods for designing polynucleotides for inhibiting genes expressed in mammalian cells are described. Preferred gene transfer polynucleotides for inhibiting target genes ("inhibitory gene transfer polynucleotides") include two or more different hairpin sequences that can be expressed in target mammalian cells to produce two or more different RNA guide strand sequences, each sequence complementary to a different region of the target mRNA. The first (guide) sequence comprises 19 to 22 consecutive bases complementary to the target mRNA, and the second (guide) sequence comprises 19 to 22 consecutive bases complementary to the target mRNA. The first and second guide strand sequences are different from each other but complementary to the same target mRNA. Alternatively, the gene transfer polynucleotide includes a third hairpin sequence that can be expressed in the target mammalian cell to produce an RNA guide strand sequence comprising 19 to 22 consecutive bases complementary to the target mRNA, and the first, second and third guide strand sequences are different from each other. Each hairpin sequence in the inhibitory gene transfer polynucleotide includes a guide strand sequence and a complementary passenger strand sequence. Each guide strand sequence is separated from its corresponding passenger strand sequence by a sequence that forms an unpaired loop of 5 to 35 bases in the expressed RNA. Each passenger strand sequence includes at least 19 bases, which are at least 78% identical to the reverse complement of its corresponding guide strand sequence (i.e., relative to the same reverse complement of the corresponding guide strand sequence, it contains no more than 4 mismatches, including mutations, single base deletions or single base insertions, among these 19 bases). The difference between the guide strand and the passenger strand sequence is selected to facilitate the processing of the transcribed hairpin by the mammalian RNA interference pathway and loading the guide strand into the RISC complex to reduce the expression of the target mRNA. Preferably, the hairpin sequence of the present invention in the gene transfer polynucleotide (i.e., the combination of the guide strand, loop and passenger strand sequences) is a sequence that is not naturally expressed in mammalian cells or a sequence from a virus that can infect mammalian cells. Preferably, the hairpin sequence of the present invention is expressed by one or more artificial microRNAs.
[0018] The inhibitory gene transfer polynucleotide comprises two or more hairpin sequences, each hairpin sequence is operably connected to a heterologous promoter active in the target mammalian cell. Each hairpin sequence can be operably connected to the same promoter, or they can be connected to a separate promoter. Preferably, the promoter is transcribed by RNA polymerase II or RNA polymerase III, more preferably, the promoter is transcribed by RNA polymerase II. In some embodiments, the promoter is an inducible promoter.
[0019] In some embodiments, the inhibitory gene transfer polynucleotide comprises (a) a fragment encoding a multiple hairpin amiRNA sequence, wherein the fragment comprises (i) a first guide chain sequence comprising a continuous 19-22 nucleotide sequence that is completely complementary to a first target site of a natural mammalian cell mRNA, and a first passenger chain sequence comprising a continuous 19-22 nucleotide sequence that is at least 78% complementary to the first guide chain sequence, wherein the first guide chain and the first passenger chain sequences are separated by 5 to 35 nucleotides; (ii) a second guide chain sequence and a second passenger chain sequence, wherein the second guide chain sequence comprises a continuous 19 nucleotide sequence, and the continuous 19 nucleotide sequence is complementary to the first target site of the natural mammalian cell mRNA. A second target site that is completely complementary to the first target site of a native mammalian cell mRNA that is identical to the first guide chain sequence, the second passenger chain sequence comprises a continuous 19-22 nucleotide sequence that is at least 78% complementary to the second guide chain sequence, wherein the second guide chain and the second passenger chain sequence are 5 to 35 nucleotides apart, and wherein the first and second guide chain sequences are different from each other; and (b) a eukaryotic promoter that is active in mammalian cells and transcribed by RNA polymerase II or RNA polymerase III and operably connected to a fragment encoding an amiRNA sequence, wherein the amiRNA sequence can be expressed and folded into multiple hairpins. The first passenger chain sequence can be the same length as the first guide chain sequence, or can be 1-3 nucleotides shorter. The first and second target sites in the mammalian cell mRNA may have some overlap or may not overlap.
[0020] Advantageously, the inhibitory gene transfer polynucleotide is stably maintained in mammalian cells, so that the target gene is permanently inhibited. Preferably, the inhibitory gene transfer polynucleotide is integrated into the genome of the mammalian cell. In order to promote the stable integration of the inhibitory gene transfer polynucleotide into the genome of the mammalian cell, it is advantageous to integrate the hairpin sequence and regulatory elements required for its expression into a transposon such as a piggyBac-like transposon, or a Mariner transposon (e.g., a Sleeping Beauty transposon), or a haT transposon (e.g., a TcBuster transposon), or a viral vector such as a lentiviral vector. Advantageous inhibitory gene transfer polynucleotides comprise two or more different hairpin sequences that can be expressed in mammalian cells, each hairpin sequence comprising a different sequence of at least 19, 20, 21 or 22 consecutive bases complementary to the target mRNA, wherein each hairpin is operably linked to a promoter active in mammalian cells, and wherein the hairpins and their operably linked promoters are flanked by inverted terminal repeats of piggyBac-like transposons, or inverted terminal repeats of Mariner transposons such as Sleeping Beauty transposons, or inverted terminal repeats of hAT transposons such as TcBuster transposons, so that the hairpins and their operably linked promoters can be transposed by corresponding transposases. Alternatively, the hairpins and their operably linked promoters are flanked by inverted terminal repeats of lentiviruses so that they can be packaged into viral particles.
[0021] The method of the present invention comprises introducing an inhibitory gene transfer polynucleotide comprising two or more different hairpin sequences that can be expressed in mammalian cells into mammalian cells to produce two or more different guide RNA sequences, each sequence being complementary to a different region of the same target mRNA. For inhibitory gene transfer polynucleotides in which the hairpin sequence is carried on a transposon vector, the method may further comprise introducing the corresponding transposase into the mammalian cells as a protein or as a nucleic acid encoding the transposase. For inhibitory gene transfer polynucleotides in which the hairpin sequence is carried on a viral vector, the method may further comprise packaging the polynucleotide into a viral particle and contacting the mammalian cell with the viral particle.
[0022] Alternatively, the inhibitory gene transfer polynucleotide also includes a gene encoding a protein that can be expressed in a mammalian target cell, wherein the protein changes the characteristics, behavior or product of the mammalian cell. For example, the gene transfer polynucleotide may include an open reading frame encoding a chimeric antigen receptor, a T cell receptor, an antibody, a bispecific antibody, a receptor or any type of therapeutic protein, operably connected to a regulatory element that allows the protein to be expressed in the target mammalian cell. In this way, a single polynucleotide can carry a sequence that produces one or more heterologous proteins in a mammalian cell, together with a sequence that transcribes to produce an interfering RNA molecule that reduces the expression of one or more endogenous genes, such as those that usually reduce the efficacy or survival of mammalian cells under certain environments or conditions. Alternatively, the gene encoding the protein that modifies the characteristics of mammalian cells is operably connected to the promoter identical to one or more hairpin sequences.
[0023] Human cell lines, such as those from human embryonic kidney (HEK) and rodent cell lines, such as those from Chinese hamster ovary (CHO), are commonly used to produce therapeutic proteins, including antibodies. These cells have intrinsic fucosyltransferase activity. The core fucose of oligosaccharides attached to Fc greatly reduces antibody-dependent cellular cytotoxicity (ADCC), which reduces the clinical efficacy and anti-cancer activity of anti-tumor antibodies in humans. Therefore, it is advantageous to reduce or eliminate the fucosylation of proteins produced in mammalian cultured cell lines so that they will produce antibodies with higher ADCC activity. We disclose methods for designing polynucleotides containing amiRNA sequences to reduce the fucosylation of heterologously produced proteins (including antibodies) produced in mammalian cells. Also disclosed are sequences of polynucleotides containing amiRNA that can be used to reduce the fucosylation level of heterologously produced proteins.
[0024] For rodent and human cell lines used to produce proteins that are normally targeted to lysosomes, large amounts of synthesized protein can be directed to lysosomes and subsequently degraded. This can lead to reduced protein production and compromise cell viability. Therefore, it is advantageous to disrupt pathways that normally transport these proteins to the lysosomes of production cells, such as the mannose 6-phosphate receptor, the lysosomal integral membrane protein LIMP-2, and sortilin. We disclose methods for designing polynucleotides comprising amiRNA sequences to reduce lysosomal trafficking in mammalian cells, as well as polynucleotide sequences comprising amiRNA that can be used to reduce lysosomal trafficking in cells.
[0025] The development of human and rodent cell lines for making proteins generally involves the introduction of heterologous DNA encoding the protein to be produced. The heterologous DNA generally contains a gene encoding a selectable marker to allow identification / selection of cells that have taken up the heterologous DNA. A particularly useful class of selectable markers is a marker that allows cells to survive and grow without the addition of nutrients. In order for such selection to work, the cell must lack a functional endogenous copy of the selectable marker, so it relies on the added copy. Cultivated mammalian cells have been modified by directed or non-directed deletion or mutation of their endogenous genes involved in amino acid and nucleotide synthesis, particularly glutamine synthetase and dihydrofolate reductase genes. The deletion of genes in chromosomes is complex and time-consuming. Another method is to use RNA interference to permanently reduce the expression of endogenous glutamine synthetase or dihydrofolate reductase genes. We disclose a method for designing a polynucleotide comprising an amiRNA sequence for reducing the expression of glutamine synthetase and dihydrofolate reductase in mammalian cells, as well as a sequence of a polynucleotide comprising amiRNA that can be used to achieve such reduction.
[0026] For rodent and human cell lines used to produce proteins that are normally cleaved by proteolysis, this cleavage can lead to reduced protein yields, or to heterogeneous protein products. Therefore, it may be advantageous to disrupt the protease. We disclose methods for designing polynucleotides comprising amiRNA sequences for reducing proteolysis in mammalian cells, as well as sequences of polynucleotides comprising amiRNAs that can be used to reduce proteolysis.
[0027] For rodent and human cell lines used to produce proteins, high levels of protein expression can reduce cell survival. Therefore, it may be advantageous to disrupt genes involved in normal cell apoptosis pathways. We disclose methods for designing polynucleotides comprising amiRNA sequences for reducing apoptosis in mammalian cells, as well as sequences of polynucleotides comprising amiRNAs that can be used to reduce apoptosis.
[0028] The ability to enhance the function, persistence and proliferation of human T cells is a current bottleneck in cancer immunotherapy. There is a great demand for technologies that improve T cell performance, expansion and genetic manipulation. There are many applications for controlling and expanding the ability of T cells, including the following. (i) Improving the function of T cell therapy to improve efficacy and / or safety, such as in combination with CAR-T. (ii) Reversing T cell exhaustion of tumor-infiltrating T cells. (iii) Improving the survival rate of human T cells in mice for preclinical studies (in vivo). (iv) Identification of antigen-specific T cells and cloning of T cell receptors in vitro. (v) Developing T cell lines that can be maintained in vitro and still perform the biological functions of T cells (such as cell killing). Modifications that can be made by introducing inhibitory gene transfer systems that work through RNA interference (such as inhibitory gene transfer systems containing amiRNA) include enhancing the ability of immune cells to survive and / or proliferate under certain conditions or in certain environments, changing the number or type of proteins expressed on the surface of immune cells, preventing immune cells from being inactivated by internal or external stimuli, and changing the response of immune cells to proteins or small molecules that contact cells. We disclose methods for designing polynucleotides comprising amiRNA sequences for modifying immune cell function, as well as sequences of polynucleotides comprising amiRNA that can be used to improve immune cell function.
[0029] Immune cell genes whose expression may be reduced by RNA interference from inhibitory gene transfer polynucleotides to enhance the proliferation, survival or function of immune cells in hostile environments (e.g., within tumors), include: thymocyte selection-associated high-mobility group box proteins TOX and TOX1, T-cell immunoglobulin mucin receptor 3, nuclear factor of activated T cells, programmed cell death protein 1, nuclear receptor 4A1 (Nur77), nuclear receptor 4A2 (Nurr1), nuclear receptor 4A3 (NOR1), Fas cell surface death receptor (tumor necrosis factor receptor superfamily member 6), cytotoxic T-lymphocyte-associated protein 4, caspase 3, caspase 7, caspase 8, caspase 9, caspase 10, death receptor 4 (tumor necrosis factor receptor superfamily member 10A), death receptor 5 (tumor necrosis factor receptor superfamily member 10B), cytotoxic T-lymphocyte protein 4 (CTLA-4), apoptosis regulators BAX and BAD (Bcl2-related cell death agonist).
[0030] Modified mammalian cells, including modified human immune cells, whose genomes contain inhibitory gene transfer polynucleotides, which contain two or more different hairpin sequences that can be expressed in mammalian cells to produce two or more different guide RNA sequences, each sequence complementary to a different region of the target mRNA is an aspect of the present invention. In addition, animal immune cells, whose genomes contain inhibitory gene transfer polynucleotides, which contain two or more different hairpin sequences that can be expressed in mammalian cells to produce two or more different guide RNA sequences, each guide RNA sequence complementary to a different region of the target mRNA, are also valuable as experimental models and animal therapeutic agents. Modified mammalian cells, including modified human immune cells, said cells contain inhibitory gene transfer polynucleotides, which have been integrated by the action of piggyBac-like transposase, and contain at least two hairpins, each hairpin containing a different sequence of at least 19, 20, 21 or 22 consecutive bases complementary to different regions of the same target mRNA, and each hairpin is operably linked to a promoter active in mammalian immune cells, wherein the hairpins and the promoter are flanked by inverted terminal repeats of the piggyBac-like transposon. Modified mammalian cells, including modified human immune cells, comprising an inhibitory gene transfer polynucleotide integrated by the action of Sleeping Beauty transposase, the polynucleotide comprising at least two hairpins, each hairpin comprising a different sequence of at least 19, 20, 21 or 22 consecutive bases complementary to different regions of the same target mRNA, and each hairpin is operably linked to a promoter active in mammalian immune cells, wherein the hairpins and promoters are flanked by reverse terminal repeats of the Sleeping Beauty transposon. Modified mammalian cells, including modified human immune cells, comprising an inhibitory gene transfer polynucleotide integrated by the action of TcBuster transposase, the polynucleotide comprising at least two hairpins, each hairpin comprising a different sequence of at least 19, 20, 21 or 22 consecutive bases complementary to different regions of the same target mRNA, and each hairpin is operably linked to a promoter active in mammalian immune cells, wherein the hairpins and promoters are flanked by reverse terminal repeats of the TcBuster transposon. Modified mammalian cells, including modified human immune cells, comprising an inhibitory gene transfer polynucleotide integrated by the action of a lentiviral system, the polynucleotide comprising at least two hairpins, each hairpin comprising a different sequence of at least 19, 20, 21 or 22 consecutive bases complementary to a different region of the same target mRNA, and each hairpin is operably linked to a promoter active in mammalian immune cells, wherein the hairpins and the promoter are flanked by inverted terminal repeats of the lentivirus.Preferably, the immune cells whose genome comprises the inhibitory gene transfer polynucleotide have improved proliferation, survival or functional properties relative to immune cells whose genome does not comprise the inhibitory gene transfer polynucleotide.
[0031] Gene transfer polynucleotide sequences for achieving genome modification in mammalian cells are provided. 4. Description of the drawings
[0033] Figure 1A , B: Schematic diagram of the guide strand and passenger strand sequence structure. The nucleotides of the coding strand of a single miRNA hairpin are shown. The guide strand sequence is represented by 22 consecutive nucleotides N1 to N 22 The sequence of the guide strand is preferably the exact reverse complement of the target mRNA, and the expression of the target mRNA will be reduced. The sequence of the passenger strand is represented by 22 consecutive nucleotides N'1 to N' 22 . The passenger strand sequence is preferably an incomplete reverse complement of the guide strand sequence. Corresponding bases in the guide strand sequence and the passenger strand sequence are represented by horizontal lines. For bases connected by solid lines, the bases in the passenger strand are preferably complementary bases to the bases in the guide strand. Preferably, for one or more bases connected by dotted lines, the bases in the passenger strand are preferably not complementary bases to the bases in the guide strand. If the base in the guide strand is A or T, the base in the passenger strand sequence is preferably C. If the base in the guide strand sequence is C or G, the base in the passenger strand sequence is preferably A. Most preferably, the passenger strand sequence base at position N'1 is not complementary to the guide strand sequence base N1. Most preferably, position N' 12 The passenger strand sequence base and the guide strand sequence base N 12 Not complementary. Mismatches may also occur if one or more bases in the passenger strand are deleted. The guide and passenger strand sequences are connected by an unstructured loop sequence of 5-35 nucleotides, denoted L1-L Z The guide strand sequence can be located at Figure 1A 5' of the loop sequence shown, it may also be located Figure 1B 3' of the loop sequence shown.
[0034] Figure 2A-B: Schematic diagram of a partial multi-hairpin amiRNA gene. Processing of a hairpin sequence comprising a guide strand sequence, an unstructured loop, and a passenger strand sequence is improved if the amiRNA gene contains additional features to produce a guide strand sequence that is loaded into the RISC complex to inhibit target gene expression. These include additional stem structures attached to the 5' and 3' of the hairpin sequence. Element A is a sequence complementary to element E that stabilizes hairpin 1, although the complementarity between elements A and E does not need to be perfect to perform this function. Similarly, element G is a sequence complementary to element K that stabilizes hairpin 2, although the complementarity between elements A and E does not need to be perfect to perform this function. Optionally, the hairpins are separated by an unstructured spacer element F. Two or more hairpins are operably linked to the same promoter, and the first hairpin is separated from the promoter by a spacer sequence. Hairpin 1 is shown as having a configuration with a guide followed by a loop and then a passenger, and hairpin 2 is in Figure 2A The same structure is shown in Figure 2B . A passenger-loop-guide construct is shown in . Any other construct combination is acceptable. Additional hairpins can be placed after the second hairpin. Optionally, the last hairpin in a multi-hairpin amiRNA gene is followed by a polyadenylation signal sequence.
[0035] Figure 3A -G: Mass spectra of antibodies containing glycans produced by a stably transfected CHO cell line expressing a multi-hairpin amiRNA gene targeting FUT8. Proteins were purified from antibody-producing cells and analyzed by mass spectrometry as described in Section 6.1.1.1. The arrows indicate (i) the predicted molecular weight of 50,424 Da, G0-modified heavy chain: the conserved heptasaccharide core consists of 2 N-acetylglucosamine, 3 mannose, and 2 other N-acetylglucosamine residues, which are β-1,2 linked to α-6 mannose and α-3 mannose to form two arms; (ii) 50,571 Da, G 0F modified heavy chain: conserved heptasaccharide core plus one fucose residue; (iii) 50,586 Da, heavy chain modified by G1: conserved heptasaccharide core plus one galactose residue and (iv) 50,733 Da, heavy chain modified by G1: conserved heptasaccharide core plus one galactose residue plus one fucose residue. In all cases, the heavy chain also lost its C-terminal lysine residue. 3A: no amiRNA transposon; 3B-G: as Figure 1A -Multi-hairpin amiRNA transposon in the configuration shown in B.
[0036] Figure 4A-D: Mass spectra of antibodies containing glycans produced by a stably transfected CHO cell line expressing multiple amiRNA sequences linked to different promoters. Proteins were purified from antibody-producing cells and analyzed by mass spectrometry as described in Section 6.1.1.2. Arrows indicate (i) the predicted molecular weight of 50,424 Da, G0-modified heavy chain: the conserved heptasaccharide core consists of 2 N-acetylglucosamine, 3 mannose and 2 other N-acetylglucosamine residues, which are β-1,2 linked to α-6 mannose and α-3 mannose to form two arms; (ii) 50,570 Da, G 0F Modified heavy chain: conserved heptasaccharide core plus one fucose residue; (iii) 23,443 Da, light chain. In all cases, the heavy chain also lost its C-terminal lysine residue. Figure 4A : No amiRNA transposon; Figure 4B : Multiple hairpin amiRNA operably linked to EEF2 promoter SEQ ID NO: 726; Figure 4C : Multiple hairpin amiRNA operably linked to the PGK promoter SEQ ID NO: 726; Figure 4D : Multi-hairpin amiRNA SEQ ID NO: 726 operably linked to the Ubb promoter.
[0037] Figure 5A -B: Mass spectra of antibodies containing glycans produced by a CHO cell line expressing multiple amiRNA genes and subsequently transiently transfected with antibody genes. Proteins were purified from antibody-producing cells and analyzed by mass spectrometry as described in Section 6.1.1.3. Arrows indicate (i) the predicted molecular weight of 50,521 Da, G0-modified heavy chain: a conserved heptasaccharide core consisting of 2 N-acetylglucosamine, 3 mannose, and 2 other N-acetylglucosamine residues, which are β-1,2 linked to α-6 mannose and α-3 mannose to form two arms; (ii) 50,668 Da, G 0F Modified heavy chain: conserved heptasaccharide core plus one fucose residue; (iii) 23,444 Da, light chain. In all cases, the heavy chain also lost its C-terminal lysine residue. Figure 5A : No amiRNA transposon; Figure 5B : Multiple hairpin amiRNA SEQ ID NO: 726 operably linked to the EF1 promoter.
[0038] 5. Description
[0039] 5.1 Definitions
[0040] Unless the context clearly dictates otherwise, use of the singular forms "a," "an," and "the" include plural references. Thus, for example, reference to "a polynucleotide" includes a plurality of polynucleotides, reference to "a substrate" includes a plurality of such substrates, reference to "a variant" includes a plurality of variants, and so forth.
[0041] Terms such as "linked," "attached," "connected," and "conjugated" are used interchangeably herein and include direct and indirect connections, attachments, connections, or conjugations, unless the context clearly dictates otherwise. Where a numerical range is recited, it is understood that each intermediate integer value between the stated upper and lower limits of the range and each fraction thereof, as well as each subrange between these values, is also specifically disclosed. The upper and lower limits of any range may independently be included in or excluded from the range, and each range in which one, neither, or both limits are included is also included in the invention. Where the values in question have inherent limitations, such as when a component can be present at a concentration of 0% to 100%, or when the pH of an aqueous solution can be between 1 and 14, these inherent limitations are explicitly disclosed. Where a numerical value is explicitly recited, it is understood that numerical values of approximately the same quantity or amount as the stated numerical value are also within the scope of the invention. Where a combination is disclosed, each subcombination of the elements of the combination is also specifically disclosed and within the scope of the invention. Conversely, where different elements or groups of elements are disclosed individually, their combinations are also disclosed. Where any element of the invention is disclosed as having multiple alternatives, examples of the invention are also disclosed herein in which each alternative is excluded either alone or in any combination with the other alternatives; more than one element of an invention may have such exclusions, and all combinations of elements having such exclusions are hereby disclosed.
[0042] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton, et.al., Dictionary of Microbiology and Molecular Biology, 2nd Ed., John Wiley and Sons, New York (1994), and Hale & Marham, The Harper Collins Dictionary of Biology, Harper Perennial, NY, 1991 provide a general dictionary of many of the terms used in the present invention for the skilled artisan. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. Unless otherwise indicated, nucleic acids are written from left to right in the 5' to 3' direction; amino acid sequences are written from left to right in the amino to carboxyl direction, respectively. The terms defined immediately below are more fully defined by reference to the entire specification.
[0043] "Artificial microRNA" or "amiRNA" is a sequence comprising a natural microRNA scaffold in which the guide strand and / or passenger strand sequence has been modified so that the guide strand is directed to an mRNA target that is not a natural target. Other portions of the natural microRNA scaffold may also be modified, for example to improve the processing of enzymes in the RNA interference pathway. An amiRNA sequence comprising two or more guide strands and passenger strands operably linked to the same promoter is referred to as a "multi-hairpin amiRNA gene".
[0044] The term "codon usage" or "codon bias" refers to the relative frequency of using different synonymous codons to encode amino acids in an open reading frame. A nucleic acid sequence with a codon preference for a specific target cell has a balance of synonymous codon selection that results in efficient translation in that cell type. This balance is usually not calculated from the observed genomic codon frequency, but must be determined empirically, such as in U.S. Patents 7,561,972, 7,561,973, and 8,401,798, and Welchet.al. (2009), "Design Parameters to Control Synthetic Gene Expression inEscherichia coli". PLoS ONE 4(9): e7002. https: / / doi.org / 10.1371 / journal.pone.0007002. When a nucleic acid originally isolated from one cell type is introduced into a target cell of another type, the codon preference of the cell at the target site can be selected so that at least 1, and sometimes 5, 20, 15, 20, 50, 100 or more, of the synonymous codons differ between the nucleic acid introduced into the target cell and the original nucleic acid.
[0045] Two polynucleotides are "complementary" if a hydrogen base bonds to a base in the other. To be fully complementary, an adenine (A) in the first polynucleotide must correspond to a thymine (T) in the second (and vice versa), and a cytosine (C) in the first polynucleotide must correspond to a guanine (G) in the second (and vice versa). The two polynucleotides must also be antiparallel. If two polynucleotides are complementary, one may be described as the "reverse complement" of the other to indicate that their bases are complementary when one is in the 5' to 3' direction and the other in the 3' to 5' direction. As used herein, when one polynucleotide sequence is described as complementary to another, it is intended to indicate that the sequences are antiparallel and are capable of base pairing with each other.
[0046] The "architecture" of a polynucleotide refers to the functional sequence elements within the polynucleotide, as well as the order and orientation of these elements.
[0047] The terms "corresponding transposon" and "corresponding transposase" are used to indicate the active relationship between a transposase and a transposon. A transposase transposes its corresponding transposon. Many transposases may correspond to one transposon, and many transposons may correspond to one transposase.
[0048] The term "counter-selectable marker" refers to a polynucleotide sequence that confers a selective disadvantage on a host cell. Examples of selectable markers include sacB, rpsL, tetAR, pheS, thyA, gata-1, ccdB, kid, and barnase (Bernard, 1995, Journal / Gene, 162:159-160; Bernard et.al.,1994.Journal / Gene,148:71-74;Gabantet.al.,1997,Journal / Biotechniques,23:938-941;Gababt et.al.,1998,Journal / Gene,207:87-92;Gababt et.al.,2000,Journal / Biotechniques,28:784-788; Galvao and deLorenzo,2005,Journal / Appl Environ Microbiol,71:883-892;Hartzog et.al., 2005, Journal / Yeat, 22:789-798; Knipfer et.al., 1997, Journal / Plasmid, 37:129-140; Reyratet.al., 1998, Journal / Infect Immun, 66:4011-4017; Soderholm et.al., 2001, Journal / Biotechniques, 31:306-310,312; Tamura et.al., 2005, Journal / Appl Environ Microbiol, 71:587-590; Yazynin et.al., 1999, Journal / FEBS Lett, 452:351-354). Counter-selectable markers usually confer a selective disadvantage under certain circumstances. For example, they can confer sensitivity to compounds that can be added to the host cell environment, or they can kill hosts with one genotype but not hosts with a different genotype. Conditions that do not impose a selective disadvantage on cells carrying the counter-selectable marker are described as "permissive." Conditions that do confer a selective disadvantage on cells carrying the counter-selectable marker are described as "restrictive."
[0049] The term "coupling element" or "translation coupling element" refers to a DNA sequence that allows the expression of a first polypeptide to be linked to the expression of a second polypeptide. Internal ribosome entry site elements (IRES elements) and cis-acting hydrolase elements (CHYSEL elements) are examples of coupling elements.
[0050] The term "DNA sequence", "RNA sequence" or "polynucleotide sequence" refers to a continuous nucleic acid sequence. The sequence can be an oligonucleotide with a length of 2 to 20 nucleotides to a full-length genomic sequence of thousands or hundreds of thousands of base pairs.
[0051] The term "expression construct" refers to any polynucleotide designed for transcribing RNA. For example, a construct comprising at least one promoter, which is operably connected or can be operably connected to a downstream gene, coding region or polynucleotide sequence [e.g., a cDNA or genomic DNA fragment encoding a polypeptide or protein, or an RNA effector molecule, such as an antisense RNA, a triple helix forming RNA, a ribozyme, an artificially selected high-affinity RNA ligand (aptamer), a double-stranded RNA, such as an RNA molecule comprising a stem-loop or hairpin dsRNA, or a two-finger or multi-finger dsRNA or microRNA, or any RNA]. An "expression vector" is a polynucleotide comprising a promoter, which can be operably connected to a second polynucleotide. The expression construct is transfected or transformed into a recipient cell to allow the cell to express an RNA effector molecule, polypeptide or protein encoded by the expression construct. The expression construct can be a genetically engineered plasmid, a virus, a recombinant virus or an artificial chromosome derived from, for example, a bacteriophage, an adenovirus, an adeno-associated virus, a retrovirus, a lentivirus, a poxvirus or a herpesvirus. Such an expression vector can include sequences from bacteria, viruses or bacteriophages. Such vectors include chromosome, episome and virus-derived vectors, for example derived from bacterial plasmid, phage, yeast episome, yeast chromosome element and viral vectors, derived from the vectors of its combination, for example derived from those vectors of plasmid and phage genetic elements, clay and phagemid. Expression construct can be replicated in living cells, also can be artificially synthesized. For purposes of the application, terms "expression construct", "expression vector", "carrier" and "plasmid" are used interchangeably to show application of the present invention in a general, illustrative sense, and are not intended to limit the present invention to the expression construct of a particular type.
[0052] The term "expressed polypeptide" refers to a polypeptide encoded by a gene on an expression construct.
[0053] The term "expression system" means any in vivo or in vitro biological system used to produce one or more gene products encoded by a polynucleotide.
[0054] "Gene" refers to a transcription unit, including a promoter and the sequence expressed therefrom as RNA or protein. The sequence to be expressed can be genomic, cDNA, one or more non-coding RNAs, including siRNA or microRNA, and other possibilities. Other elements, such as introns and other regulatory sequences may or may not be present.
[0055] A "gene transfer system" includes a vector or a gene transfer vector, or a polynucleotide comprising a gene to be transferred cloned into a vector (a "gene transfer polynucleotide" or a "gene transfer construct"). A gene transfer system may also include other features that facilitate the gene transfer process. For example, a gene transfer system may include a vector and a lipid or viral packaging mixture to allow a first polynucleotide to enter a cell, or it may include a polynucleotide comprising a transposon and a second polynucleotide sequence encoding a corresponding transposase to increase the cost-effective genomic integration of the transposon. The transposase and the transposon of the gene transfer system may be on the same nucleic acid molecule or on different nucleic acid molecules. The transposase of the gene transfer system may be provided as a polynucleotide or as a polypeptide.
[0056] The "guide" strand of an inhibitory double-stranded RNA (such as shRNA or miRNA) binds to the RNA-induced silencing complex (RISC) and participates in gene silencing. The guide strand sequence is the reverse complement of the target mRNA sequence, which inhibits its expression.
[0057] The term "hairpin" is used to describe a polynucleotide sequence in which two regions of the same chain are reverse complementary to each other in nucleotide sequence, resulting in intramolecular base pairing to form a double-stranded region and an unpaired loop. The term is used herein to describe a DNA sequence encoding such a structure, although DNA is usually double-stranded by intermolecular base pairing. The term is also used to refer to an RNA sequence that adopts a hairpin structure. The DNA hairpin of the present invention is intended to be expressed as RNA. The RNA hairpin of the present invention is used as a substrate for RNA interference pathway enzymes, which are processed into guide strands loaded onto the RISC complex. The "guide strand" of a hairpin is a sequence that is loaded into the RISC complex after transcription and processing. The guide strand is complementary to the target mRNA.
[0058] Two elements are "heterologous" to each other if they are not naturally associated. For example, a nucleic acid sequence encoding a protein linked to a heterologous promoter refers to a promoter other than the promoter that naturally drives protein expression. A heterologous nucleic acid flanked by transposon ends or ITRs refers to a heterologous nucleic acid that is not naturally flanked by those transposon ends or ITRs, such as a nucleic acid encoding a polypeptide other than a transposase, including an antibody heavy chain or light chain. A nucleic acid is heterologous to a cell if it is not naturally present in the cell, or if it is naturally present in the cell but is located at a different position than the position (e.g., an episome or a different genomic position).
[0059] A "hyperactive" transposase is a transposase that is more active than the naturally occurring transposase from which it was derived. Thus, a "hyperactive" transposase is not a naturally occurring sequence.
[0060] The term "host" refers to any prokaryotic or eukaryotic organism that can be a nucleic acid receptor. "Host", as the term is used herein, includes prokaryotic or eukaryotic organisms that can be genetically engineered. For examples of such hosts, see Maniatis et.al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). As used herein, the terms "host", "host cell", "host system" and "expression host" can be used interchangeably.
[0061] "IRES" or "internal ribosome entry site" refers to a specialized sequence that directly promotes ribosome binding, independent of the cap structure.
[0062] An "isolated" polypeptide or polynucleotide refers to one that has been removed from its natural environment, produced using recombinant technology, or chemically or enzymatically synthesized. A polypeptide or polynucleotide of the invention may be purified, i.e., substantially free of any other polypeptides or polynucleotides and associated cellular products or other impurities.
[0063] The terms "nucleoside" and "nucleotide" include those that contain not only known purine and pyrimidine bases, but also other modified heterocyclic bases. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, or other heterocycles. Modified nucleosides or nucleotides may also include modifications to sugar moieties, for example, wherein one or more hydroxyls are substituted by halogens, aliphatic groups, or are functionalized to ethers, amines, etc. The term "nucleotide unit" is intended to include nucleosides and nucleotides.
[0064] An "open reading frame" or "ORF" refers to a portion of a polynucleotide that, when translated into amino acids, does not contain a stop codon. The genetic code reads DNA sequences in groups of three base pairs, which means that a double-stranded DNA molecule can be read in any of six possible reading frames - three in the forward direction and three in the reverse direction. An ORF also typically includes a start codon, at which translation can begin.
[0065] The term "operably linked" refers to a functional connection between two sequences such that one sequence changes the behavior of another sequence. For example, if the first polynucleotide affects the transcription and / or translation of the second polynucleotide, a first polynucleotide comprising a nucleic acid expression control sequence (e.g., a promoter, an IRES sequence, an enhancer, or an array of transcription factor binding sites) and a second polynucleotide are operably linked. Similarly, if the first amino acid sequence causes the second amino acid sequence to be secreted or localized to a subcellular location, a first amino acid sequence comprising a secretion signal or a subcellular localization signal and a second amino acid sequence are operably linked.
[0066] The term "orthogonal" refers to the lack of interaction between two systems. A first transposon and its corresponding first transposase and a second transposon and its corresponding second transposase are orthogonal if the first transposase does not excise or transpose the second transposon and the second transposase does not excise or transpose the first transposon.
[0067] The term "overhang" or "DNA overhang" refers to the single-stranded portion at the end of a double-stranded DNA molecule. Complementary overhangs are those that will base pair with each other.
[0068] The "passenger" strand of an inhibitory double-stranded RNA (eg, shRNA or miRNA) is the strand that is degraded after transport into the cytoplasm and does not directly participate in gene silencing.
[0069] "PiggyBac-like transposase" refers to a transposase having at least 20% sequence identity to the piggyBac transposase from Trichoplusia ni (Trichoplusia ni) (SEQ ID NO: 1047) identified using the TBLASTN algorithm and described more fully in Sakar, A. et.al., 2003. Mol. Gen. Genomics 270: 173-180. "Molecular evolutionary analysis of the extensive piggyBac transposon family and related 'domesticated' species", and further characterized as a DDE-like DDD motif with aspartic acid residues at positions corresponding to D268, D346 and D447 of the maximum alignment with the piggyBac transposase of Trichoplusia ni. PiggyBac-like transposases are also characterized in that they are able to precisely excise transposons at a high frequency. A "piggyBac-like transposon" refers to a transposon whose ends are identical or at least 80% identical to the ends of a naturally occurring transposon, preferably at least 90, 95, 96, 97, 98, 99% or 100% identical to the ends of a naturally occurring transposon encoding a piggyBac-like transposase. The piggyBac-like transposon includes an inverted terminal repeat (ITR) sequence consisting of approximately 12-16 bases located at each end. These repeats may be identical at both ends, or the repeats at both ends may differ at 1, 2, 3 or 4 positions in the two ITRs. The transposon is flanked by a 4-base sequence corresponding to the integration target sequence, which is replicated upon transposon integration (target site repeat, target sequence repeat or TSD).PiggyBac-like transposons and transposases are naturally present in a variety of organisms, including Argyrogramma agnate (GU477713), Anopheles gambiae (XP_312615; XP_320414; XP_310729), Aphis gossypii (GU329918), Acyrthosiphon pisum (XP_001948139), Agrotis ypsilon (GU477714), Bombyx mori (BAD11135), Ciona intestinalis (XP_002123602), Chilo suppressalis (JX294476), Drosophila melanogaster (AAL39784), Daphnia pulicaria (AAM76342), Helicoverpaarmigera (ABS18391), Homo sapiens (AAM76343), and Homo sapiens (AAM76344). sapiens (NP_689808), Heliothis virescens (ABD76335), Macdunnoughia crassisigna (EU287451), Macaca fascicularis (AB179012), Mus musculus (NP_741958), Pectinophora gossypiella (GU270322), Rattus norvegicus (XP_220453), Tribolium castaneum (XP_001814566) and Trichoplusia ni (AAA87375) and Xenopus tropicalis (BAF82026), although transposition activity in these organisms has hardly been described.
[0070] The terms "polynucleotide," "oligonucleotide," "nucleic acid," and "nucleic acid molecule" are used interchangeably to refer to a polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. The term refers only to the primary structure of the molecule. Thus, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), and triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). It also includes modified, for example by alkylation and / or by capping, as well as unmodified forms of polynucleotides. More specifically, the terms "polynucleotide," "oligonucleotide," "nucleic acid," and "nucleic acid molecule" include polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), including tRNA, rRNA, hRNA, siRNA, and mRNA, whether spliced or unspliced, any other type of polynucleotide that is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing non-nucleotide backbones, such as polyamides [e.g., peptide nucleic acids ("PNA")] and polymorpholines (commercially available from Anti-Virals, Inc., Corvallis, Oreg., as Neugene) polymers, and other synthetic sequence-specific nucleic acid polymers, provided that the polymer contains nucleobases in a configuration that allows base pairing and base stacking, such as found in DNA and RNA. The terms "polynucleotide," "oligonucleotide," "nucleic acid," and "nucleic acid molecule" have no intentional distinction in length, and these terms are used interchangeably herein. These terms refer only to the primary structure of the molecule. Thus, these terms include, for example, 3'-deoxy-2', 5'-DNA, oligodeoxyribonucleotide N3'P5' phosphoramidates, 2'-O-alkyl substituted RNA, double-stranded and single-stranded DNA, and double-stranded and single-stranded RNA and hybrids thereof, including, for example, hybrids between DNA and RNA or between PNA and DNA or RNA, and also include known types of modifications, such as labeling, alkylation, "capping", replacement of one or more nucleotides with an analog, internucleotide modifications, such as having uncharged bonds (e.g., methylphosphonate, phosphotriester, phosphoramidate, carbamate, etc.) and negatively charged bonds. Those with charged bonds (e.g., phosphorothioates, phosphorodithioates, or the like), and those with positively charged bonds (e.g., aminoalkylphosphates, aminoalkylphosphotriesters), those containing side chain moieties, such as proteins [including enzymes (e.g., nucleases), toxins, antibodies, signal peptides, poly-L-lysine, etc.], those with intercalators (e.g., acridine, psoralen, etc.), those containing chelates (composed of, for example, metals, radioactive metals, boron, oxidized metals, or the like), those containing alkylating agents, those with modified bonds (e.g., alpha anomeric nucleic acids, etc.), and unmodified forms of polynucleotides or oligonucleotides.
[0071] "Promoter" refers to a nucleic acid sequence sufficient to direct transcription of an operably linked nucleic acid molecule. A promoter may be used with or without other transcriptional control elements (e.g., enhancers) that are sufficient to render promoter-dependent gene expression controllable in a cell type-specific, tissue-specific, or time-specific manner, or that may be induced by an external signal or agent; such elements may be located within the 3' region of a gene or within an intron. Ideally, the promoter is operably linked to a nucleic acid sequence, e.g., a cDNA or gene sequence, or an effector RNA coding sequence, to enable expression of the nucleic acid sequence, or the promoter is provided in an expression cassette into which a selected nucleic acid sequence to be transcribed may be conveniently inserted. A regulatory element (e.g., a promoter) that is active in mammalian cells refers to a regulatory element that can be configured to result in expression levels of at least 1 transcript per cell in mammalian cells into which the regulatory element has been introduced.
[0072] "RNA interference" is a biological process in which RNA molecules inhibit gene expression or translation by neutralizing targeted mRNA molecules. Historically, RNAi has had other names, including cosuppression, post-transcriptional gene silencing (PTGS), and inhibition. MicroRNAs, including artificial microRNAs, inhibit gene expression through RNA interference.
[0073] The term "selectable marker" refers to a polynucleotide fragment or its expression product, which allows one to select for or against a molecule or cell containing it, usually under specific conditions. These markers can encode activities such as, but not limited to, the production of RNA, peptides or proteins, or can provide binding sites for RNA, peptides, proteins, inorganic and organic compounds or compositions. Examples of selectable markers include, but are not limited to: (1) DNA fragments encoding products that provide resistance to otherwise toxic compounds (e.g., antibiotics); (2) DNA fragments encoding products that are otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); (3) DNA fragments encoding products that inhibit the activity of gene products; (4) DNA fragments encoding products that are easily identifiable [e.g., phenotypic markers such as β-galactosidase, green fluorescent protein (GFP), and cell surface proteins)]; (5) DNA fragments that bind products that are otherwise detrimental to cell survival and / or function. DNA fragments; (6) DNA fragments that otherwise inhibit the activity of any of the DNA fragments described in items 1-5 above (e.g., antisense oligonucleotides); (7) DNA fragments that bind to products of modified substrates (e.g., restriction endonucleases); (8) DNA fragments that can be used to isolate desired molecules (e.g., specific protein binding sites); (9) DNA fragments that encode specific nucleotide sequences that may otherwise be non-functional (e.g., for PCR amplification of a subset of molecules); and / or (10) DNA fragments that, when absent, directly or indirectly confer sensitivity to a specific compound.
[0074] Sequence identity can be determined by using algorithm alignment sequence, such as BESTFIT, FASTA and TFASTA (in Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575Science Dr., Madison, Wis.), using default gap parameters, or by inspection and optimal comparison (that is, producing the sequence similarity of the highest percentage in the comparison window). The percentage of sequence identity is by comparing the sequences of two optimal comparisons on the comparison window, determining the number of positions where the same residues occur in the two sequences to produce the number of matching positions, the number of matching positions is divided by the total number of matching and non-matching positions, not calculating the gap (i.e. window size) in the comparison window, then multiplying the result by 100 to obtain the percentage of sequence identity and thus calculate. Unless otherwise stated, the comparison window between two sequences is defined by the shorter entire length of the two sequences.
[0075] "Target nucleic acid" is the nucleic acid into which the transposon is to be inserted. Such a target may be part of a chromosome, an episome, or a vector.
[0076] An "integration target sequence" or "target sequence" or "target site" of a transposase is a site or sequence in a target DNA molecule where a transposon can be inserted by the transposase. The piggyBac transposase from Trichoplusia ni primarily inserts its transposon into the target sequence 5'-TTAA-3'. Other useful target sequences for the PiggyBac transposon are 5'-CTAA-3', 5'-TTAG-3', 5'-ATAA-3', 5'-TCAA-3', 5'-AGTT-3', 5'-ATTA-3', 5'-GTTA-3', 5'-TTGA-3', 5'-TTTA-3', 5'-TTAC-3', 5'-ACTA-3', 5'-AGGG-3', 5'-CTAG-3', 5'-GTAA-3', 5'-AGGT-3', 5'-ATCA-3', 5'-CTCC-3', 5'-TAAA-3', 5'-TCTC-3', 5'-TGAA-3', 5' -AAAT-3',5'-AATC-3',5'-ACAA-3',5'-ACAT-3',5'-ACTC-3',5'-AGTG-3',5'-ATAG-3',5'-CAAA-3',5'-CACA-3',5'-CATA-3',5'-CCAG-3',5' -CCCA-3',5'-CGTA-3',5'-CTGA-3',5'-GTCC-3',5'-TAAG-3',5'-TCTA-3',5'-TGAG-3',5'-TGTT-3',5'-TTCA-3',5'-TTCT-3' and 5'-TTTT-3'(Li et al., 2013. Proc. Natl. Acad. Scivol. 110, no. 6, E478-487) and 5'-TTAT. The piggyBac-like transposase transposes its transposon using a cut-and-paste mechanism, which causes its 4-base-pair target sequence to be repeated upon insertion into the DNA molecule. Thus, the target sequence is found on each side of the integrated piggyBac-like transposon.
[0077] The term "translation" refers to the process by which a polynucleotide sequence is "read" by ribosomes to synthesize a polypeptide.
[0078] A "transposase" is a polypeptide that catalyzes the excision of a corresponding transposon from a donor polynucleotide (eg, a vector) and (assuming the transposase is not integration-defective) the subsequent integration of the transposon into a target nucleic acid.
[0079] The term "transposition" is used herein to refer to the role of a transposase in excising a transposon from one polynucleotide and then integrating it into a different site in the same polynucleotide, or into a second polynucleotide.
[0080] The term "transposon" refers to a polynucleotide that can be excised from a first polynucleotide (e.g., a vector) and integrated into a second position of the same polynucleotide or integrated into a second polynucleotide, e.g., a cell's genome or extrachromosomal DNA, by the action of a corresponding trans-transposase. A transposon includes a first transposon end and a second transposon end, which are polynucleotide sequences that are recognized and transposed by a transposase. A transposon generally further includes a first polynucleotide sequence between the two transposon ends, so that the first polynucleotide sequence is transposed with the two transposon ends by the action of a transposase. The first polynucleotide in a natural transposon generally includes an open reading frame encoding a corresponding transposase, which recognizes and transposes the transposon. The transposon of the present invention is a "synthetic transposon" comprising a heterologous polynucleotide sequence, which is transposable due to its juxtaposition between the two transposon ends. A synthetic transposon may or may not further include a flanking polynucleotide sequence outside the transposon end, such as a sequence encoding a transposase, a vector sequence encoding a selection marker, or a sequence.
[0081] The term "transposon end" refers to a cis-acting nucleotide sequence sufficient for recognition and transposition by a corresponding transposase. The transposon ends of piggyBac-like transposons include complete or imperfect repeats such that the corresponding repeats in the two transposon ends are the reverse complements of each other. These are called inverted terminal repeats (ITRs) or terminal inverted repeats (TIRs). The transposon ends may or may not include additional sequences near the ITRs that promote or enhance transposition.
[0082] The term "vector" or "DNA vector" or "gene transfer vector" refers to a polynucleotide that is used to perform a "carrying" function for another polynucleotide. For example, a vector is generally used to allow a polynucleotide to propagate within a living cell, or to allow a polynucleotide to be packaged for delivery into a cell, or to allow a polynucleotide to be integrated into the genomic DNA of a cell. The vector may further include additional functional elements, for example, it may include a transposon.
[0083] 5.2 Genetic Elements Useful for Expression in Cultured Mammalian Cells
[0084] 5.2.1 Gene transfer system
[0085] The gene transfer system includes a polynucleotide to be transferred to a host cell. The gene transfer system may include any transposon described herein and its corresponding transposase. Although transposons are the preferred gene transfer system because of their large cargo size and the ability to incorporate multiple different open reading frames and all of their associated regulatory elements without affecting the packaging and delivery of the gene transfer system, the gene transfer system for delivering the inhibitory gene transfer polynucleotide may include one or more polynucleotides having other features that promote efficient gene transfer without the need for a transposase or transposon, such as a viral system, such as a lentiviral system, an adenoviral system, or an adeno-associated viral system.
[0086] The components of the gene transfer system can be transfected into one or more cells by combining the components with lipid vesicles [such as cationic lipid vesicles, DNA condensation agents (such as calcium phosphate, polylysine or polyethyleneimine)] through particle bombardment, electroporation, microinjection and other techniques, and inserting the components (i.e., its nucleic acid) into a viral vector and contacting the viral vector with the cell. In the case of using a viral vector, the viral vector may include any of a variety of viral vectors known in the art, including a viral vector selected from a retroviral vector, an adenoviral vector or an adeno-associated viral vector. The retroviral vector may be a lentiviral vector including two LTRs, each LTR being at least 90% identical to a sequence selected from SEQ ID NOs: 115-116. The adeno-associated viral vector may contain two ITRs, each ITR being at least 90% identical to a sequence selected from SEQ ID NOs: 1117-1123. The gene transfer system can be formulated in a suitable manner known in the art, or formulated as a pharmaceutical composition or a kit.
[0087] If the heterologous polynucleotide is integrated into the genome of the host cell, the consistency of expression of the gene from the heterologous polynucleotide in the cultured mammalian cells can be improved. The integration of the polynucleotide into the genome of the host cell generally also makes it stable in heritability by placing it in the same mechanism that ensures the replication and division of the genomic DNA. This stable heritability is required to achieve good and consistent expression over a long growth period. For stable modification of cultured mammalian cells, including consistent expression of inhibitory RNAs (such as miRNAs and amiRNAs), the stability of the modification and the consistency of the expression level are important, especially for therapeutic applications.
[0088] 5.2.2 Transposon Elements
[0089] If the heterologous polynucleotides are part of a transposon, they can be integrated into the target genome more efficiently, for example so that they can be integrated by a transposase. A particular benefit of transposons is that the entire polynucleotide between the transposon ITRs is integrated. This is in contrast to random integration, in which a polynucleotide introduced into a eukaryotic cell is often randomly fragmented in the cell and only part of the polynucleotide is integrated into the target genome, usually at a low frequency. There are several different classes of transposons. piggyBac-like transposons include transposons from the looper moth Trichoplusia ni, Xenopus piggyBac-like transposon, Bombyx piggyBac-like transposon, Heliothis piggyBac-like transposon, Helicoverpa piggyBac-like transposon, Agrotis piggyBac-like transposon, Amyelois piggyBac-like transposon, piggyBat piggyBac-like transposon and Oryzias piggyBac-like transposon. hAT transposons include TcBuster. Mariner transposons include Sleeping Beauty. Each of these transposons can be integrated into the genome of mammalian cells by the corresponding transposase. Heterologous polynucleotides incorporated into transposons can be integrated into cultured mammalian cells as well as hepatocytes, nerve cells, muscle cells, blood cells, embryonic stem cells, somatic stem cells, hematopoietic cells, embryos, fertilized eggs and sperm cells (some of which can be operated in an in vitro environment). Preferred cells can also be pluripotent cells (whose offspring can differentiate into several restricted cell types, such as hematopoietic stem cells or other stem cells) or totipotent cells (that is, whose offspring can become cells of any cell type in an organism, for example, embryonic stem cells).
[0090] A preferred gene transfer system comprising an inhibitory polynucleotide containing an inhibitory RNA expression sequence comprises a transposon in combination with a corresponding transposase protein that transposes the transposon, or a nucleic acid encoding a corresponding transposase protein that can be expressed in a target cell.
[0091] When the gene transfer system has multiple components, such as one or more polynucleotides comprising transposon ends flanked by genes for expression in target cells, and a transposase (which can be provided as a protein or encoded by a nucleic acid), these components can be transfected into the cell simultaneously or sequentially. For example, a transposase protein or its encoding nucleic acid can be transfected into the cell before, simultaneously with, or after transfection of the corresponding transposon. In addition, administration of any component of the gene transfer system can occur repeatedly, for example, by administering at least two doses of the component.
[0092] The transposase protein may be encoded by a polynucleotide comprising RNA or DNA. Preferred RNA molecules include those with appropriate substitutions to reduce toxic effects on cells, such as substitution of uridine with pseudouridine and substitution of cytosine with 5-methylcytosine. The mRNA encoding the transposase may be prepared to have a 5'-cap structure to increase expression in target cells. Exemplary cap structures are cap analogs [G(5')ppp(5')G], anti-reverse cap analogs [3'-O-Me-m 7 G(5')ppp(5')G, clean cap [m7G(5')ppp(5')(2'OMeA)pG], one mCap[m7G(5')ppp(5')G]. The mRNA encoding the transposase can be prepared so that some bases are partially or completely replaced, for example, uridine can be replaced by pseudouridine, and cytosine can be replaced by 5-methyl-cytosine. Any combination of these caps and replacements can be made. Similarly, the nucleic acid encoding the transposase protein or transposon of the present invention can be transfected into cells in the form of linear fragments or circularized fragments, plasmids or recombinant viral DNA. If the transposase is introduced as a DNA sequence encoding the transposase, the open reading frame encoding the transposase is preferably operably linked to a promoter active in the target mammalian cell.
[0093] A favorable piggyBac-like transposon for modifying the genome of mammalian cells is a Xenopus (African clawed frog) transposon, which comprises an ITR having a sequence given by SEQ ID NO: 1004, a heterologous polynucleotide to be transposed, and a second ITR having a sequence given by SEQ ID NO: 1005. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', adjacent to the ITR and away from the heterologous polynucleotide. The transposon may further comprise a sequence adjacent to the ITR and close to the heterologous polynucleotide, the heterologous polynucleotide having at least 95% identity to SEQ ID NO: 1000 or 1001 on one side (preferably the left side) of the heterologous polynucleotide, and a sequence adjacent to the ITR and close to the heterologous polynucleotide having at least 95% identity to SEQ ID NO: 1002 or 1003 on the other side (preferably the right side) of the heterologous polynucleotide. The transposon may be transposed by a corresponding Xenopus transposase comprising a sequence at least 90% identical to the sequence given in SEQ ID NO: 1049 or 1050, for example any one of SEQ ID NOs: 1049-1081. Preferably, the transposase is a hyperactive variant of a naturally occurring transposase. Preferably, the hyperactive variant transposase comprises one or more of the following amino acid changes relative to the sequence of SEQ ID NO: 1049: Y6L, Y6H, Y6V, Y6I, Y6C, Y6G, Y6A, Y6S, Y6F, Y6R, Y6P, Y6D, Y6N, S7G, S7V, S7D, E9W, E9D, E9E, M16E, M16N, M16D, M16S, M16Q, M16T,M16A,M16L,M16H,M16F,M16I,S18C,S18Y,S18M,S18L,S18Q,S18G,S18P,S18 A,S18W,S18H,S18K,S18I,S18V,S19C,S19V,S19L,S19F,S19K,S19E,S19D,S19G,S1 9N,S19A,S19M,S19P,S19Y,S19R,S19T,S19Q,S20G,S20M,S20L,S20V,S20H,S20W, S20A,S20C,S20Q,S20D,S20F,S20N,S20R,E21N,E21W,E21G,E21Q,E21L,E21D,E21 A,E21P,E21T,E21S,E21Y,E21V,E21F,E21M,E22C,E22H,E22R,E22L,E22K,E22S,E 22G,E22M,E22V,E22Q,E22A,E22Y,E22W,E22D,E22T,F23Q,F23A,F23D,F23W,F23K,F23T,F23V,F23M,F23N,F23P,F23H,F23E,F23C,F23R,F23Y,S24L,S24W,S24H,S24V,S24P,S24I,S24F,S24K,S24Y,S24D,S24C,S24N,S24G,S24A,S26F,S26H,S26V,S26Q,S26Y,S26W,S28K,S28Y,S28C,S28M,S28L,S28H,S28T,S28Q,V31L,V31T,V31I,V31Q,V31K,A34L,A34E,L67A,L67T,L67M,L67V,L67C,L67H,L67E,L67Y,G73H,G73N,G73K,G73F,G73V,G73D,G73S,G73W,G73L,A76L,A76R,A76E,A76I,A76V,D77N,D77Q,D77Y,D77L,D77T,P88A,P88E,P88N,P88H,P88D,P88L,N91D,N91R,N91A,N91L,N91H,N91V,Y141I,Y141M,Y141Q,Y141S,Y141E,Y141W,Y141V,Y141F,Y141A,Y141C,Y141K,Y141L,Y141H,Y141R,N145C,N145M,N145A,N145Q,N145I,N145F,N145G,N145D,N145E,N145V,N145H,N145W,N145Y,N145L,N145R,N145S,P146V,P146T,P146W,P146C,P146Q,P146L,P146Y,P146K,P146N,P146F,P146E,P148M,P148R,P148V,P148F,P148T,P148C,P148Q,P148H,Y150W,Y150A,Y150F,Y150H,Y150S,Y150V,Y150C,Y150M,Y150N,Y150D,Y150E,Y150Q,Y150K,H157Y,H157F,H157T,H157S,H157W,A162L,A162V,A162C,A162K,A162T,A162G,A162M,A162S,A162I,A162Y,A162Q,A179T,A179K,A179S,A179V,A179R,L182V,L182I,L182Q,L182T,L182W,L182R,L182S,T189C,T189N,T189L,T189K,T189Q,T189V,<h2 style=";text-align:left;direction:ltr">T189A,T189W,T189Y,T189G,T189F,T189S,T189H,L192V,L192C,L192H,L1 92M,L192I,S193P,S193T,S193R,S193K,S193G,S193D,S193N,S193F,S193 H,S193Q,S193Y,V196L,V196S,V196W,V196A,V196F,V196M,V196I,S198G, S198R,S198A,S198K,T200C,T200I,T200M,T200L,T200N,T200W,T200V,T20 0Q,T200Y,T200H,T200R,S202A,S202P,L210H,L210A,F212Y,F212N,F212M ,F212C,F212A,N218V,N218R,N218T,N218C,N218G,N218I,N218P,N218D,N 218E, A248S, A248L, A248H, A248C, A248N, A248I, A248Q, A248Y, A248M, A248D, L263V, L263A, L263M, L263R, L263D, Q270V, Q270K, Q270A, Q270C, Q270P, Q270L,Q270I,Q270E,Q270G,Q270Y,Q270N,Q270T,Q270W,Q270H,S294R,S2 94N,S294G,S294T,S294C,T297C,T297P,T297V,T297M,T297L,T297D,E304 D,E304H,E304S,E304Q,E304C,S308R,S308G,L310R,L310I,L310V,L333M,L333W,L333F,Q336Y,Q336N,Q336M,Q336A,Q336T,Q336L,Q336I,Q336G,Q33 6F,Q336E,Q336V,Q336C,Q336H,A354V,A354W,A354D,A354C,A354R,A354E,A354K,A354H,A354G,C357Q,C357H,C357W,C357N,C357I,C357V,C357M,C 357R, C357F, C357D, L358A, L358F, L358E, L358R, L358Q, L358V, L358H, L358C, L358M, L358Y, L358K, L358N, L358I, D359N, D359A, D359L, D359H, D359R,D359S,D359Q,D359E,D359M,L377V,L377I,V423N,V423P,V423T,V423F,V423H,V423C,V423S,V423G,V423A,V423R,V423L,P426L,P426K,P426Y,P426F,P426T,P426W,P426V,P426C,P426S,P426Q,P426H,P426N,K428R,K428Q,K428N,K428T,K428F,S434A,S434T,S438Q,S438A,S438M,T447S,T447A,T447C,T447Q,T447N,T447G,L450M,L450V,L450A,L450I,L450E,A462M,A462T,A462Y,A462F,A462K,A462R,A462Q,A462H,A462E,A462N,A462C,V467T,V467C,V467A,V467K,I469V,I469N,I472V,I472L,I472W,I472M,I472F,L476I,L476V,L476N,L476F,L476M,L476C,L476Q,P488E,P488H,P488K,P488Q,P488F,P488M,P488L,P488N,P488D,Q498V,Q498L,Q498G,Q498H,Q498T,Q498C,Q498E,Q498M,L502I,L502M,L502V,L502G,L502F,E517M,E517V,E517A,E517K,E517L,E517G,E517S,E517I,P520W,P520R,P520M,P520F,P520Q,P520V,P520G,P520D,P520K,P520Y,P520E,P520L,P520T,S521A,S521H,S521C,S521V,S521W,S521T,S521K,S521F,S521G,N523W,N523A,N523G,N523S,N523P,N523M,N523Q,N523L,N523K,N523D,N523H,N523F,N523C,I533M,I533V,I533T,I533S,I533F,I533G,I533E,D534E,D534Q,D534L,D534R,D534V,D534C,D534M,D534N,D534A,D534G,D534F,D534T,D534H,D534K,D534S,F576L,F576K,F576V,F576D,F576W,F576M,F576C,F576R,F576Q,F576A,F576Y,F576N,F576G,F57 6I,F576E,K577L,K577G,K577D,K577R,K577H,K577Y,K577I,K577E,K577V,K577N,I582V,I582K, I582R, I582M, I582G, I582N, I582E, I582A, I582Q, Y583L, Y583C, Y583F, Y583D, Y583Q, L587F, L587D, L587R, L587I, L587P, L587N, L587E, L587S, L587Y, L587M, L587Q, L587G, L587W, L587K or L587T. ,
[0094] A favorable piggyBac-like transposon for modifying the genome of a mammalian cell is a Bombyx transposon, which comprises an ITR having a sequence of SEQ ID NO: 1010, a heterologous polynucleotide to be transposed, and a second ITR having a sequence of SEQ ID NO: 1011. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence is at least 95% identical to SEQ ID NO: 1008 on one side (preferably the left side) of the heterologous polynucleotide, and a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence is at least 95% identical to SEQ ID NO: 1009 on the other side (preferably the right side) of the heterologous polynucleotide. The transposon may be transposed by a corresponding Bombyx transposase, which comprises a sequence at least 90% identical to SEQ ID NO: 1082, such as any one of SEQ ID NOs: 1082-1104. Preferably, the transposase is a hyperactive variant of a naturally occurring transposase. Preferably, the hyperactive variant transposase comprises one or more of the following amino acid changes relative to the sequence of SEQ ID NO: 1082: Q85E, Q85M, Q85K, Q85H, Q85N, Q85T, Q85F, Q85L, Q92E, Q92A, Q92P, Q92N, Q92I, Q92Y, Q92H, Q92F, Q92R, Q92D, Q92M, Q92W, Q92C, Q92G ... 2L,Q92V,Q92T,V93P,V93K,V93M,V93F,V93W,V93L,V93A,V93I,V93Q,P96A,P96T,P96M, P96R,P96G,P96V,P96E,P96Q,P96C,F97Q,F97K,F97H,F97T,F97C,F97W,F97V,F97E,F97P ,F97D,F97A,F97R,F97G,F97N,F97Y,H165E,H165G,H165Q,H165T,H165M,H165V,H165L, H165C,H165N,H165D,H165K,H165W,H165A,E178S,E178H,E178Y,E178F,E178C,E178A,E1 78Q,E178G,E178V,E178D,E178L,E178P,E178W,C189D,C189Y,C189I,C189W,C189T,C189 K,C189M,C189F,C189P,C189Q,C189V,A196G,L200I,L200F,L200C,L200M,L200Y,A201Q,<h2 style=";text-align:left;direction:ltr">A201L,A201M,L203V,L203D,L203G,L203E,L203C,L203T,L203M,L203A,L2 03Y,N207G,N207A,L211G,L211M,L211C,L211T,L211V,L211A,W215Y,T217 V, T217A, T217I, T217P, T217C, T217Q, T217M, T217F, T217D, T217K, G219S, G219A, G219C, G219H, G219Q, Q235C, Q235N, Q235H, Q235G, Q235W, Q235Y, Q23 5A,Q235T,Q235E,Q235M,Q235F,Q238C,Q238M,Q238H,Q238V,Q238L,Q238T,Q238I,R242Q,K246I,K253V,M258V,F261L,S263K,C271S,N303C,N303R,N 303G,N303A,N303D,N303S,N303H,N303E,N303R,N303K,N303L,N303Q,I312F,I312C,I312A,I312L,I312T,I312V,I312G,I312M,F321H,F321R,F321N, F321Y, F321W, F321D, F321G, F321E, F321M, F321K, F321A, F321Q, V323I, V323L, V323T, V323M, V323A, V324N, V324A, V324C, V324I, V324L, V324T, V324 K, V324Y, V324H, V324F, V324S, V324Q, V324M, V324G, A330K, A330V, A330P, A330S, A330C, A330T, A330L, Q333P, Q333T, Q333M, Q333H, Q333S, P337W, P33 7E, P337H, P337I, P337A, P337M, P337N, P337D, P337K, P337Q, P337G, P337S, P337C, P337L, P337V, F368Y, L373C, L373V, L373I, L373S, L373T, V389I, V 389M, V389T, V389L, V389A, R394H, R394K, R394T, R394P, R394M, R394A, Q395P, Q395F, Q395E, Q395C, Q395V, Q395A, Q395H, Q395S, Q395Y, S399N, S399E,S399K,S399H,S399D,S399Y,S399G,S399Q,S399R,S399T,S399A,S399V,S399M,R402Y,R402K,R402D,R402F,R402G,R402N,R402E,R402M,R402S,R402Q,R402T,R402C,R402L,R402V,T403W,T403A,T403V,T403F,T403L,T403Y,T403N,T403G,T403C,T403I,T403S,T403M,T403Q,T403K,T403E,D404I,D404S,D404E,D404N,D404H,D404C,D404M,D404G,D404A,D404Q,D404L,D404P,D404V,D404W,D404F,N408F,N408I,N408A,N408E,N408M,N408S,N408D,N408Y,N408H,N408C,N408Q,N408V,N408W,N408L,N408P,N408K,S409H,S409Y,S409N,S409I,S409D,S409F,S409T,S409C,S409Q,N441F,N441R,N441M,N441G,N441C,N441D,N441L,N441A,N441V,N441W,G448W,G448Y,G448H,G448C,G448T,G448V,G448N,G448Q,E449A,E449P,E449T,E449L,E449H,E449G,E449C,E449I,V469T,V469A,V469H,V469C,V469L,L472K,L472Q,L472M,C473G,C473Q,C473T,C473I,C473M,R484H,R484K,T507R,T507D,T507S,T507G,T507K,T507I,T507M,T507E,T507C,T507L,T507V,G523Q,G523T,G523A,G523M,G523S,G523C,G523I,G523L,I527M,I527V,Y528N,Y528W,Y528M,Y528Q,Y528K,Y528V,Y528I,Y528G,Y528D,Y528A,Y528E,Y528R,Y543C,Y543W,Y543I,Y543M,Y543Q,Y543A,Y543R,Y543H,E549K,E549C,E549I,E549Q,E549A,E549H,E549C,E549M,E549S,E549F,E549L,K550R,K550M,K550Q,S556G,S556V,S5 56I,P557W,P557T,P557S,P557A,P557Q,P557K,P557D,P557G,P557N,P557L,P557V,H559 K,H559S,H559C,H559I,H559W,V560F,V560P,V560I,V560H,V560Y,V560K,N561P,N561Q, N561G,N561A,V562Y,V562I,V562S,V562M,V567I,V567H,V567N,S583M,E601V,E601F,E60 1Q,E601W,E605R,E605W,E605K,E605M,E605P,E605Y,E605C,E605H,E605A,E605Q,E605S ,E605V,E605I,E605G,D607V,D607Y,D607C,D607N,D607W,D607T,D607A,D607H,D607Q,D 607E, D607L, D607K, D607G, S609R, S609W, S609H, S609V, S609Q, S609G, S609T, S609K, S609N, S609Y, L610T, L610I, L610K, L610G, L610A, L610W, L610D, L610Q, L610S, L610F or L610N. ,
[0095] A favorable piggyBac-like transposon for modifying the genome of a mammalian cell is a piggyBat transposon, which comprises an ITR having a sequence of SEQ ID NO: 1016, a heterologous polynucleotide to be transposed, and a second ITR having a sequence of SEQ ID NO: 1017. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence has at least 95% identity to SEQ ID NO: 1018 on one side (preferably the left side) of the heterologous polynucleotide, and a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence has at least 95% identity to SEQ ID NO: 1019 on the other side (preferably the right side) of the heterologous polynucleotide. The transposon may be transposed by a corresponding piggyBat transposase, which comprises a sequence at least 90% identical to SEQ ID NO: 1046. Preferably, the transposase is a hyperactive variant of a naturally occurring transposase. Preferably, the overactive variant transposase comprises one or more of the following amino acid changes relative to the sequence of SEQ ID NO: 1046: A14V, D475G, P491Q, A561T, T546T, T300A, T294A, A520T, G239S, S5P, S8F, S54N, D9N, D9G, 1345V, M481V, EI lG, K130T, G9G, R427H, S8P, S36G, D10G, S36G.
[0096] A favorable piggyBac-like transposon for modifying the genome of a mammalian cell is a piggyBac transposon comprising an ITR having a sequence of SEQ ID NO: 1014, a heterologous polynucleotide to be transposed, and a second ITR having a sequence of SEQ ID NO: 1015. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence has at least 95% identity to SEQ ID NO: 1012 on one side (preferably the left side) of the heterologous polynucleotide, and a sequence immediately adjacent to the ITR and proximal to the heterologous polynucleotide, which sequence has at least 95% identity to SEQ ID NO: 1013 on the other side (preferably the right side) of the heterologous polynucleotide. The transposon may be transposed by a corresponding piggyBac transposase comprising a sequence at least 90% identical to SEQ ID NO: 1047. Preferably, the transposase is a hyperactive variant of a naturally occurring transposase. Preferably, the overactive variant transposase comprises one or more of the following amino acid changes relative to the sequence of SEQ ID NO: 1047: G2C, Q40R, I30V, G165S, T43A, S61R, S103P, S103T, M194V, R281G, M282V, G316E, I426V, Q497L, N505D, Q573L, S509G, N570S, N538K, Q591P, Q591R, F594L, M194V, I30V, S103P, G165S, M282V, S509G, N538K,N571S,C41T,A1424G,C1472A,G1681A,T150C,A351G,A279G,T1638C,A898G,A880G,G1558A,A687G,G715A,T13C ,C23T,G161A,G25A,T1050C,A1356G,A26G,A1033G,A1441G,A32G,A389C,A32G,A389C,A32G,T1572A,G456A,T1641C,Tl 155C,G1280A,T22C,A106G,A29G,C137T,A14V,D475G,P491Q,A561T,T546T,T300A,T294A,A520T,G239S,S5P,S8F,S54N,D9N,D9G,1345 V,M481V,E1lG,K130T,G9G,R427H,S8P,S36G,Dl0G,S36G,A51T,C153A,C277T,G201A,G202A,T236A,A103T,A104C,T140C,G138T,T118A,C74T,A179C,S3N,I30V,A46S,A46T,I82W,S103P,R119P,C125A,C125L ,G165S,Y177K,Y177H,F180L,F180I,F180V,M185L,A187G,F200W,V207 P,V209F,M226F,L235R,V240K,F241L,P243K,N258S,M282Q,L296W,L29 6Y,L296F,M298V,M298A,M298L,P311V,P311I,R315K,T319G,Y327R,Y3 28V,C340G,C340L,D421H,V436I,M456Y,L470F,S486K,M503I,M503L,V552K,A570T,Q591P,Q591R,R65A,R65E,R95A,R95E,R97A,R97E,R135A,R135E,R161A,R161E,R192A,R192E,R208A,R208E,K176A,K176E,K195A,K195E,S171E,M14V,D270N,I30V,G165S,M282L,M282I,M282V or M282A. ,
[0097] An advantageous piggyBac-like transposon for modifying the genome of cultured mammalian cells is an Amyelois transposon comprising an ITR having a sequence of SEQ ID NO: 1022, a heterologous polynucleotide, and a second ITR having a sequence of SEQ ID NO: 1023. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITRs and distal to the heterologous polynucleotide. The transposon may further comprise a sequence at least 95% identical to SEQ ID NO: 1020 on one side of the heterologous polynucleotide, and a sequence at least 95% identical to SEQ ID NO: 1021 on the other side of the heterologous polynucleotide. The transposon may be transposed by a corresponding Amyelois transposase comprising a sequence at least 90% identical to SEQ ID NO: 1105. Preferably, the transposase is an overactive variant of a naturally occurring transposase. Preferably, relative to SEQ ID The sequence of NO:1105, the overactive variant transposase comprises one or more of the following amino acid changes: P65E, P65D, R95S, R95T, V100I, V100L, V100M, L115D, L115E, E116P, H121Q, H121N, K139E, K139D, T159N, T159Q, V166F, V166Y,V166W,G179N,G179Q,W187F,W187Y,P198R,P198K,L203R,L203K,I209L,I 209V,I209M,N211R,N211K,E238D,L273I,L273V,L273M,D304K,D304R,I323L,I3 23M,I323V,Q329G,Q329R,Q329K,T345L,T345I,T345V,T345M,K362R,T366R,T36 6K,T380S,L408M,L408I,L408V,E413S,E413T,S416E,S416D,I426M,I426L,I426 V,S435G,L458M,L458I,L458V,A472S,A472T,V475I,V475L,V475M,N483K,N483R ,I491M,I491V,I491L,A529P,K540R,S560K,S560R,T562K,T562R,S563K,S563R.
[0098] An advantageous piggyBac-like transposon for modifying the genome of cultured mammalian cells is a Heliothis transposon comprising an ITR having a sequence of SEQ ID NO: 1026, a heterologous polynucleotide, and a second ITR having a sequence of SEQ ID NO: 1027. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence at least 95% identical to SEQ ID NO: 1024 on one side of the heterologous polynucleotide, and a sequence at least 95% identical to SEQ ID NO: 1025 on the other side of the heterologous polynucleotide. The transposon may be transposed by a corresponding Heliothis transposase comprising a sequence at least 90% identical to SEQ ID NO: 1106. Preferably, the transposase is an overactive variant of a naturally occurring transposase. Preferably, relative to SEQ ID NO: 1106, the transposase may be a heterologous polynucleotide having a sequence at least 95% identical to SEQ ID NO: 1106. Preferably, the transposase is ... The sequence of ID NO: 1106, the hyperactive variant transposase comprises one or more of the following amino acid changes: S41V, S41I, S41L, L43S, L43T, V81E, V81D, D83S, D83T, V85L, V85I, V85M, P125S, P125T, Q126S, Q126T, Q131R, Q131K, Q131T, Q131S, S136V, S136I, S136L, S136M, E140C, E140A, N151Q, K169E, K169D, N212S, I239L, I239V, I239M, H241N, H241Q, T2 68D, T268E, T297C, M300R, M300K, M305N, M305Q, L312I, C316A, C316M, L321V, L321M, N322T, N322S, P351G, H357R, H357K, H357D, H357E, K360Q, K360N, E379P, K397S, K397T, Y421F, Y421W, V450I, V450L, V450M, Y495F, Y495W, A447N, A447D, A449S, A449V, K476L, V492A, I500M, L585K, and T595K.
[0099] An advantageous piggyBac-like transposon for modifying the genome of cultured mammalian cells is an Oryzias transposon comprising an ITR having a sequence of SEQ ID NO: 1030, a heterologous polynucleotide and a second ITR having a sequence of SEQ ID NO: 1031. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence at least 95% identical to SEQ ID NO: 1028 on one side of the heterologous polynucleotide and a sequence at least 95% identical to SEQ ID NO: 1029 on the other side of the heterologous polynucleotide. The transposon may be transposed by a corresponding Oryzias transposase comprising a sequence at least 90% identical to SEQ ID NO: 1107. Preferably, the transposase is an overactive variant of a naturally occurring transposase. Preferably, relative to SEQ ID NO: 1031, the transposase may be a polynucleotide having a sequence at least 95% identical to SEQ ID NO: 1107. Preferably, the transposase is ... The sequence of NO:1107, the hyperactive variant transposase comprises one or more of the following amino acid changes: E22D, A124C, Q131D, Q131E, L138V, L138I, L138M, D160E, Y164F, Y164W, I167L, I167V, I167M, T202R, T202K, I206L, I206V, I206M, I210L, I210V, I210M, N214D, N214E, V253I, V253L, V253M, V258L, V258I, V258M, A284 L, A284I, A284M, A284V, V386I, V386M, V386L, M400L, M400I, M400V, S408E, S408D, L409I, L409V, L409M, V458L, V458M, V458I, V467I, V467M, V467L, L468I, L468V, L468M, A514R, A514K, V515I, V515M, V515L, R548K, D549K, D549R, D550R, D550K, S551K and S551R.
[0100] An advantageous piggyBac-like transposon for modifying the genome of a cultured mammalian cell is an Agrotis transposon comprising an ITR having a sequence of SEQ ID NO: 1036, a heterologous polynucleotide, and a second ITR having a sequence of SEQ ID NO: 1037. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence at least 95% identical to SEQ ID NO: 1034 on one side of the heterologous polynucleotide, and a sequence at least 95% identical to SEQ ID NO: 1035 on the other side of the heterologous polynucleotide. The transposon may be transposed by a corresponding Agrotis transposase comprising a sequence at least 90% identical to SEQ ID NO: 1108. Preferably, the transposase is a hyperactive variant of a naturally occurring transposase.
[0101] An advantageous piggyBac-like transposon for modifying the genome of cultured mammalian cells is a Helicoverpa transposon comprising an ITR having a sequence of SEQ ID NO: 1040, a heterologous polynucleotide and a second ITR having a sequence of SEQ ID NO: 1041. The transposon may further be flanked by copies of the tetranucleotide 5'-TTAA-3', immediately adjacent to the ITR and distal to the heterologous polynucleotide. The transposon may further comprise a sequence at least 95% identical to SEQ ID NO: 1038 on one side of the heterologous polynucleotide, and a sequence at least 95% identical to SEQ ID NO: 1039 on the other side of the heterologous polynucleotide. The transposon may be transposed by a corresponding Helicoverpa transposase comprising a sequence at least 90% identical to SEQ ID NO: 1109. Preferably, the transposase is an overactive variant of a naturally occurring transposase.
[0102] An advantageous Mariner transposon for modifying the genome of a mammalian cell is a Sleeping Beauty transposon, for example comprising an ITR having the sequence of SEQ ID NO: 1044, a heterologous polynucleotide and a second ITR having the sequence of SEQ ID NO: 1045. An advantageous Mariner transposon for modifying the genome of a mammalian cell comprises a first transposon end having at least 90% sequence identity to SEQ ID NO: 1042 and a second transposon end having at least 90% sequence identity to SEQ ID NO: 1043. The transposon can be transposed by a corresponding Sleeping Beauty transposase comprising a sequence at least 90% identical to SEQ ID NO: 1048, including hyperactive variants thereof.
[0103] An advantageous hAT transposon for modifying the genome of a mammalian cell is a TcBuster transposon, for example a transposon comprising an ITR having the sequence of SEQ ID NO: 1112, a heterologous polynucleotide, and a second ITR having the sequence of SEQ ID NO: 1113. An advantageous hAT transposon for modifying the genome of a mammalian cell comprises a first transposon end having at least 90% sequence identity to SEQ ID NO: 1110 and a second transposon end having at least 90% sequence identity to SEQ ID NO: 1111. The transposon can be transposed by a corresponding TcBuster transposase comprising a sequence at least 90% identical to SEQ ID NO: 1114, including hyperactive variants thereof.
[0104] The transposase protein can be introduced into the cell as a protein or a nucleic acid encoding the transposase, for example as a ribonucleic acid, including mRNA or any polynucleotide recognized by the cell translation mechanism; as DNA, for example as extrachromosomal DNA, including free DNA; as plasmid DNA, or as a viral nucleic acid. In addition, the nucleic acid encoding the transposase protein can be transfected into the cell as a nucleic acid vector such as a plasmid, or as a gene expression vector (including a viral vector). The nucleic acid can be circular or linear. The DNA encoding the transposase protein can be stably inserted into the genome of the cell or a vector for constitutive or inducible expression. In the case where the transposase protein is transfected into the cell or inserted into the vector as DNA, the transposase coding sequence is preferably operably connected to a heterologous promoter. A variety of promoters can be used, including constitutive promoters, tissue-specific promoters, inducible promoters, species-specific promoters, cell type-specific promoters, etc. All DNA or RNA sequences encoding transposase proteins are particularly contemplated. Alternatively, the transposase can be introduced directly into cells as a protein, for example using cell-penetrating peptides (as described in Ramsey and Flynn, 2015. Pharmacol. Ther. 154: 78-86 "Cell-penetrating peptides transport therapeutics into cells"); using small molecules, including salt plus propane betaine (as described in Astolfo et.al., 2015. Cell 161: 674-690); or electroporation (as described in Morgan and Day, 1995. Methods in Molecular Biology 48: 63-71 "The introduction of proteins into mammalian cells by electroporation").
[0105] 5.2.3 Promoter Elements
[0106] The gene transfer system for expressing polypeptides in cultured mammalian cells includes a polynucleotide to be transferred to the host cell. The polynucleotide includes a promoter active in cultured mammalian cells and is operably linked to the heterologous sequence to be expressed. Advantageous gene transfer polynucleotides for expressing amiRNA in mammalian cells include PolII promoters, such as the EF1a promoter from any mammalian or avian species, including human, rat, mouse, chicken, and Chinese hamster, (e.g., a sequence selected from SEQ ID NOS: 894-915); the promoter of the immediate early gene 1, 2, or 3 from human, primate, or rodent cytomegalovirus (CMV) (e.g., a sequence selected from SEQ ID NOS: 916-927); the promoter of the eukaryotic elongation factor 2 (EEF2) from any mammalian or avian species, including human, rat, mouse, chicken, and Chinese hamster, (e.g., a sequence selected from SEQ ID NOS: 928-938); the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter from any mammalian or yeast species (e.g., a sequence selected from SEQ ID NOS: 949-965), the actin promoter from any mammalian or avian species, including human, rat, mouse, chicken, and Chinese hamster (e.g., a sequence selected from SEQ ID NOS: 950-951); 939-948); PGK promoter from any mammalian or avian species, including human, rat, mouse, chicken and Chinese hamster (e.g., a sequence selected from SEQ ID NOS: 966-974 or 1188), or a ubiquitin promoter (e.g., SEQ ID NO: 975), or a viral promoter, such as an HSV-TK promoter or an SV40 promoter operably linked to a multiple hairpin amiRNA sequence (e.g., a sequence selected from SEQ ID NOS: 976-982). Alternatively, the multiple hairpin amiRNA sequence can be operably linked to a Pol III promoter such as a U6 promoter (e.g., a sequence selected from SEQ ID NOS: 987-991) or an H1 promoter (e.g., SEQ ID NO: 992).
[0107] 5.2.4 MicroRNA Elements
[0108] Small inhibitory RNA (siRNA) has been used to reduce the activity of certain genes in mammalian cultured cells by RNA interference. siRNA can be expressed in cells by a nucleic acid encoding a short hairpin RNA (shRNA) that is operably linked to a promoter naturally transcribed by RNA polymerase III ("Pol III promoter"). Naturally occurring shRNA can also be expressed from a nucleic acid operably linked to a promoter naturally transcribed by RNA polymerase II ("Pol II promoter"). The Pol II promoter is generally responsible for the transcription of most protein-coding genes. The product of the shRNA gene that is expressible by natural Pol II is called microRNA (miRNA).
[0109] Expression of targeted shRNA in mammalian cells can be achieved by engineering natural miRNAs, replacing the natural guide strand sequence with a sequence complementary to the target mRNA whose expression is to be reduced, thereby creating artificial miRNAs (amiRNAs) such as the miR-30 microRNA (Zenget. al., 2002. Both Natural and Designed Micro RNAs Technique Can Inhibit the Expression of Cognate mRNAs When Expressed in Human Cells. Molecular Cell: 9, 1327–1333).
[0110] Reduction of gene expression in mammalian cells can be achieved by RNA interference using amiRNAs. Success is often limited due to the limited efficacy of any single inhibitory RNA. Strategies that have been described to improve the efficacy of RNA interference include incorporating mismatches into intramolecular RNA duplexes (Wu et al., 2011. Improved siRNA / shRNA Functionality by Mismatched Duplex. PLoS ONE 6(12): e28580. doi: 10.1371 / journal.pone.0028580; Myburgh et al., 2014. Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. Molecular Therapy-Nucleic Acids 3, e207; doi: 10.1038 / mtna.2014.58), inserting spacers within amiRNA genes between the Pol II promoter and the amiRNA hairpin sequence (Rousset et al., 2019. Optimizing Synthetic miRNA Minigene Architecture for Efficient miRNA Hairpin Concatenation and Multi-target Gene Knockdown. Molecular Therapy-Nucleic Acids 14, 351-363.), and tandem of amiRNA hairpins within amiRNA genes (Sun et al., 2006. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. BioTechniques 41: 59-63 doi 10.2144 / 000112203).
[0111] Although amiRNA genes including multiple copies of the same hairpin have been shown to be more effective than amiRNA genes with only a single hairpin copy, even with three identical hairpins in a single lentiviral vector, it is difficult to reduce the expression of the target gene to less than 10% of the normal level (Sun et al., 2006ibid, Rousset et al., 2019ibid). Another application of genes including multiple amiRNA hairpins is to inhibit multiple genes at the same time (Hu et al., 2009. Construction of an Artificial MicroRNA Expression Vector for Simultaneous Inhibition of Multiple Genes in Mammalian Cells. Int. J. Mol. Sci. 10, 2158-2168; Choi et al, 2015. Mol. Ther. 23, 310-320. "Multiplexing Seven miRNA-Based shRNAs to Suppress HIV Replication").
[0112] We designed amiRNA genes including multiple different hairpins, instead of using multiple identical inhibitory RNAs derived from multiple identical hairpins to target a sequence in a target mRNA, each hairpin is used to express different inhibitory RNA guide chains complementary to different regions in the same target mRNA. Since the guide chain sequences derived from each hairpin are directed to different regions of the gene, they are essentially independent. In addition, if multiple hairpins are included in the same RNA transcript, hairpin processing can be improved to produce RISC-related guide chains. In addition, the use of multiple independent guide chains reduces the risk of unwanted off-target effects because it is not necessary to express any individual guide chain at extremely high levels. Therefore, it is advantageous to use a polynucleotide including two, three, four, five or more hairpins, which will be expressed in mammalian cells to produce two, three, four, five or more different inhibitory RNA guide chains, each of which is complementary to different sequences in the same target mRNA. When multiple hairpins for expressing inhibitory RNA guide chains are operably connected to the same promoter, we refer to them as multi-hairpin amiRNA genes. Preferably, when integrated into the genome of a mammalian cell, the multi-hairpin amiRNA gene reduces the expression of the target gene to below the expression level of the target gene in the mammalian cell, the mammalian cell genome comprising an amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand. Preferably, when integrated into the genome of a mammalian cell population, the multi-hairpin amiRNA gene reduces the average expression level of the target gene in the population to below the expression level of the target gene in the mammalian cell population, the genome of the population comprising an amiRNA gene comprising a hairpin for expressing a single hairpin inhibitory RNA guide strand. Preferably, when integrated into the genome of a mammalian cell population, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 50% of the natural level, and its proportion in the population is greater than the proportion in the population whose expression is reduced to less than 50% in the mammalian cell population, the genome of the mammalian cell population comprising an amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand. Preferably, when integrated into the genome of a population of mammalian cells, the multi-hairpin amiRNA gene reduces expression of the target gene to less than 40% of the natural level, and its proportion in the population is greater than the proportion in the population in which expression is reduced to less than 40% in a population of mammalian cells, wherein the genome of the population of mammalian cells includes the amiRNA gene, which comprises a hairpin for expressing a single inhibitory RNA guide strand.Preferably, when integrated into the genome of a population of mammalian cells, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 30% of the natural level, and its proportion in the population is greater than the proportion in the population in which the expression is reduced to less than 30% in the population of mammalian cells, the genome of which includes the amiRNA gene, the amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand. Preferably, when integrated into the genome of a population of mammalian cells, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 20% of the natural level, and its proportion in the population is greater than the proportion in the population in which the expression is reduced to less than 20% in the population of mammalian cells, the genome of which includes the amiRNA gene, the amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand. Preferably, when integrated into the genome of a population of mammalian cells, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 10% of the natural level, and its proportion in the population is greater than the proportion in the population in which the expression is reduced to less than 10% in the population of mammalian cells, the genome of which includes the amiRNA gene, the amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand. Preferably, when integrated into the genome of a population of mammalian cells, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 5% of the natural level, and its proportion in the population is greater than the proportion in the population in which the expression is reduced to less than 5% in the population of mammalian cells, the genome of which includes the amiRNA gene, the amiRNA gene comprising a hairpin for expressing a single inhibitory RNA guide strand.
[0113] Preferably, when integrated into the genome of a mammalian cell, the multi-hairpin amiRNA gene reduces the expression of the target gene to less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the natural expression level of the target gene. This reduction in expression can be directly detected as a reduction in mRNA levels or protein levels, but can also be detected as a corresponding reduction in the function or activity responsible for the target gene. For example, if the product of the target gene is an intracellular protein, preferably, when integrated into the genome of a mammalian cell, the multi-hairpin amiRNA gene reduces the activity of the intracellular target gene product to less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the natural activity of the intracellular target gene product. If the product of the target gene is an extracellular protein, preferably, when integrated into the genome of a mammalian cell, the multi-hairpin amiRNA gene reduces the activity of the target gene product secreted by the cell to less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the natural activity of the target gene product secreted from the cell. If the product of the target gene is a transmembrane protein, such as a receptor protein with a signaling function, preferably, when integrated into the genome of a mammalian cell, the multi-hairpin amiRNA gene reduces the signal transduction of the target gene product to less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the natural signal transduction of the target gene product. If the normal expression of the target gene results in the modification of the product produced by the mammalian cell, when the multi-hairpin amiRNA gene is integrated into the genome of the mammalian cell, the expression of the target gene is preferably reduced so that less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the product made by the mammalian cell is modified by the action of the target gene product. If normal expression of the target gene results in an altered product produced by a mammalian cell, when the multi-hairpin amiRNA gene is integrated into the genome of the mammalian cell, the expression of the target gene is preferably reduced so that the degree of product modification caused by the expression of the target gene is reduced to less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the degree to which the product would be modified in the absence of the multi-hairpin amiRNA gene. Product modification includes proteolytic cleavage, glycosylation, or other post-translational modification of proteins produced by mammalian cells.
[0114] The guide strand sequence of amiRNA comprises 19, 20, 21 or 22 bases complementary to the mRNA of the target gene. The guide strand sequence can be complementary to any part of the mRNA, preferably complementary to the 3'UTR of the mRNA, the 5'UTR of the mRNA or the coding region of the mRNA. Preferably, the 5' base of the guide strand sequence is thymine (T). The passenger strand sequence of amiRNA is complementary to the guide strand sequence. If the passenger strand sequence is not completely complementary to the guide strand sequence, the appropriate processing of amiRNA is generally favorable. If the passenger strand sequence is mismatched at a base complementary to the 5' base of the guide strand sequence, processing is generally improved. Figure 1A -B shows a general schematic diagram of an exemplary amiRNA hairpin. Preferably, the passenger strand sequence is at the 5' base ( Figure 1A -B contains a mismatch with the guide strand sequence at the base N1). If the 5' base of the guide strand sequence is adenine (A) or thymine (T), the passenger strand sequence preferably contains a cytosine (C) at the corresponding complementary position ( Figure 1A -B). If the 5' base of the guide strand sequence is cytosine (C) or guanine (G), the passenger strand sequence preferably contains an adenine (A) at the corresponding complementary position. One, two or three additional mismatches can be incorporated into the passenger strand sequence as mismatched bases, insertions or deletions. The most favorable mismatches occur in the passenger strand sequence at positions 9, 10, 11, 12 or 13 ( Figure 1A -Bases N9, N in B 10 、N 11 、N 12 and N 13 ) produces a mismatch at one or more corresponding positions that are complementary to each other. Most preferably, the passenger strand sequence has a base at position 12 corresponding to the guide strand sequence ( Figure 1A -Base N' in B 12 ) contains mismatches. The guide and passenger strand sequences of amiRNAs usually consist of 5 to 35 nucleotides ( Figure 1A -Base L1-L in B Z ). Preferably, the loop comprises a sequence derived from a naturally occurring miRNA, such as a sequence selected from SEQ ID NOs: 683-692.
[0115] Preferred gene transfer polynucleotides ("inhibitory polynucleotides") for inhibiting target genes include multi-hairpin amiRNA genes, which contain at least two different amiRNA hairpin sequences, whose guide strand sequences are different and each is complementary to a different sequence in the same target mRNA. The multi-hairpin amiRNA gene includes a first (guide strand) sequence of at least 19, 20, 21 or 22 consecutive bases complementary to the target mRNA and a first (passenger strand) sequence of at least 19, 20, 21 or 22 bases that are at least 78% identical to the reverse complementary sequence of the first guide strand sequence (i.e., within 19 bases, it contains no more than 4 mismatches, including mutations, single base deletions or single base insertions relative to the same reverse complementary sequence of the first guide strand sequence). The first guide strand sequence and the first passenger strand sequence are separated by 5 to 35 bases. The first guide strand sequence, the first passenger strand sequence, and the sequence separating them are collectively referred to as the first hairpin. The multi-hairpin amiRNA gene further includes a second (guide chain) sequence of at least 19, 20, 21 or 22 consecutive bases complementary to the target mRNA and a second (passenger chain) sequence of at least 19, 20, 21 or 22 bases that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence (i.e., within 19 bases, it contains no more than 4 mismatches, including mutations, single base deletions or single base insertions relative to the same reverse complementary sequence of the second guide chain sequence). The second guide chain sequence and the second passenger chain sequence are separated by 5 to 35 bases. The second guide chain sequence, the second passenger chain sequence, and the sequence separating them are collectively referred to as the second hairpin. The first and second guide chain sequences are different from each other but are complementary to the same target mRNA.
[0116] The multi-hairpin amiRNA gene further includes a third guide chain sequence of at least 19, 20, 21 or 22 consecutive bases complementary to the target mRNA and a third passenger chain sequence of at least 19, 20, 21 or 22 bases that are at least 78% identical to the reverse complementary sequence of the third guide chain sequence (i.e., within 19 bases, relative to the same reverse complementary sequence of the third guide chain sequence, it contains no more than 4 mismatches, including mutations, single base deletions or single base insertions). The third guide chain sequence and the third passenger chain sequence are separated by 5 to 35 bases. The third guide chain sequence, the third passenger chain sequence, and the sequence separating them are collectively referred to as the third hairpin. The first, second, and third guide chain sequences are each complementary to different regions of the same target mRNA.
[0117] The multi-hairpin amiRNA gene further includes a promoter active in mammalian cells, preferably transcribed by RNA polymerase II or RNA polymerase III. Each hairpin is operably linked to the promoter. Preferably, the promoter is heterologous to the hairpin. If the promoter is transcribed by RNA polymerase II, it is advantageous for the inhibitory polynucleotide to further include a spacer polynucleotide operably linked to the promoter: the amiRNA hairpin can be placed in the 3'UTR of the spacer polynucleotide, or they can be placed in an intron transcribed by the Pol II promoter. The spacer polynucleotide may include an open reading frame encoding an expressible polypeptide, or it may include a sequence that does not encode an expressible polypeptide. Preferably, the spacer polynucleotide includes 50 to 3,000 nucleotides, more preferably the spacer includes 100 to 1,500 nucleotides. Alternatively, the spacer includes an open reading frame to be expressed in mammalian cells, such as a chimeric antigen receptor or a selection marker. Example spacer polynucleotide sequences are given in SEQ ID NO: 723-724.
[0118] Each hairpin can include sequences in addition to the guide and passenger strand sequences to enhance the stem-loop structure of the transcribed RNA to increase the chances of processing the guide strand and loading it into the RISC complex. Figure 2A -B shows a schematic diagram of an exemplary multi-hairpin amiRNA gene. Short sequences (between 5 and 20 bases) can be added to the 5' and 3' of the guide-loop-passenger hairpin to stabilize it and improve the processing of RNA loading into the RISC complex. These Figure 2A -B is shown as elements A and E stabilizing hairpin 1 and elements G and K stabilizing hairpin 2. For example, a short sequence having SEQ ID NO: 697 can be added to the 5' side of the guide-loop-passenger hairpin sequence, and a short sequence having SEQ ID NO: 698 can be added to the 3' side of the guide-loop-passenger hairpin sequence to enhance RNA hairpin formation. Alternative exemplary stem stabilizing sequence pairs that can be added to the 5' and 3' of the guide-loop-passenger strand sequence, respectively, to enhance RNA hairpin formation are SEQ ID NOs: 699 and 700, SEQ ID NOs: 701 and 702, SEQ ID NOs: 703 and 704, SEQ ID NOs: 705 and 706, SEQ ID NOs: 709 and 710, SEQ ID NOs: 711 and 712, SEQ ID NOs: 713 and 714, or an additional stem having the sequence 5'-GTAGCAC-3' at 5' and an additional stem having the sequence 5'-TACTGC-3' at 3'. These stem sequences are derived from sequences flanking the guide-loop-passenger hairpin portion of the miRNA sequence in naturally occurring miRNAs. Corresponding sequences from other miRNAs may also be used. Figure 1A-B, although most of the exemplary sequences given herein have the guide strand sequence before the passenger strand sequence, the order can be 5'-guide-loop-passenger-3', or it can be 5'-passenger-loop-guide-3'. The sequences loaded into the RISC complex are not determined by the order in which they appear. "Guide-loop-passenger" is intended to mean a sequence that includes these three elements in a 5'-guide-loop-passenger-3' or 5'-passenger-loop-guide-3' structure.
[0119] In a polynucleotide comprising multiple hairpins it is advantageous to provide some separation between the hairpins to improve RNA processing (see e.g. Figure 2A -element F in B). The sequence separating the hairpins should be relatively unstructured. Exemplary unstructured sequences between the hairpins that can be incorporated into the inhibitory polynucleotide include those given in SEQ ID NOs: 715-722.
[0120] It is advantageous to provide some unstructured sequence 5' to the first hairpin in the inhibitory polynucleotide. Exemplary unstructured sequences that can be incorporated 5' to the first hairpin of the inhibitory polynucleotide include the sequences given in SEQ ID NOs:693-694. It is advantageous to provide some unstructured sequence 3' to the last hairpin of the inhibitory polynucleotide. Exemplary unstructured sequences that can be incorporated 3' to the last hairpin of the inhibitory polynucleotide include the sequences given in SEQ ID NOs:695-696.
[0121] Although some sequence elements of artificial miRNAs are derived from naturally occurring miRNAs, the combination of the guide, loop, and passenger strand sequences in each artificial miRNA of the present invention, or the combination of the guide, loop, and passenger strand sequences and the 5' and 3' hairpin stabilizing sequences in each artificial miRNA of the present invention, are not naturally occurring miRNA sequences.
[0122] Figure 2A -B shows an exemplary general structure of a multi-hairpin amiRNA gene. It includes (i) a promoter operably linked to (ii) a spacer sequence, preferably 50 to 3,000 nucleotides; (iii) an unstructured sequence, optionally from the 5' region of a naturally occurring miRNA; (iv) a first hairpin comprising (a) a first 5' stem sequence ( Figure 2A -B, element A), which may alternatively be derived from the 5' stem of a naturally occurring miRNA (but preferably is not a guide or passenger strand sequence); (b) a first guide (or passenger) strand sequence ( Figure 2A -B, element B); (c) first loop sequence ( Figure 2A-B, element C); (d) a first passenger (if the sequence in (b) is a guide strand sequence) or a guide (if the sequence in (b) is a passenger strand sequence) strand sequence ( Figure 2A -B, element D); (e) first 3' stem sequence ( Figure 2A -B, element E), which can optionally be derived from the 3' stem of a naturally occurring miRNA (but preferably is not a guide or passenger strand sequence), and wherein the first 5' stem sequence and the first 3' stem sequence increase the stability of the hairpin formed by the first guide strand sequence and the first passenger strand sequence; (v) the optional unstructured sequence separates the first hairpin from the second hairpin ( Figure 2A -B, element F); (vi) comprising (f) a second 5' stem sequence ( Figure 2A -B, element G) a second hairpin, which may alternatively be derived from the 5' stem of a naturally occurring miRNA (but preferably is not a guide or passenger strand sequence); (g) a second guide (or passenger) strand sequence ( Figure 2A -B, element H); (h) second loop sequence ( Figure 2A -B, element I); (j) a second passenger (if the sequence in (g) is a guide strand sequence) or a guide (if the sequence in (g) is a passenger strand sequence) strand sequence ( Figure 2A -B, element J); (k) second 3' stem sequence ( Figure 2A -B, element K), which can optionally be derived from the 3' stem of a naturally occurring miRNA (but preferably not the guide strand or passenger strand sequence), and wherein the second 5' stem sequence and the second 3' stem sequence increase the stability of the hairpin formed by the second guide strand sequence and the second passenger strand sequence; and wherein the first guide strand sequence and the second guide strand sequence are complementary to the same target mRNA expressed by a mammalian endogenous cell gene, and the first and second guide strand sequences are different from each other.
[0123] The inhibitory polynucleotide can be incorporated into cultured mammalian cells, or on a transient vector, on a viral vector, such as an adenovirus-associated virus vector (AAV vector), on a lentiviral vector, or on a vector that is integrated into the cell genome by a random integration process. The copy number of the inhibitory gene transfer polynucleotide including the multi-hairpin amiRNA gene can be increased by incorporating it into a transposon and then inserting multiple copies of the transposon into the genome of the mammalian cell using the corresponding transposase, and the multi-hairpin amiRNA gene is integrated into the genome of the cultured mammalian cell. As described in Section 5.2.2, the advantageous inhibitory gene transfer polynucleotide includes two transposon ends.
[0124] By introducing a transposon and a corresponding transposase (as described in Section 5.2.2) into a eukaryotic cell, a gene transfer inhibitory polynucleotide comprising a multiple hairpin amiRNA gene (with transposon ends on both sides) can be stably integrated into the genome of the eukaryotic cell as a transposase protein or as a polynucleotide encoding a transposase. Alternatively, the gene transfer inhibitory polynucleotide may also include a selection marker, which can be used to identify cells whose genomes include gene transfer inhibitory polynucleotides and multiple hairpin amiRNA genes. Phenotypic tests can also be performed on these cells to determine the extent to which target mRNA expression is reduced. In some cases, the inhibition of the target mRNA may result in a selectable phenotype.
[0125] Although it is preferred to combine two or more amiRNA hairpins to express guides complementary to the same target mRNA into a single polynucleotide, two or more amiRNA guides complementary to different target sites of the same target mRNA can be expressed by using two separate inhibitory gene transfer polynucleotides instead, provided that both polynucleotides are integrated into the genome of the cultured mammalian cells. Preferably, the inhibitory gene transfer polynucleotide comprises a transposon end or a lentiviral repeat sequence. It is also an aspect of the present invention to culture mammalian cells whose genome comprises a first and a second amiRNA hairpin, wherein the first and second guide strand sequences are complementary to the first and second target sites of the same mRNA, and wherein the first and second guide strand sequences are different from each other. Preferably, the expression level of the target gene encoding the mRNA is reduced to a level lower than the expression level of the target gene in a cultured mammalian control cell whose genome comprises only the first or second amiRNA hairpin.
[0126] Genome includes the cell of inhibitory polynucleotide, and described inhibitory polynucleotide includes multiple hairpin amiRNA, and the activity of the gene encoded by target mRNA in this cell may be permanently reduced or eliminated. Then such cell is useful and valuable for producing molecule, and these molecules can be modified due to the direct or indirect effect of target mRNA in addition. Such produced molecule may include protein, sugar, metabolite and other cell products. The mammalian cell phenotype that can be modified by inhibitory polynucleotide includes glycosylation of protein, intracellular transport of protein, proteolytic cleavage of protein, the demand of specific nutrition for cell growth and the ability of cell to survive under various conditions. The immune cell phenotype that can be modified by suppressing gene transfer polynucleotide includes the proliferation, survival, life span, anergy and exhaustion of immune cell.
[0127] 5.2.5 Insulator components
[0128] When a heterologous polynucleotide is integrated into the genome of a mammalian cell, it is generally necessary to prevent the genetic elements within the heterologous polynucleotide from affecting the expression of endogenous immune cell genes. Similarly, it is generally necessary to prevent the genes in the heterologous polynucleotide from being affected by elements in the immune cell genome, such as being silenced by incorporation into heterochromatin. Insulator elements are known to have enhancer blocking activity (helping to prevent genes in heterologous polynucleotides from affecting the expression of endogenous immune cell genes) and barrier activity (helping to prevent genes in heterologous polynucleotides from being silenced by incorporation into heterochromatin). Enhancer blocking activity can be produced by the binding of the transcriptional repressor CTCF protein. Barrier activity can be caused by the binding of vertebrate barrier proteins such as USF1 and VEZF1. Useful insulator sequences include binding sites for CTCF, USF1 or VEZF1. Advantageous gene transfer systems include polynucleotides that include insulator sequences containing binding sites for CTCF, USF1 or VEZF1. More preferably, the gene transfer system comprises a polynucleotide containing two insulator sequences, each of which comprises a binding site for CTCF, USF1 or VEZF1, wherein the two insulator sequences flank any promoter or enhancer within the heterologous polynucleotide. Advantageous examples of insulator sequences are given in SEQ ID NOs: 993-999.
[0129] If a heterologous polynucleotide including a promoter or enhancer is integrated into the genome of a mammalian cell without an insulator sequence, there is a risk that the promoter or enhancer element within the heterologous polynucleotide will affect the expression of endogenous immune cell genes (e.g., oncogenes), or that the promoter or enhancer element within the heterologous polynucleotide will be silenced by incorporation into heterochromatin. When a heterologous polynucleotide is integrated into the target genome after random fragmentation, some genetic elements are usually lost, while others may be rearranged. Therefore, if a heterologous polynucleotide contains an insulator element flanking enhancer and promoter elements, the insulator element may be rearranged or lost, and the enhancer and promoter elements may be able to affect and be affected by the genomic environment in which they are integrated. It is therefore advantageous to use a transposon gene transfer system in which the entire sequence between the two transposon ITRs is integrated into the immune cell genome without rearrangement. Therefore, an advantageous gene transfer system for integration into the immune cell genome includes a transposon in which the elements are arranged in the following order: left transposon end; first insulator sequence; sequence for expression in immune cells; second insulator sequence; right transposon end. Sequences for expression in immune cells can include any number of regulatory sequences operably linked to any number of open reading frames.
[0130] 5.2.6 Chimeric Antigen Receptor Elements
[0131] Chimeric antigen receptors (CARs) consist of an (extracellular) antigen-binding domain, a transmembrane domain, and one or more (intracellular) co-stimulatory / signaling regions.
[0132] The antigen binding domain can be derived from a single chain variable fragment (scFv) that specifically recognizes an antigen. scFv is usually derived from the variable domains of the heavy and light chains of an antibody or T cell receptor.
[0133] The transmembrane domain may be derived from a transmembrane protein. Examples include CD8, CD28, inducible T cell co-stimulator (ICOS), DNAX accessory molecule 1 (DNAM-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), signaling lymphocyte activation molecule 1 (SLAM)-1, T cell immunoglobulin mucin domain 1 (TIM-1), interferon receptors such as interferon receptor A1 or A2, members of the tumor necrosis factor receptor superfamily such as TNFRSF4 (OX40), TNFRSF5 (CD40), TNFRSF5 (CD27), TNFRSF11A (RANK), TNFR SF13B (CD267), TNFRSF9 (4-1BB), TNFRSF13C (CD268), TNFRSF14 (CD270), TNFRSF17 (CD269), TNFRSF18 (GITR), TNFRSF3 (CD18), TNFRSF6 (Fas), TNFRSF8 (CD30), TNFRSF10A (death receptor 4), TNFRSF10B (death receptor 5), TNFRSF19 (TROY), TNFRSF21 (DR6), and TNFRSF25 (DR3). Exemplary transmembrane domain sequences are given in SEQ ID NOs: 1124-1150.
[0134] The intracellular domain can include a sequence from an intracellular domain of a protein that has a stimulatory effect on T cells. Examples include CD28, inducible T cell co-stimulator (ICOS), members of the tumor necrosis factor receptor superfamily, such as TNFRSF4 (OX40), TNFRSF5 (CD40), TNFRSF11A (RANK), TNFRSF13B (CD267), TNFRSF9 (4-1BB), TNFRSF13C (CD268), TNFRSF14 (CD270), TNFRSF17 (CD269), TNFRSF18 (GITR), DNAX auxiliary molecule 1 (DNAM-1), signal lymphocyte activation molecule 1 (SLAM-1), T cell immunoglobulin mucin domain 1 (TIM-1) and CD3 zeta domain. Exemplary stimulatory domain sequences are given in SEQ ID NOs: 1151-1172.
[0135] 5.2.7 Selection of Target Cells Comprising Gene Transfer Polynucleotides
[0136] If the gene transfer polynucleotide includes a gene encoding a selectable marker, target cells whose genomes include a stably integrated gene transfer polynucleotide can be identified by exposing the target cells to conditions that favor cells expressing the selectable marker ("selective conditions"). Thus, it may be advantageous for the gene transfer polynucleotide to include a gene encoding a selectable marker.
[0137] One type of selectable marker that can be advantageously incorporated into the gene transfer polynucleotide is one that provides a growth advantage to cells by allowing them to survive in the presence of deleterious substances such as antibiotics, enzyme inhibitors or cytotoxic agents [e.g., neomycin (resistance conferred by aminoglycoside 3'-phosphotransferases, such as polypeptides having a sequence selected from the group consisting of SEQ ID NOs: 878-881), puromycin (resistance conferred by puromycin acetyltransferases, such as polypeptides having a sequence selected from the group consisting of SEQ ID NOs: 884-886), blasticidin (resistance conferred by blasticidin acetyltransferase and blasticidin deaminase, such as polypeptides having a sequence given by SEQ ID NO: 887), hygromycin B (resistance conferred by hygromycin B phosphotransferase, such as polypeptides having a sequence selected from the group consisting of SEQ ID NOs: 882-883), and zeocin (resistance conferred by a binding protein encoded by a ble gene, such as a polypeptide having a sequence given by SEQ ID NO: 875)].
[0138] Another type of selection marker that can be advantageously incorporated into the gene transfer polynucleotide is those selection markers that provide growth advantages to cells by allowing cells to anabolize useful substances. An example of such a selection marker is glutamine synthetase (GS, for example a polypeptide having a sequence selected from SEQ ID NOs: 888-892), which allows selection by glutamine metabolism. Glutamine synthetase is an enzyme responsible for the biosynthesis of glutamine from glutamate and ammonia, and it is an important component of the only pathway for glutamine formation in mammalian cells. In the absence of glutamine in the growth medium, the GS enzyme is essential for the survival of cultured mammalian cells. Certain cell lines, such as mouse myeloma cells, cannot express enough GS enzyme to survive without the addition of glutamine. In these cells, the transfected GS gene can act as a selection marker by allowing growth in a medium without glutamine. In other cell lines, for example, Chinese hamster ovary (CHO) cells express enough GS enzyme to survive without exogenous addition of glutamine. These cell lines can be manipulated by genome editing techniques including CRISPR / Cas9 to reduce or eliminate the activity of the GS enzyme. In all of these cases, a GS inhibitor such as methionine sulfoximine (MSX) can be used to inhibit the endogenous GS activity of the cells. The selection protocol includes introducing a gene transfer polynucleotide comprising a sequence encoding a first polypeptide and a glutamine synthase selection marker, and then treating the cells with a glutamine synthase inhibitor such as methionine sulfoximine. The higher the level of methionine sulfoximine used, the higher the level of glutamine synthetase expression required in order for the cells to synthesize enough glutamine to survive. Some of these cells will also show increased expression of the first polypeptide.
[0139] Preferably, the GS gene is operably linked to a weak promoter or other sequence element that attenuates expression as described herein, so that high-level expression occurs only when multiple copies of the gene transfer polynucleotide are present, or they are integrated into the genome at a location where high-level expression occurs. In this case, it may not be necessary to use the inhibitor methionine sulfoximine: if expression of glutamine synthetase is attenuated, then simply synthesizing enough glutamine for cell survival may provide sufficiently stringent selection.
[0140] Another example of a selectable marker gene that can be advantageously incorporated into a gene transfer polynucleotide to provide a growth advantage to a cell by allowing the cell to anabolize useful substances is a gene encoding a dihydrofolate reductase (DHFR, such as a polypeptide having a sequence selected from SEQ ID NO: 876-877), which is necessary for catalyzing the reduction of 5,6-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF). Some cell lines do not express enough DHFR to survive if hypoxanthine and thymidine (HT) are not added. In these cells, the transfected DHFR gene can act as a selectable marker by allowing growth in a culture medium without hypoxanthine and thymidine. DHFR-deficient cell lines, such as Chinese hamster ovary (CHO) cells, can be generated by genome editing techniques including CRISPR / Cas9 to reduce or eliminate the activity of endogenous DHRF enzymes. DHFR confers resistance to methotrexate (MTX). DHFR can be inhibited by higher levels of methotrexate. The selection scheme comprises that the construct comprising the sequence of the first polypeptide of coding and DHFR selection marker is introduced into the cell with or without endogenous DHFR gene, and then uses DHFR inhibitor for example methotrexate treatment cell.The higher the methotrexate level used, the higher the DHFR expression level required for cell synthesis to survive.Some of these cells will also show that the expression of the first polypeptide increases.Preferably, the DHFR gene is operably connected with weak promoter or other sequence elements that weaken expression as mentioned above, so that only when multiple copies of gene transfer polynucleotide exist, or when they are integrated into the position where high level expression occurs in the genome, high level expression will occur.
[0141] Another type of selectable marker includes those marks that can be then selected by visual detection, but they do not provide any intrinsic growth advantage for cells.Examples include fluorescence or chromogenic proteins (genes such as encoding GFP, RFP, etc.), such as flow cytometry can be used to select.Other selectable markers that do not provide any intrinsic growth advantage for cells include genes encoding transmembrane proteins, which can be combined with second molecules (proteins or small molecules), and this molecule can be fluorescently labeled, thereby flow cytometry can be used to select the presence of transmembrane proteins.Other selectable markers that do not provide any intrinsic growth advantage for cells include genes encoding luciferase.
[0142] High levels of expression can be obtained from genes encoded on gene transfer polynucleotides that are integrated in genomic regions with high transcriptional activity, or integrated into the genome in multiple copies, or present in multiple copies outside the chromosome. It is often advantageous to operably link the gene encoding the selectable marker to expression control elements that result in low-level expression of the selected polypeptide from the gene transfer polynucleotide and / or to use conditions that provide more stringent selection. Under these conditions, in order for the expressing cell to produce sufficient levels of the selectable polypeptide encoded on the gene transfer polynucleotide to survive under the selection conditions, the gene transfer polynucleotide must be present in a favorable position in the cell genome that is conducive to high-level expression, or a sufficiently high number of gene transfer polynucleotides must be present so that these factors compensate for the low expression levels that can be achieved due to the expression control elements.
[0143] The genomic integration of transposon, wherein the selective marker is operably connected to the regulatory element of only weak expression marker, usually requires the transposon to be inserted into the target genome by transposase. By operably connecting the selective marker to the element causing weak expression, select to comprise multiple transposon copies or wherein the transposon is integrated in a favorable genome position to achieve high expression of the cell. Using a gene transfer system comprising a transposon and a corresponding transposase increases the possibility of producing a cell with multiple transposon copies, or wherein the transposon is integrated in a favorable genome position to carry out high expression of the possibility. When the transposon comprises a selective marker operably connected to a weak promoter, the gene transfer system comprising a transposon and a corresponding transposase is therefore particularly advantageous.
[0144] The gene to be expressed from the gene transfer polynucleotide can be included as a selectable marker on the same gene transfer polynucleotide, with the two genes operably linked to different promoters. In this case, low expression levels of the selectable marker can be achieved by using a weakly active constitutive promoter such as the phosphoglycerol kinase (PGK) promoter (e.g., a promoter selected from SEQ ID NOS: 966-974 or 1188), the herpes simplex virus thymidine kinase (HSV-TK) promoter (e.g., SEQ ID NO: 977), the MC1 promoter (e.g., SEQ ID NO: 978), the ubiquitin promoter (e.g., SEQ ID NO: 975). Other weakly active promoters can be intentionally constructed, for example, by truncating a promoter that is attenuated, such as the truncated promoter from Simian Virus 40 (SV40) (e.g., SEQ ID NOs: 979-980), or the truncated HSV-TK promoter (e.g., SEQ ID NOs: 976 or 982).
[0145] The expression of the selection marker can also be reduced by making the mRNA unstable, for example, by incorporating an amiRNA hairpin into the 3'UTR of the selection marker. Inserting multiple miRNA hairpins into the 3'UTR of the GFP gene may reduce the expression of GFP, even if the miRNA does not target GFP (Sun et al., 2006. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. BioTechniques 41: 59-63 doi10.2144 / 000112203). This may be because miRNA processing removes stable 3'UTR structures, such as the polyA tail of a gene. Therefore, by inserting the miRNA hairpin sequence into the 3'UTR of the gene encoding the selection marker, the expression level of the selection marker can be advantageously reduced, thereby increasing the productivity of other genes encoded on the gene transfer polynucleotide. An example is shown in sections 6.1.2.1 and 6.1.2.2, in which the inclusion of an amiRNA hairpin in the 3'UTR of a gene encoding a metabolic enzyme increases the yield of another gene encoded on the same gene transfer polynucleotide. Compared with including a single amiRNA hairpin, including 2 or 3 amiRNA hairpins results in significantly higher expression levels of other genes encoded on the gene transfer polynucleotide. Two and three hairpins are also more effective in suppressing their target genes. Advantageous gene transfer polynucleotides include genes encoding a selectable marker operably connected to a Pol II promoter, and further comprise the first and second amiRNA hairpins in the 3'UTR of the selectable marker. Preferably, the first amiRNA hairpin includes a first guide chain sequence of at least 19, 20, 21 or 22 continuous bases complementary to the mRNA target, and the second amiRNA hairpin includes a second guide chain sequence of at least 19, 20, 21 or 22 continuous bases complementary to a different sequence in the same mRNA target as the first guide chain sequence. Preferably, the first guide chain sequence is different from the second guide chain sequence. Alternatively, the gene transfer polynucleotide comprises a third amiRNA hairpin in the 3'UTR of the selection marker, wherein the third amiRNA hairpin comprises a third guide strand sequence of at least 19, 20, 21 or 22 consecutive bases complementary to a different sequence within the same mRNA target, and wherein the third guide strand sequence is different from the first and second guide strand sequences. Preferably, the selection marker provides a growth advantage to the cell, for example by allowing the cell to synthesize useful substances, or survive in the presence of harmful substances such as antibiotics, enzyme inhibitors or cytotoxic substances.Preferably, the selectable marker is other than a fluorescent protein, a chromogenic protein, or a protein that catalyzes a fluorescent or chromogenic reaction and does not directly benefit the cell.
[0146] Advantageous selection marker genes include an open reading frame encoding a polypeptide having a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 875-892, the open reading frame being operably linked to a weak promoter, such as a sequence selected from SEQ ID NOs: 966-982. Optionally, there is an attenuated 5'UTR between the promoter and the glutamine synthetase open reading frame, such as a sequence selected from SEQ ID NOs: 983-986. The 3'UTR of the selection marker gene includes a multiple hairpin amiRNA sequence between the open reading frame and the polyadenylation sequence. Preferably, the selection marker gene is part of a transposon and can be transposed by a corresponding transposase.
[0147] Compared with non-transposon structure, transposon and transposase are used in combination with weakly expressed selective markers to have some advantages. One is that the expression of selective marker and the connection between other genes on transposon are very high, because transposase can integrate the whole sequence between two transposon ends into the genome. On the contrary, when heterologous DNA is introduced into the nucleus of eukaryotic cells (such as mammalian cells), it will gradually decompose into random fragments, which may be integrated into the genome of the cell or degraded. Therefore, if the gene transfer polynucleotide including sequence to be expressed and selective marker is introduced into cell group, some cells will integrate the sequence of encoding selective marker, but do not integrate the sequence of encoding other sequences to be expressed, and vice versa. In these cases, the cell of selecting to express high-level selective marker has certain correlation only with the cell that also expresses high-level other genes to be expressed. On the contrary, because transposase has integrated all sequences between transposon ends, the cell expressing high-level selective marker is also very likely to express high-level other genes to be expressed.
[0148] A second advantage of transposons and transposases is that they are more efficient at integrating DNA sequences into the genome. Thus, a higher portion of the cell population is likely to have one or more copies of the gene transfer polynucleotide integrated into their genome, so the likelihood that both the selection marker and the first polypeptide are well expressed is correspondingly higher.
[0149] The third advantage of piggyBac-like transposons and transposases is that piggyBac-like transposases tend to insert their corresponding transposons into transcriptionally active chromatin. Therefore, each cell is likely to integrate the gene transfer polynucleotide into a region of the genome where genes are well expressed, so the probability that both the selection marker and the first polypeptide are well expressed is correspondingly higher.
[0150] 5.3 MicroRNAs for Inhibiting Fucosylation of Secreted Proteins
[0151] Fucosylation of antibodies inhibits antibody-dependent cell-mediated cytotoxicity (ADCC). Therefore, attempts have been made to use RNA interference to reduce core fucosylation in cultured mammalian cells, including by targeting fucosyltransferase 8 (FUT8), which catalyzes the transfer of α1,6-linked fucose to the first N-acetylglucosamine in N-linked glycans. Mori et al. identified two siRNAs against FUT8 that resulted in 60% of secreted antibodies being defucosylated, compared to only 10% in the absence of siRNA (Mori et al., 2004. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng. 88: 901-8.). Beuger et al. identified a shRNA targeting FUT8 that produced up to 88% of defucosylated antibodies (Beuger et al., 2009. Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. Biotechnol Appl Biochem. 53: 31-7). U.S. Patents 6946292, 7737325, 7749753, 7846725 and 8003781 describe strategies for inhibiting one or more genes in the fucosylation pathway, including GDP-mannose 4,6-dehydratase (GMD), α-(1,6)-fucosyltransferase and GDP-fucose transporter 1 (GFT) using RNA interference.Imai-Nishiya et al. designed a pair of siRNA molecules targeting FUT8 and GDP-mannose 4,6-dehydratase (GMD). If fucose is not present in the culture medium, this pair of siRNA molecules can completely eliminate fucosylation (Imai-Nishiya et al., 2007. Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnology 2007, 7: 84). However, the presence of fucose impairs the synergistic effect of knocking out these two genes. Natural microRNAs targeting FUT8 have also been identified, including miR-122 and miR-34a (Bernardi C. et.al., 2013. Effects of MicroRNAs on Fucosyltransferase 8 (FUT8) Expression in Hepatocarcinoma Cells. PLoS ONE 8(10):e76540. https: / / doi.org / 10.1371 / journal.pone.0076540), although the effects of these microRNAs were modest.
[0152] In many of the RNA interference examples given above, cells with high levels of defucosylation were selected by treating the cells with a fucose-specific lectin (e.g., Lensculinaris lectin), which kills cells with fucosylated surface molecules. This is because any single siRNA sequence is less than 100% effective, and when a gene expressing siRNA is introduced into cells, variations in expression levels can lead to significant differences between cells. To overcome these limitations, we designed multi-hairpin amiRNA genes that included one, two, or three guide strand sequences that were complementary to different sequences within the same mRNA target (the mRNA of FUT8). We also used a piggyBac-like transposon vector to ensure that the amiRNA genes were integrated into transcriptionally active regions of the genome.
[0153] The examples described in Section 6.1.1 (including Sections 6.1.1.1, 6.1.1.2, and 6.1.1.3) show that integration of a transposon comprising multiple hairpin amiRNAs having a guide strand sequence complementary to the 3'UTR of CHO FUT8 into the CHO genome results in cells producing antibodies completely lacking fucose (detected by highly sensitive mass spectrometry). In contrast to previously reported methods, no subsequent lectin-based selection is required to kill cells that are still producing fucosylated proteins. Cells are selected only for integration of transposons comprising multiple hairpin amiRNA genes into the genome. By combining the effectiveness of multiple guide strand sequences for multiple different sequences within the same target mRNA, the integration of transposons into the mammalian genome is catalyzed by an efficient transposase, resulting in elimination of detectable target enzyme expression in the entire cell population without the need for further selection steps. Each of the multiple hairpin amiRNA sequences used in these embodiments includes a first guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a first passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. Each multiple hairpin amiRNA sequence further includes a second guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a second passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. Each multi-hairpin amiRNA sequence further comprises a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is 5 to 35 bases away from its respective passenger strand sequence. For multi-hairpin amiRNA SEQ ID NOs 724 and 726, each guide strand sequence is separated from its respective passenger strand sequence by a sequence comprising SEQ ID NO: 683. For multi-hairpin amiRNA SEQ ID NO 727, each guide strand sequence is separated from its respective passenger strand sequence by a sequence comprising SEQ ID NO: 684.
[0154] The advantageous gene transfer polynucleotide for inhibiting fucosylation of hamster cells includes a multi-hairpin amiRNA sequence that inhibits FUT8. The FUT8 inhibitory multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The FUT8 inhibitory multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The FUT8 inhibitory multi-hairpin amiRNA sequence can optionally include a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 1, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. An exemplary sequence for separating the guide strand sequence from its passenger strand sequence is a sequence selected from the sequence SEQ ID NO: 683-692. Exemplary guide strand sequences and their respective passenger strand sequences for inhibiting hamster FUT8 are SEQ ID NOs: 75 and 379, SEQ ID NOs: 76 and 380, SEQ ID NOs: 77 and 381, SEQ ID NOs: 78 and 382, SEQ ID NOs: 79 and SEQ ID NOs: 383, and 80 and 384.
[0155] The advantageous gene transfer polynucleotide for inhibiting fucosylation of hamster cells includes a multi-hairpin amiRNA sequence that inhibits GMD. The GMD-inhibiting multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 3, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The GMD-inhibiting multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 3, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The GMD inhibitory multi-hairpin amiRNA sequence can optionally include a third guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 3, and a third passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. Exemplary sequences for separating the guide chain sequence from its passenger chain sequence are sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide chain sequences for inhibiting hamster GMD and their respective passenger chain sequences are SEQ ID NOs: 87 and 391, SEQ ID NOs: 88 and 392, SEQ ID NOs: 89 and 393, SEQ ID NOs: 90 and 394, SEQ ID NOs: 91 and 395, and SEQ ID NOs: 92 and 396.
[0156] The advantageous gene transfer polynucleotide for inhibiting fucosylation in hamster cells includes a multi-hairpin amiRNA sequence that inhibits GFT. The GFT-inhibiting multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 5, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The GFT-inhibiting multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 5, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The GFT-inhibiting multiple hairpin amiRNA sequence optionally includes a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO:5, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. An exemplary sequence for separating a guide strand sequence from its passenger strand sequence is a sequence comprising a sequence selected from the group consisting of SEQ ID NOs:683-692. Exemplary guide strand sequences for inhibiting hamster GFT and their respective passenger strand sequences are SEQ ID NOs:93 and 397, SEQ ID NOs:94 and 398, SEQ ID NOs:95 and 399, SEQ ID NOs:96 and 400, SEQ ID NOs:97 and 401, and SEQ ID NOs:98 and 402.
[0157] Advantageous inhibitory polynucleotides for inhibiting hamster cell fucosylation include a first guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to a native mammalian cell mRNA, and a first passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the first guide chain sequence, wherein the first guide chain and the first passenger chain sequences are separated by 5 to 35 nucleotides, and a second guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to the native mammalian cell mRNA identical to the first guide chain sequence, and a second passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the second guide chain sequence, wherein the second guide chain and the second passenger chain sequences are separated by 5 to 35 nucleotides, and wherein the first and second guide chain sequences are different from each other, and wherein the native mammalian cell mRNA comprises a sequence that is at least 98% identical, or at least 99% identical, or completely identical to a sequence selected from SEQ ID NOs: 1-6. Exemplary multi-hairpin amiRNAs for inhibiting fucosylation in hamster cells include SEQ ID NOs: 725-733.
[0158] The gene transfer polynucleotides for inhibiting fucosylation in human cells include a multi-hairpin amiRNA sequence that inhibits FUT8. The FUT8 inhibitory multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19 or 20 or 21 or 22 nucleotide sequence complementary to SEQ ID NO: 7, and a first passenger chain sequence containing a continuous 19 or 20 or 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The FUT8 inhibitory multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19 or 20 or 21 or 22 nucleotide sequence complementary to SEQ ID NO: 7, and a second passenger chain sequence containing a continuous 19 or 20 or 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The FUT8 inhibitory multi-hairpin amiRNA sequence can optionally include a third guide strand sequence comprising a continuous 19 or 20 or 21 or 22 nucleotide sequence complementary to SEQ ID NO: 7, and a third passenger strand sequence comprising a continuous 19 or 20 or 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. Exemplary sequences for separating the guide strand sequence from its passenger strand sequence are sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide strand sequences for inhibiting human FUT8 and their respective passenger strand sequences are SEQ ID NOs: 81 and 385, SEQ ID NOs: 82 and 386, SEQ ID NOs: 83 and 387, SEQ ID NOs: 84 and 388, SEQ ID NOs: 85 and 389, and SEQ ID NOs: 86 and 390.
[0159] Advantageous gene transfer polynucleotides for inhibiting fucosylation in human cells include multi-hairpin amiRNA sequences that inhibit GMD. The GMD-inhibiting multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 8, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The GMD-inhibiting multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 8, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The GMD inhibitory multi-hairpin amiRNA sequence can optionally include a third guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 8, and a third passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. Exemplary sequences for separating the guide chain sequence from its passenger chain sequence are sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide chain sequences for inhibiting hamster GMD and their respective passenger chain sequences are SEQ ID NOs: 99 and 403, SEQ ID NOs: 100 and 404, and SEQ ID NOs: 101 and 405.
[0160] The advantageous gene transfer polynucleotide for inhibiting fucosylation in hamster cells includes a multi-hairpin amiRNA sequence that inhibits GFT. The GFT-inhibiting multi-hairpin amiRNA sequence includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 9, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The GFT-inhibiting multi-hairpin amiRNA sequence further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 9, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The GFT-inhibiting multi-hairpin amiRNA sequence can optionally include a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 9, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. Exemplary sequences for separating the guide strand sequence from its passenger strand sequence are sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide strand sequences for inhibiting hamster GFT and their respective passenger strand sequences are SEQ ID NOs: 102 and 406, SEQ ID NOs: 103 and 407, and SEQ ID NOs: 104 and 408.
[0161] Advantageous inhibitory polynucleotides for inhibiting human cell fucosylation include a first guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to a natural mammalian cell mRNA, and a first passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the first guide chain sequence, wherein the first guide chain and the first passenger chain sequences are separated by 5 to 35 nucleotides, and a second guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to the same natural mammalian cell mRNA as the first guide chain sequence, and a second passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the second guide chain sequence, wherein the second guide chain and the second passenger chain sequences are separated by 5 to 35 nucleotides, and wherein the first and second guide chain sequences are different from each other, and wherein the natural mammalian cell mRNA comprises a sequence that is at least 98% identical, or at least 99% identical, or completely identical to a sequence selected from SEQ ID NOs: 7-9. Exemplary multi-hairpin amiRNAs for inhibiting fucosylation in human cells include SEQ ID NOs: 734-736.
[0162] 5.4 MicroRNAs for regulating intracellular trafficking of secretory proteins
[0163] There are several pathways for trafficking proteins to lysosomes. When cultured mammalian cells are used to heterologously produce a protein that is normally delivered to lysosomes, trafficking the heterologous protein to lysosomes competes with its secretion and also risks clogging the lysosomes and compromising the health (and productivity) of the cultured mammalian cells. Two proteins that have been shown to be involved in trafficking proteins to lysosomes are sortilin and prosaposin. Inhibiting the expression of these two proteins by multi-hairpin amiRNAs can modulate protein trafficking to lysosomes.
[0164] Advantageous gene transfer polynucleotides for regulating intracellular protein trafficking in hamster cells include a multi-hairpin amiRNA sequence that inhibits prosaposin. The multi-hairpin amiRNA sequence that inhibits prosaposin includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 10, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits prosaposin further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is complementary to SEQ ID NO: 10, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting prosaposin includes a third guide chain sequence that can optionally contain a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 10, and a third passenger chain sequence that contains a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. Exemplary sequences for separating the guide chain sequence from its passenger chain sequence include sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide chain sequences for inhibiting hamster prosaposin and their respective passenger chain sequences are SEQ ID NOs: 105 and 409, SEQ ID NOs: 106 and 410, and SEQ ID NOs: 107 and 411.
[0165] Advantageous gene transfer polynucleotides for regulating intracellular protein trafficking in hamster cells include multi-hairpin amiRNA sequences that inhibit sortilin. The multi-hairpin amiRNA sequence that inhibits sortilin includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 11, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits sortilin further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is complementary to SEQ ID NO: 11, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting sortilin can optionally include a third guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 11, and a third passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. Exemplary sequences for separating the guide chain sequence from its passenger chain sequence are sequences selected from the sequence SEQ ID NO: 683-692. Exemplary guide chain sequences for inhibiting hamster sortilin and their respective passenger chain sequences are SEQ ID NOs: 108 and 412, SEQ ID NOs: 109 and 413, and SEQ ID NOs: 110 and 414.
[0166] Advantageous inhibitory polynucleotides for regulating protein trafficking in hamster cells include a first guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to a native mammalian cell mRNA, and a first passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the first guide chain sequence, wherein the first guide chain and the first passenger chain sequences are separated by 5 to 35 nucleotides, and a second guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is completely complementary to the same native mammalian cell mRNA as the first guide chain sequence, and a second passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% complementary to the second guide chain sequence, wherein the second guide chain and the second passenger chain sequences are separated by 5 to 35 nucleotides, and wherein the first and second guide chain sequences are different from each other, and wherein the native mammalian cell mRNA comprises a sequence that is at least 98% identical, or at least 99% identical, or completely identical to a sequence selected from SEQ ID NOs: 10 and 11. Exemplary multi-hairpin amiRNAs for regulating intracellular protein trafficking in hamster cells include sequences selected from SEQ ID NOs: 737-739.
[0167] 5.5 MicroRNAs for regulating proteolytic cleavage of secreted proteins
[0168] Mammalian cultured cells produce a variety of proteases. Some of these may adversely affect heterologous proteins produced by cells. Examples of proteases produced by Chinese hamster cells include carboxypeptidases, such as those having mRNA sequences that are at least 98% identical, or at least 99% identical, or identical to the sequences given in SEQ ID NOs: 12-20.
[0169] The advantageous gene transfer polynucleotide for reducing the proteolytic processing of heterologously produced proteins in hamster cells comprises a multi-hairpin amiRNA sequence that inhibits carboxypeptidase. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase comprises a first guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to a sequence selected from SEQ ID NO: 12-20, and a first passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase further comprises a second guide chain sequence, the second guide chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to the same mRNA as the first guide chain sequence, and a second passenger chain sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase can optionally include a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to the mRNA identical to the first and second guide strand sequences, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complement of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases.
[0170] Carboxypeptidase D has been identified as being responsible for removing C-terminal lysine from antibody heavy chains (Hu et al, 2016. Biotechnol. Bioeng. 113, 2100-6 "Carboxypeptidase D is the Only Enzyme Responsible for Antibody C-Terminal Lysine Cleavage in Chinese Hamster Ovary (CHO) Cells"). Advantageous gene transfer polynucleotides for inhibiting carboxypeptidase D in hamster cells include a multi-hairpin amiRNA sequence that inhibits carboxypeptidase D. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase D includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 17, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase D further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 17, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence that inhibits carboxypeptidase D can optionally include a third guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 17, and a third passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. An exemplary sequence for separating a guide chain sequence from its passenger chain sequence is a sequence selected from the sequence SEQ ID NO: 683-692. Exemplary guide strand sequences and their respective passenger strand sequences for inhibiting hamster carboxypeptidase D are SEQ ID NOs: 111 and 415, SEQ ID NOs: 112 and 416, SEQ ID NOs: 113 and 417, SEQ ID NOs: 1173 and 1174, SEQ ID NOs: 1175 and 1176, SEQ ID NOs: 1177 and 1178. Exemplary multi-hairpin amiRNAs for inhibiting carboxypeptidase D in hamster cells include SEQ ID NOs: 740 and 1179.
[0171] 5.6 Glutamine synthetase
[0172] Destroying the natural mammalian genes that usually provide cells with proteins necessary for growth, division or survival, such as genes encoding essential metabolic enzymes, can provide opportunities for developing metabolic selection systems. Some exemplary metabolic selection systems are described in Section 5.2.7. Typically, this is achieved by permanently and irreversibly destroying genes encoding essential metabolic enzymes, which can use targeted destruction methods (such as zinc finger nucleases, TALE effector nucleases, CRISPR Cas9 directed nucleases and AAV directed nucleases) or random methods, such as radiation or other random mutagenesis cells, and then identifying cells in which the genes encoding essential metabolic enzymes are destroyed. If an enzyme, growth factor, nutrient or other molecule is provided exogenously to compensate for the lack of the missing essential metabolic enzyme product, the cells in which the expression of essential metabolic genes is destroyed can survive, grow and divide in the absence of the essential gene. Then, the cells in which the expression of basic metabolic genes has been destroyed can be used as hosts for subsequently introducing expression polynucleotides, and the expression polynucleotides include selectable markers, whose function is to supplement or compensate for the lack of basic metabolic gene functions, and one or more other genes to be expressed in cells. These cells are then placed under conditions of removing enzymes, growth factors, nutrients or other molecules that allow cell growth. Only cells that have taken up the expression polynucleotide comprising the gene encoding the complementary selectable marker will survive.Previously described examples include CRISPR disruption of the glutamine synthetase gene in human cultured cells (Yu et al, 2018. Biotechnol Bioeng. 115:1367-1372. “Glutamine synthetase gene knockout-human embryonic kidney 293E cells for stable production of monoclonal antibodies.”), zinc finger disruption of glutamine synthetase in CHO cells (Fane et al 2012. Biotechnol Bioeng. 109:1007-15. “Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.”), zinc finger disruption of the DHFR gene in mammalian cells (Santiago et al 2008. Proc Natl Acad Sci US A. 105:5809–5814. “Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases”), and deletion of DHFR in CHO cells by irradiation (Urlaub et al. 2014. al, 1983. Cell. 33: 405-12. "Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells.").
[0173] Permanent disruption of gene sequences is a method previously used to inhibit expression of essential metabolic enzymes because, in order to provide the appropriate selection pressure, expression of the essential metabolic enzyme must be reduced to below the level that allows cell growth. There must also be no "leakage": if some cells are able to recover expression of the essential metabolic enzyme, they will grow in the absence of the expression polynucleotide containing the complementary selection marker, which will create a background of cells that do not express the gene encoded on the expression polynucleotide. RNA interference is generally not efficient enough at inhibiting expression of essential metabolic genes, nor is it stable enough to ensure sustained inhibition of expression of essential metabolic genes. However, the benefits of the RNA interference approach are that it can be performed very rapidly and that it can inhibit all copies of a gene in a diploid or polyploid cell simultaneously without having to independently determine that each genomic copy has been inactivated by mutation. Furthermore, as shown in the examples in Section 6.1.3, a method comprising introducing a multi-hairpin amiRNA gene to inhibit an essential metabolic gene into the genome of a cell pool, and selecting cells whose genomes contain the multi-hairpin amiRNA gene, can result in a cell pool in which the expression of essential metabolic enzymes is inhibited to a level that prevents the growth of more than 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the cells in the pool. This is in contrast to directed cleavage methods such as zinc finger nucleases, TAL effector nucleases (TALENs), CRISPR / Cas9 nucleases or AAV. These methods are considered effective if they can mutate and inactivate the target gene in 1% to 10% of the transfected cells. Therefore, the multi-hairpin amiRNA method is at least 10 times more efficient than these nuclease-based gene disruption technologies.
[0174] The multi-hair clip amiRNA gene can be integrated into the genome of a mammalian cell to suppress a natural mammalian gene, which usually provides cells with proteins necessary for growth (including survival and division). The multi-hair clip amiRNA can be placed in the 3'UTR of a second gene for intracellular expression. Preferably, the gene encodes an essential metabolic enzyme so that the cell cannot grow without the essential gene unless enzymes, growth factors, nutrients or other molecules are provided exogenously (we refer to this as exogenously provided complement factors). Cells usually store various nutrients in the cell, so if the cell can only divide 1, 2, 3 or 4 times after removing the exogenously provided complement factors, it is considered that the cell will not grow. Therefore, after removing the exogenously provided supplementary factors, the cell population whose expression of essential metabolic enzymes has been successfully suppressed increases its viable cell density by no more than 2 times, 4 times, 8 times or 16 times. Preferably, the expression of essential metabolic enzymes is suppressed so that less than 50%, 40%, 30%, 20%, 10%, 5%, 2% or 1% of the natural enzyme activity is retained in the cell. The example of this protein includes the essential metabolic enzymes participating in amino acid synthesis, the essential metabolic enzymes participating in amino acid precursor synthesis, the essential metabolic enzymes participating in nucleotide synthesis, the essential metabolic enzymes participating in nucleotide precursor synthesis, the essential metabolic enzymes participating in fatty acid synthesis and the essential metabolic enzymes participating in vitamin synthesis. If the multi-hair clip amiRNA gene is stably integrated into the mammalian cell genome, and stably expressed, the essential metabolic enzymes are stably suppressed (there is no second compensatory gene). Then the second gene of the essential metabolic enzyme that is supplemented or compensated is used as a selection marker in mammalian cells. The second gene may encode another version of the suppressed essential metabolic enzyme, and the enzyme is resistant to the suppression of the multi-hair clip amiRNA, for example, by the complementary position between the mRNA of the essential metabolic enzyme and the guide strand sequence encoded by the multi-hair clip amiRNA gene, including the difference of its mRNA sequence. The second gene can encode one or more enzymes alternatively, and these enzymes provide alternative metabolic pathways to provide the essential nutrients missing. Then the second polynucleotide including the second complementary gene can be introduced into mammalian cells, and selection pressure can be applied by withdrawing, immediately or by gradually reducing the enzyme, growth factor, nutrient or other molecules provided by exogenous. Only those cells that have taken up the second polynucleotide and expressed the second gene can survive this selection. The second polynucleotide may include other genes that will also be expressed. Preferably, the second polynucleotide is a transposon or a viral vector. An advantage of this strategy is that withdrawing nutrients is usually a very mild option compared to adding drugs.Drugs commonly used as selection markers often have pleiotropic effects that may have adverse effects on mammalian cells (Lanza et al, 2013; Yallop et al, 2003; Yallop et al, 2001; Flintoff et al, 1982). For example, inhibition of the glutamine synthetase gene using methionine sulfoxide reduces cell growth and increases the production of toxic metabolic wastes lactate and ammonia in CHO cells (Noh et al (2018). Comprehensive characterization of glutamine synthetase-mediated selection for the establishment of recombinant CHO cells producing monoclonal antibodies. Scientific Reports, 8,
[5361] . https: / / doi.org / 10.1038 / s41598-018-23720-9).
[0175] The method of stably introducing a polynucleotide for expression into a mammalian cell comprises (a) introducing a gene transfer suppressor polynucleotide comprising a gene expressible in the mammalian cell, the gene encoding an interfering RNA having a guide strand sequence complementary to the mRNA of an essential metabolic enzyme; (b) growing the cell in the presence of an enzyme, growth factor, nutrient or other exogenous molecule, allowing the cell to survive, grow and divide while inhibiting the expression of the essential metabolic enzyme; (c) introducing a gene comprising (i) encoding a selectable marker expressible in the mammalian cell, wherein the selectable marker functionally complements the mRNA of the essential metabolic enzyme. Lack, and eliminate the need for exogenous provision of enzymes, growth factors, nutrients or other molecules, which enable cells to survive, grow and divide while suppressing the expression of essential metabolic enzymes, and (ii) a second polynucleotide of a second gene that can be expressed in mammalian cells is introduced into the cell; and (d) cells are grown in the absence of exogenously provided enzymes, growth factors, nutrients or other molecules in (b) so that the cells can survive, grow and divide while suppressing the expression of essential metabolic enzymes, so that the survival, growth and division of the cells depend on the expression of a selection marker from the second polynucleotide. Preferably, the first and second polynucleotides are integrated into the mammalian cell genome. The method optionally also includes (e) culturing cells under conditions where the second gene in the second polynucleotide is expressed. Alternatively, the second gene encodes a protein product, and the method further includes (f) collecting or purifying the protein product encoded by the second gene.
[0176] One type of selectable marker that can be advantageously incorporated into a gene transfer polynucleotide is those that provide a growth advantage to a cell by allowing the cell to anabolize useful substances. An example of such a selectable marker is glutamine synthetase (GS, for example a polypeptide sequence selected from SEQ ID NOs: 888-892), which allows selection by glutamine metabolism. Glutamine synthetase is the enzyme responsible for the biosynthesis of glutamine from glutamate and ammonia, and is an important component of the sole pathway for glutamine formation in mammalian cells. Glutamine synthetase is essential for the survival of cultured mammalian cells in the absence of glutamine in the growth medium. Some cell lines, such as mouse myeloma cells, do not express enough glutamine synthetase to survive without the addition of glutamine.
[0177] In some cell lines, such as HEK cells and Chinese hamster ovary (CHO) cells, sufficient glutamine synthetase is expressed to enable the cells to survive without exogenously added glutamine. These cells can be manipulated by genome editing techniques including CRISPR / Cas9 to reduce or eliminate the activity of endogenous glutamine synthetase. However, even with CRISPR, this is a laborious process that may introduce off-target mutations in other genes. Another approach is to stably integrate a polynucleotide including a multi-hairpin amiRNA targeting an endogenous glutamine synthetase gene into the genome of the cell. The exogenously provided glutamine synthetase gene can then be used as a selection marker, provided that the exogenously provided gene does not include the sequence targeted by the guide strand sequence. This can be achieved by altering the codons used to encode glutamine synthetase if the guide targets a sequence in the open reading frame. If the guide targets a sequence within the 5'UTR, this can be achieved by altering the 5'UTR. If the guide targets a sequence in the polyadenylation signal sequence / 3'UTR, this can be achieved by altering the polyadenylation signal in the 3'UTR.
[0178] 5.6.1 Reduction of endogenous glutamine synthetase microRNA
[0179] Advantageous gene transfer polynucleotides for inhibiting glutamine synthetase in hamster cells by RNA interference include multi-hairpin amiRNA sequences that inhibit glutamine synthetase. The multi-hairpin amiRNA sequence that inhibits glutamine synthetase includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 21, and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits glutamine synthetase further includes a second guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 21, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence that inhibits glutamine synthetase can optionally include a third guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 21, and a third passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide chain sequence, and wherein the first, second and third guide chain sequences are different from each other. Each guide chain sequence is separated from its respective passenger chain sequence by 5 to 35 bases. An exemplary sequence for separating a guide chain sequence from its passenger chain sequence is a sequence selected from the sequence SEQ ID NO: 683-692. Exemplary guide strand sequences and their respective passenger strand sequences for inhibiting hamster glutamine synthetase are SEQ ID NOs: 114 and 418, SEQ ID NOs: 115 and 419, SEQ ID NOs: 117 and 421, SEQ ID NOs: 118 and 422, SEQ ID NOs: 119 and 423, SEQ ID NOs: 120 and 424, SEQ ID NOs: 121 and 425, SEQ ID NOs: 122 and 426, SEQ ID NOs: 123 and 427, SEQ ID NOs: 124 and 428, SEQ ID NOs: 125 and 429, SEQ ID NOs: 126 and 430, SEQ ID NOs: 127 and 431, SEQ ID NOs: 128 and 432, SEQ ID NOs: 129 and 433, and SEQ ID NOs: 116 and 420.
[0180] The multi-hairpin amiRNA SEQ ID NO: 741 includes a guide strand sequence complementary to three different sequences within the CHO glutamine synthetase mRNA target (SEQ ID NO: 21). The multi-hairpin amiRNA SEQ ID NO: 741 includes a first guide strand sequence having SEQ ID NO: 114 and a first passenger strand sequence having SEQ ID NO: 418; SEQ ID NO: 741 further includes a second guide strand sequence having SEQ ID NO: 115 and a second passenger strand sequence having SEQ ID NO: 419; SEQ ID NO: 741 further includes a third guide strand sequence having SEQ ID NO: 116 and a third passenger strand sequence having SEQ ID NO: 420. The guide strand sequences SEQ ID NO: 114, SEQ ID NO: 115, and SEQ ID NO: 116 are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by a sequence including SEQ ID NO: 683. Incorporating the multi-hairpin amiRNA into a transposon vector can increase the likelihood that the amiRNA gene is integrated into a transcriptionally active region of the genome. As described in Section 6.1.3, integration of the multi-hairpin amiRNA having SEQ ID NO: 741 into the genome of hamster cells reduces the expression of glutamine synthetase, thereby rendering the cells completely dependent on exogenously supplied glutamine for survival.
[0181] A similar strategy can be used to create a human cell line lacking glutamine synthetase, such as a HEK cell line. A favorable gene transfer polynucleotide for inhibiting glutamine synthetase in human cells by RNA interference comprises a multi-hairpin amiRNA sequence that inhibits glutamine synthetase. The multi-hairpin amiRNA sequence that inhibits glutamine synthetase includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to the mRNA of human glutamine synthetase (e.g., SEQ ID NO: 23), and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complement sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence for inhibiting glutamine synthetase further comprises a second guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to the mRNA of human glutamine synthetase (e.g., SEQ ID NO: 23), a second passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide strand sequence, and wherein the first and second guide strand sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting glutamine synthetase may alternatively comprise a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to the mRNA of human glutamine synthetase (e.g., SEQ ID NO: 23), and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. Exemplary sequences for separating a guide strand sequence from its passenger strand sequence include sequences selected from the group consisting of SEQ ID NOs: 683-692. Exemplary guide strand sequences and their respective passenger strand sequences for inhibiting human glutamine synthetase are SEQ ID NOs: 130 and 434, SEQ ID NOs: 131 and 435, SEQ ID NOs: 132 and 436, SEQ ID NOs: 133 and 437, SEQ ID NOs: 134 and 438, SEQ ID NOs: 135 and 439, SEQ ID NOs: 136 and 440, SEQ ID NOs: 137 and 441, SEQ ID NOs: 138 and 442, SEQ ID NOs: 139 and 443, SEQ ID NOs: 140 and 444, SEQ ID NOs: 141 and 445, and SEQ ID NOs: 142 and 446.
[0182] 5.6.2 Complementation of Glutamine Synthetase Auxotrophy
[0183] In cells lacking a functional glutamine synthetase gene, including cells in which endogenous glutamine synthetase expression is reduced due to RNA interference (e.g., by integrating a multi-hairpin amiRNA gene comprising SEQ ID NO: 741 into the genome of the cell), an exogenously added glutamine synthetase gene can act as a selection marker by allowing growth in a medium without glutamine. Preferably, a gene transfer polynucleotide comprising an exogenous glutamine synthetase gene is introduced into the cell. Preferably, the exogenous glutamine synthetase gene comprises a sequence feature that prevents its expression from being inhibited by any RNA interference that causes a host cell to be auxotrophic for glutamine synthetase. If the RNA interference molecule (including the amiRNA guide strand) is complementary to the coding portion of the endogenous glutamine synthetase, the exogenous gene encoding the glutamine synthetase can avoid inhibition when the coding sequence is altered, such as by silent mutations in the targeted region. If the RNA interference molecule (including the amiRNA guide strand) is complementary to the 3'UTR or 5'UTR portion of endogenous glutamine synthetase, the exogenous gene encoding glutamine synthetase can be prevented from being inhibited by replacing the natural UTR sequence with an alternative sequence, e.g., a synthetic sequence or UTR sequence obtained or adapted from other natural genes.
[0184] The selection scheme involves introducing a gene transfer polynucleotide comprising a sequence encoding a glutamine synthetase selectable marker and then culturing the cells in a medium that does not contain sufficient glutamine to allow the cells to survive in the absence of the exogenous gene encoding glutamine synthetase.
[0185] Preferably, the foreign gene encoding the glutamine synthetase gene is operably linked to a weak promoter or other sequence element that attenuates expression, so that high-level expression occurs only when multiple copies of the gene transfer polynucleotide are present, or if they are integrated into the genome at a location where high-level expression occurs. In this case, it may not be necessary to use a glutamine synthetase inhibitor, such as methionine sulfoximine: if the expression of glutamine synthetase is attenuated, then simply synthesizing enough glutamine for cell survival can provide sufficiently stringent selection. Exemplary glutamine synthetase polypeptide sequences are given as SEQ ID NOs: 888-892.
[0186] 5.7 Dihydrofolate Reductase
[0187] Another example of a selectable marker gene that can be advantageously incorporated into a gene transfer polynucleotide to provide a growth advantage for a cell by allowing the cell to anabolize useful substances is a gene encoding dihydrofolate reductase (DHFR, for example, a polypeptide sequence selected from SEQ ID NO: 876-877), which is necessary for catalyzing the reduction of 5,6-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF). If hypoxanthine and thymidine (HT) are not added, some cell lines will not express enough DHFR to survive. In these cells, the transfected DHFR gene can act as a selection marker by allowing growth in a culture medium without hypoxanthine and thymidine. DHFR confers resistance to methotrexate (MTX). DHFR can be inhibited by higher levels of methotrexate. The selection scheme includes introducing a construct comprising a sequence encoding a DHFR selection marker into a cell with or without an endogenous DHFR gene, and then treating the cell with a DHFR inhibitor such as methotrexate. The higher the level of methotrexate used, the higher the level of DHFR expression required for the cells to synthesize enough DHFR to survive. Preferably, the DHFR gene is operably linked to a weak promoter or other sequence element that attenuates expression as described above, so that high-level expression will only occur if multiple copies of the gene transfer polynucleotide are present, or if they are integrated into the genome at a location where high-level expression occurs.
[0188] Preferably, the DHFR gene is operably linked to a weak promoter or other sequence element that attenuates expression as described herein, so that high-level expression occurs only when multiple copies of the gene transfer polynucleotide are present, or if they are integrated into the genome at a location where high-level expression occurs. In this case, it may not be necessary to use a DHFR inhibitor, such as methotrexate: if DHFR expression is attenuated, simply synthesizing enough tetrahydrofolate for cell survival may provide sufficiently stringent selection.
[0189] In some cell lines, such as HEK cells and Chinese hamster ovary (CHO) cells, sufficient DHFR enzyme is expressed to allow the cells to survive without exogenously added HT. These cells can be manipulated using genome editing technologies including CRISPR / Cas9 to reduce or eliminate the activity of the DHFR enzyme. However, even with CRISPR, this is a laborious process that may introduce off-target mutations in other genes. Another approach is to stably integrate a polynucleotide including a multi-hairpin amiRNA targeting the endogenous DHFR mRNA into the cellular genome.
[0190] 5.7.1 Reduction of endogenous dihydrofolate reductase microRNA
[0191] Advantageous gene transfer polynucleotides for inhibiting dihydrofolate reductase in hamster cells include a multi-hairpin amiRNA sequence that inhibits dihydrofolate reductase. The multi-hairpin amiRNA sequence that inhibits dihydrofolate reductase includes a first guide chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to hamster DHFR mRNA (whose sequence is given by SEQ ID NO: 22), and a first passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide chain sequence. The multi-hairpin amiRNA sequence that inhibits dihydrofolate reductase further includes a second guide chain sequence, which contains a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 22, and a second passenger chain sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide chain sequence, and wherein the first and second guide chain sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting dihydrofolate reductase can optionally include a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 22, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. Exemplary sequences for separating the guide strand sequence from its passenger strand sequence are sequences selected from the sequence SEQ ID NOs: 683-692. Exemplary guide strand sequences for inhibiting hamster dihydrofolate reductase and their respective passenger strand sequences are SEQ ID NOs: 143 and 447, SEQ ID NOs: 144 and 448, and SEQ ID NOs: 145 and 449.
[0192] The multi-hairpin amiRNA SEQ ID NO: 742 includes guide strand sequences complementary to different sequences within the CHO dihydrofolate reductase mRNA target (SEQ ID NO: 22). The multi-hairpin amiRNA sequence includes a first guide strand sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 22, and a first passenger strand sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complement sequence of the first guide strand sequence. The multi-hairpin amiRNA sequence further includes a second guide strand sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is complementary to SEQ ID NO: 22, and a second passenger strand sequence containing a continuous 19, 20, 21 or 22 nucleotide sequence that is at least 78% identical to the reverse complement sequence of the second guide strand sequence, and wherein the first and second guide strand sequences are different from each other. The multiple hairpin amiRNA sequence further comprises a third guide strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence complementary to SEQ ID NO: 22, and a third passenger strand sequence comprising a continuous 19, 20, 21 or 22 nucleotide sequence at least 78% identical to the reverse complement of the third guide strand sequence, and wherein the first, second and third guide strand sequences are different from each other. Each guide strand sequence is separated from its respective passenger strand sequence by 5 to 35 bases. For multiple hairpin amiRNA SEQ ID NO 742, each guide strand sequence is separated from its respective passenger strand sequence by a sequence comprising SEQ ID NO: 683. The multi-hairpin amiRNA SEQ ID NO: 742 includes a first guide strand sequence having SEQ ID NO: 143 and a first passenger strand sequence having SEQ ID NO: 447; SEQ ID NO: 742 further includes a second guide strand sequence having SEQ ID NO: 144 and a second passenger strand sequence having SEQ ID NO: 448; SEQ ID NO: 742 further includes a third guide strand sequence having SEQ ID NO: 145 and a third passenger strand sequence having SEQ ID NO: 449. The guide strand sequences SEQ ID NO: 143, SEQ ID NO: 144, and SEQ ID NO: 145 are all different from each other.
[0193] 5.7.2 Complementation of DHFR auxotrophy
[0194] In cells lacking a functional DHFR gene, including cells whose endogenous DHFR expression is reduced due to RNA interference, the exogenously added DHFR gene can act as a selection marker by allowing growth in a HT-free medium. Preferably, a gene transfer polynucleotide comprising an exogenous DHFR gene is introduced into the cell. Preferably, the exogenous DHFR gene includes sequence features that prevent its expression from being used to inhibit any RNA interference that makes the host cell a DHFR auxotrophic type. If the RNA interference molecule including the amiRNA guide strand is directed to the coding portion of the endogenous DHFR, the exogenous gene encoding the DHFR can avoid being inhibited when the coding sequence changes (e.g., by silent mutations in the targeting region). If the RNA interference molecule including the amiRNA guide strand is directed to the 3'UTR or 5'UTR portion of the endogenous DHFR, the exogenous gene encoding the DHFR can avoid being inhibited by replacing the natural UTR sequence with an alternative sequence (e.g., a UTR sequence extracted or adapted from other natural genes).
[0195] The selection protocol involves introducing a gene transfer polynucleotide comprising a sequence encoding a DHFR selectable marker and then culturing the cells in a medium lacking sufficient HT to allow the cells to survive in the absence of the exogenous gene encoding DHFR.
[0196] Preferably, the exogenous gene encoding the DHFR gene is operably linked to a weak promoter or other sequence elements that reduce expression, so that high-level expression occurs only when multiple copies of the gene transfer polynucleotide are present, or they are integrated into the genome at a location where high-level expression occurs. In this case, it may not be necessary to use a DHFR inhibitor, such as methionine sulfoximine: if DHFR expression is reduced, then simply synthesizing enough glutamine for cell survival can provide sufficiently stringent selection. Exemplary DHFR polypeptide sequences are given as SEQ ID NOs: 876-877.
[0197] 5.8 Endogenous gene targets for altering immune cell function
[0198] In order for immune cells to adequately respond to threats to the body, they must be able to survive long enough to attack their targets. For treatments and studies that require ex vivo manipulation of immune cells, the proliferation of immune cells is advantageous. However, neither ex vivo culture conditions nor certain in vivo environments (such as those within solid tumors) are optimal for immune cell growth. For example, T cells from heavily pretreated lymphoma patients showed lower in vitro expansion rates and clinical response rates after engineering with anti-CD19 chimeric antigen receptors compared to T cells from untreated patients. Further, T cells exposed to target antigens for a long time can become unresponsive or exhausted, which is usually mediated by receptors expressed by T cells and present on the surface of T cells. Therefore, methods are needed to enhance the function, persistence and proliferation of human immune cells, especially under conditions that are naturally hostile to immune cells.
[0199] RNA interference is a favorable mechanism for inhibiting endogenous cellular genes. One way to enhance the persistence and proliferation of human immune cells is to integrate into the genome immune cell inhibitory polynucleotides that inhibit the expression of certain endogenous immune cell target genes. Candidate target genes include those whose normal function is to reduce proliferation, participate in apoptosis, or participate in disability or exhaustion pathways. Artificial microRNAs can be encoded on a polynucleotide that also carries a second gene that can change the function of immune cells, such as a chimeric antigen receptor. Preferably, the polynucleotide is a transposon or a viral vector to ensure that the amiRNA and the chimeric antigen receptor are integrated into the immune cell genome together.
[0200] Candidate RNA interference target genes whose normal function is to reduce proliferation or participate in apoptosis include caspase 3, caspase 7, caspase 8, caspase 9, caspase 10, death receptor 4 (tumor necrosis factor receptor superfamily member 10A), death receptor 5 (tumor necrosis factor receptor superfamily member 10B), FAS (tumor necrosis factor receptor superfamily member 6), cytotoxic T-lymphocyte protein 4, apoptosis regulators BAX and BAD (Bcl2-related cell death agonist). Candidate RNA interference target genes whose normal function is to participate in the exhaustion pathway include transcription factors thymocyte selection-related high-mobility group box proteins TOX and TOX2, programmed cell death protein 1 (PD-1), T cell immunoglobulin mucin receptor 3 (TIM-3), and nuclear receptor subfamily 4A group 4 members 1, 2, and 3 (NR4A1, NR4A2, and NR4A3).
[0201] 5.8.1 TOX
[0202] The thymocyte selection-associated high-mobility group box protein TOX is associated with the induction and / or maintenance of a low-response, exhausted or dysfunctional state triggered by chronic antigen stimulation, characterized by upregulation of several inhibitory receptors and loss of effector function (Seo et al. 2019. Proc. Natl. Acad. Sci. USA 116, 12410-12415. "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+T cell exhaustion"). Inhibition of the TOX gene in mice improves the performance of T cells expressing chimeric antigen receptors. Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0203] The favorable gene transfer polynucleotide for inhibiting TOX in human immune cells includes a multi-hairpin amiRNA sequence that inhibits TOX. The multi-hairpin amiRNA sequence that inhibits TOX includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human TOX mRNA (SEQ ID NO: 24), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the TOX mRNA sequence, which is located at the 3' end of the open reading frame (SEQ ID NO: 25). The multi-hairpin amiRNA sequence that inhibits TOX also includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 24, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence that inhibits TOX can optionally include a third guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 24, and a third passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are all different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting TOX in human immune cells are SEQ ID NOs: 146 and 450, SEQ ID NOs: 147 and 451, SEQ ID NOs: 148 and 452, SEQ ID NOs: 149 and 453, SEQ ID NOs: 150 and 454, SEQ ID NOs: 151 and 455, SEQ ID NOs: 152 and 456, SEQ ID NOs: 153 and 457, SEQ ID NOs: 154 and 458, SEQ ID NOs: 155 and 459, SEQ ID NOs: 156 and 460, SEQ ID NOs: 157 and 461. Exemplary multi-hairpin amiRNA sequences for inhibiting human TOX are SEQ ID NOs: 743-746.
[0204] Preferred embodiments include polynucleotides comprising a multi-hairpin amiRNA targeting TOX, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising a multi-hairpin amiRNA can be packaged and used to infect immune cells. Preferably, the immune cells are T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multi-hairpin amiRNA carried by the lentivirus targeting TOX include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to TOX mRNA, and each hairpin is operably linked to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0205] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting TOX, wherein the polynucleotide is a part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting TOX is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting TOX includes two hairpins, each hairpin includes a different sequence of at least 19 consecutive bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell or a B cell.
[0206] Immune cells whose genomes include inhibitory polynucleotides may have permanently reduced or eliminated TOX gene activity, wherein the multiple hairpin amiRNA includes two guide sequences complementary to two different sequences within the TOX mRNA. Alternatively, the multiple hairpin amiRNA including two guide sequences complementary to two different sequences within the TOX mRNA is operably linked to the same promoter as the gene encoding the chimeric antigen receptor. Reducing TOX expression can alleviate the phenotype of tumor infiltrating lymphocyte depletion. T cells whose genomes include inhibitory polynucleotides may have improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the TOX mRNA.
[0207] 5.8.2 TOX2
[0208] The thymocyte selection-associated high-mobility group box protein TOX2 is associated with the induction and / or maintenance of a low-response, exhausted or dysfunctional state triggered by chronic antigen stimulation, characterized by upregulation of several inhibitory receptors and loss of effector function (Seo et al. 2019. Proc. Natl. Acad. Sci. USA 116, 12410-12415. "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+T cell exhaustion"). Inhibition of the TOX2 gene in mice improves the performance of T cells expressing chimeric antigen receptors. Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0209] Advantageous gene transfer polynucleotides for inhibiting TOX2 in human immune cells include a multi-hairpin amiRNA sequence that inhibits TOX2. The multi-hairpin amiRNA sequence that inhibits TOX2 includes a first guide sequence comprising a continuous 19-nucleotide sequence complementary to the sequence of human TOX2 mRNA (SEQ ID NO: 26), and a first passenger sequence comprising a continuous 19-nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence comprises a continuous 19-nucleotide sequence complementary to the TOX2 mRNA sequence, which is located at the 3' end of the open reading frame (SEQ ID NO: 27). The multi-hairpin amiRNA sequence that inhibits TOX2 further comprises a second guide sequence comprising a continuous 19-nucleotide sequence complementary to SEQ ID NO: 26, and a second passenger sequence comprising a continuous 19-nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting TOX2 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 26, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting human TOX2 in immune cells are SEQ ID NOs: 158 and 462, SEQ ID NOs: 463 and 392, SEQ ID NOs: 160 and 464, SEQ ID NOs: 161 and 465, SEQ ID NOs: 162 and 466, SEQ ID NOs: 163 and 467, SEQ ID NOs: 164 and 468, SEQ ID NOs: 165 and 469, SEQ ID NOs: 166 and 470, SEQ ID NOs: 167 and 471, SEQ ID NOs: 168 and 472, SEQ ID NOs: 169 and 473, SEQ ID NOs: 170 and 474. Exemplary multi-hairpin amiRNA sequences for inhibiting human TOX2 are SEQ ID NOs: 747-750.
[0210] Preferred embodiments include polynucleotides comprising a multi-hairpin amiRNA targeting TOX2, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising a multi-hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multi-hairpin amiRNA carried by the lentivirus targeting TOX2 include two hairpins, each hairpin including a different sequence of at least 19 consecutive bases complementary to TOX2 mRNA, and each hairpin is operably linked to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0211] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting TOX2, wherein the polynucleotide is a part of a transposon. The transposon includes transposon ends, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting TOX2 is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting TOX2 includes two hairpins, each hairpin includes a different sequence of at least 19 consecutive bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0212] Immune cells whose genomes include inhibitory polynucleotides may permanently reduce or eliminate the activity of the TOX2 gene, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the TOX2 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within the TOX2 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in TOX2 expression can alleviate the phenotype of tumor infiltrating lymphocyte depletion. T cells whose genomes include inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the amiRNAs include two guide sequences complementary to two different sequences within the TOX2 mRNA.
[0213] 5.8.3 TOX1 and TOX2
[0214] Thymocyte selection-related high-mobility group box proteins TOX1 and TOX2 are jointly involved in inducing and / or maintaining a low-responsive, exhausted or dysfunctional state triggered by chronic antigen stimulation, characterized by upregulation of several inhibitory receptors and loss of effector function (Seo et al. 2019. Proc. Natl. Acad. Sci. USA 116, 12410-12415. "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+T cell exhaustion"). Simultaneous inhibition of TOX1 and TOX2 in mice improves the performance of T cells expressing chimeric antigen receptors. Therefore, it is advantageous to use multi-hairpin amiRNA to simultaneously inhibit the expression of these two genes in T cells.
[0215] The advantageous gene transfer polynucleotide for inhibiting TOX1 and TOX2 in human immune cells includes a multi-hairpin amiRNA sequence whose guide is complementary to the mRNAs of both. The multi-hairpin amiRNA sequence for inhibiting TOX / TOX2 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human TOX mRNA (SEQ ID NO: 24), and a first passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide sequence. The multi-hairpin amiRNA sequence for inhibiting TOX / TOX2 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human TOX mRNA (SEQ ID NO: 24), and a second passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multiple hairpin amiRNA sequence for inhibiting TOX / TOX2 further includes a third guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human TOX2 mRNA (SEQ ID NO: 26), and a third passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide sequence. The multiple hairpin amiRNA sequence for inhibiting TOX / TOX2 further includes a fourth guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 26, and a fourth passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the third and fourth guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. The hairpins can appear in the inhibitory gene transfer polynucleotide in any order. For example, two hairpins including guides complementary to TOX can be adjacent to each other, or they can be separated from each other by one or more hairpins including guides complementary to TOX2. In contrast, two hairpins comprising a guide complementary to TOX2 may be adjacent to each other, or they may be separated from each other by one or more hairpins comprising a guide complementary to TOX. Exemplary multi-hairpin amiRNA sequences for inhibiting human TOX and TOX2 are SEQ ID NOs: 751-754. Other exemplary multi-hairpin amiRNA sequences for inhibiting TOX and TOX2 can be obtained by selecting a sequence from SEQ ID NOs: 743-746 and a sequence from SEQ ID NOs: 747-750 and linking the two sequences together. The order of the two sequences is not important.
[0216] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting TOX and TOX2, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNAs can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNAs carried by the lentivirus targeting TOX and TOX2 comprise four hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases, two of which are complementary to TOX mRNA, two of which are complementary to TOX2 mRNA, and each hairpin is operably linked to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0217] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting TOX and TOX2, wherein the polynucleotides are part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting TOX and TOX2 are integrated into the genome of the immune cell. The immune cell modified by the transposon targeting TOX and TOX2 carrying multiple hairpin amiRNAs includes four hairpins, each hairpin comprising different sequences of at least 19 continuous bases, two of which are complementary to TOX mRNA, two of which are complementary to TOX2 mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0218] Immune cells whose genomes include inhibitory polynucleotides may permanently reduce or eliminate the activity of TOX and TOX2 genes, the inhibitory polynucleotides comprising multiple hairpin amiRNAs comprising four guide sequences complementary to two different sequences within TOX mRNA and two different sequences within TOX2 mRNA. Alternatively, the multiple hairpin amiRNAs comprising four guide sequences complementary to two different sequences within TOX mRNA and two different sequences within TOX2 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in TOX and TOX2 expression can alleviate the phenotype of tumor infiltrating lymphocyte depletion. T cells whose genomes include inhibitory polynucleotides comprising multiple hairpin amiRNAs comprising four guide sequences complementary to two different sequences within TOX mRNA and two different sequences within TOX2 mRNA may have an improved ability to kill tumor cells.
[0219] 5.8.4 PD-1
[0220] Programmed cell death protein 1 (PD-1) is an immune checkpoint that plays a role in downregulating the immune system by inhibiting T cell activity and promoting apoptosis. Exhausted T cells express high levels of PD-1 (Jiang et al., 2015. Cell Death & Disease 6, e1972 https: / / doi.org / 10.1038 / cddis.2015.162. "T-cell exhaustion in the tumor microenvironment"). Treatment of T cells with siRNA against PD-1 improved the function of CAR-T cells in vitro (Simon et al, 2018. Exp Dermatol. 27: 769-778. "The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 showshanced in vitro CAR-T-cell functionality for further clinical development toward the potential use in immunotherapy of melanoma"). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0221] Advantageous gene transfer polynucleotides for inhibiting PD-1 in human immune cells include multi-hairpin amiRNA sequences that inhibit PD-1. The multi-hairpin amiRNA sequence that inhibits PD-1 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human PD-1 mRNA (SEQ ID NO: 28), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the sequence of PD-1 mRNA 3' of the open reading frame (SEQ ID NO: 29). The multi-hairpin amiRNA sequence that inhibits PD-1 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 28, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting PD-1 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 28, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting human PD-1 in immune cells and their respective passenger sequences are SEQ ID NOs: 171 and 475, SEQ ID NOs: 172 and 476, SEQ ID NOs: 173 and 477, SEQ ID NOs: 174 and 478, SEQ ID NOs: 175 and 479, SEQ ID NOs: 176 and 480, SEQ ID NOs: 177 and 481, SEQ ID NOs: 178 and 482, SEQ ID NOs: 179 and 483, SEQ ID NOs: 180 and 484. Exemplary multiple hairpin amiRNA sequences for inhibiting human PD-1 are SEQ ID NOs: 755-758.
[0222] Preferred embodiments include polynucleotides including multiple hairpin amiRNA targeting PD-1, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector including multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting PD-1 include two hairpins, each of which contains a different sequence of at least 19 consecutive bases complementary to PD-1 mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0223] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting PD-1, wherein the polynucleotides are part of a transposon. The transposon includes a transposon end so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting PD-1 are integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting PD-1 includes two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0224] Immune cells whose genomes contain inhibitory polynucleotides may permanently reduce or eliminate the activity of the PD-1 gene, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs contain two guide sequences complementary to two different sequences within the PD-1 mRNA. Alternatively, the multiple hairpin amiRNAs containing two guide sequences complementary to two different sequences within the PD-1 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in PD-1 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes contain inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs contain two guide sequences complementary to two different sequences within the PD-1 mRNA.
[0225] 5.8.5 CTLA-4
[0226] Cytotoxic T lymphocyte protein 4 (CTLA-4) is a protein receptor that functions as an immune checkpoint to downregulate the immune system. Exhausted T cells express high levels of CTLA-4 (Jiang et al., 2015. Cell Death & Disease 6, e1972 https: / / doi.org / 10.1038 / cddis.2015.162. "T-cell exhaustion in the tumor microenvironment"). Treatment of T cells with siRNA against CTLA-4 improved in vitro CAR-T cell function (Simon et al, 2018. Exp Dermatol. 27: 769-778. "The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced invitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma"). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0227] Advantageous gene transfer polynucleotides for inhibiting CTLA-4 in human immune cells include a multi-hairpin amiRNA sequence that inhibits CTLA-4. The multi-hairpin amiRNA sequence that inhibits CTLA-4 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human CTLA-4 mRNA (SEQ ID NO: 30), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence comprises a continuous 19 nucleotide sequence complementary to the CTLA-4 mRNA sequence located at the 3' end of the open reading frame (SEQ ID NO: 31). The multi-hairpin amiRNA sequence that inhibits CTLA-4 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 30, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting CTLA-4 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 30, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting human CTLA-4 in immune cells are SEQ ID NOs: 181 and 485, SEQ ID NOs: 182 and 486, SEQ ID NOs: 183 and 487, SEQ ID NOs: 184 and 488, SEQ ID NOs: 185 and 489, SEQ ID NOs: 186 and 490, SEQ ID NOs: 187 and 491, SEQ ID NOs: 188 and 492, SEQ ID NOs: 189 and 493. Exemplary multi-hairpin amiRNA sequences for inhibiting human CTLA-4 are SEQ ID NOs: 759-762.
[0228] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting CTLA-4, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting CTLA-4 include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to CTLA-4 mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0229] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting CTLA-4, wherein the polynucleotide is part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting CTLA-4 is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting CTLA-4 includes two hairpins, each hairpin comprising different sequences of at least 19 consecutive bases complementary to the target mRNA, wherein the flanks of the hairpin and the promoter are reverse end repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0230] Immune cells whose genomes contain inhibitory polynucleotides may have permanently reduced or eliminated CTLA-4 gene activity, and the multiple hairpin amiRNA includes two guide sequences complementary to two different sequences in the CTLA-4 mRNA. Alternatively, the multiple hairpin amiRNA including two guide sequences complementary to two different sequences in the CTLA-4 mRNA is operably connected to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in CTLA-4 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes contain inhibitory polynucleotides may have improved ability to kill tumor cells, and the inhibitory polynucleotides include multiple hairpin amiRNAs, and the multiple hairpin amiRNAs contain two guide sequences complementary to two different sequences in the CTLA-4 mRNA.
[0231] 5.8.6 PD-1 and CTLA-4
[0232] Programmed cell death protein 1 (PD-1) is an immune checkpoint that has the effect of downregulating the immune system, while cytotoxic T lymphocyte protein 4 (CTLA-4) is a protein receptor that can act as an immune checkpoint to downregulate the immune system. Treatment of T cells with siRNA targeting PD-1 and CTLA-4 improved the function of CAR-T cells in vitro (Simon et al, 2018. Exp Dermatol. 27: 769-778. "The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma"). Therefore, it is advantageous to use multi-hairpin amiRNA to simultaneously inhibit the expression of these two genes in T cells.
[0233] The favorable gene transfer polynucleotide for inhibiting PD-1 and CTLA-4 in human immune cells includes a multi-hairpin amiRNA sequence having a guide complementary to the mRNAs of both. The multi-hairpin amiRNA sequence for inhibiting PD-1 / CTLA-4 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human PD-1 mRNA (SEQ ID NO: 28), and a first passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide sequence. The multi-hairpin amiRNA sequence for inhibiting PD-1 / CTLA-4 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 28, and a second passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting PD-1 / CTLA-4 further includes a third guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human CTLA-4 mRNA (SEQ ID NO: 30), and a third passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence. The multi-hairpin amiRNA sequence for inhibiting PD-1 / CTLA-4 further includes a fourth guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 30, and a fourth passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the third and fourth guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Hairpins can appear in the inhibitory gene transfer polynucleotide in any order. For example, two hairpins including guides complementary to PD-1 can be adjacent to each other, or they can be separated from each other by one or more hairpins containing guides complementary to CTLA-4. In contrast, two hairpins comprising a guide complementary to CTLA-4 can be adjacent to each other, or they can be separated from each other by one or more hairpins comprising a guide complementary to PD-1. Exemplary multi-hairpin amiRNA sequences for inhibiting human PD-1 and CTLA-4 are SEQ ID NOs: 763-766. Other exemplary multi-hairpin amiRNA sequences for inhibiting PD-1 and CTLA-4 can be obtained by selecting a sequence from SEQ ID NOs: 755-758 and a sequence from SEQ ID NOs: 759-762 and connecting the two sequences together. The order of the two sequences does not matter.
[0234] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting PD-1 and CTLA-4, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting PD-1 and CTLA-4 include four hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases, two of which are complementary to PD-1 mRNA, two of which are complementary to CTLA-4 mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0235] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting PD-1 and CTLA-4, wherein the polynucleotides are part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting PD-1 and CTLA-4 are integrated into the genome of the immune cell. The immune cell modified by the transposon targeting PD-1 and CTLA-4 carrying multiple hairpin amiRNAs includes four hairpins, each hairpin comprising different sequences of at least 19 consecutive bases, two of which are complementary to PD-1mRNA, two of which are complementary to CTLA-4mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0236] Immune cells whose genomes include inhibitory polynucleotides may permanently reduce or eliminate the activity of PD-1 and CTLA-4 genes, the inhibitory polynucleotides including multiple hairpin amiRNAs, the multiple hairpin amiRNAs including four guide sequences complementary to two different sequences within PD-1 mRNA and two different sequences within CTLA-4 mRNA. Alternatively, the multiple hairpin amiRNAs including four guide sequences complementary to two different sequences within PD-1 mRNA and two different sequences within CTLA-4 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. Reducing the expression of PD-1 and CTLA-4 may alleviate the tumor infiltrating lymphocyte exhaustion phenotype.
[0237] 5.8.7 TIM-3
[0238] T cell immunoglobulin mucin receptor 3 (Tim-3, hepatitis A virus cellular receptor 2) is a co-inhibitory receptor on T cells. Exhausted T cells express high levels of Tim-3 (Jiang et al., 2015. Cell Death & Disease 6, e1972 https: / / doi.org / 10.1038 / cddis.2015.162. “T-cell exhaustion in the tumor microenvironment”). Tim-3 inhibition can enhance T cell anti-tumor activity (Das et al., 2017. Immunol Rev. 276, 97–111. “Tim-3 and its role in regulating anti-tumor immunity”). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0239] The advantageous gene transfer polynucleotide for inhibiting TIM-3 in human immune cells includes a multi-hairpin amiRNA sequence that inhibits TIM-3. The multi-hairpin amiRNA sequence that inhibits TIM-3 includes a first guide sequence comprising a continuous 19 nucleotide sequence complementary to the sequence of human TIM-3 mRNA (SEQ ID NO: 32), and a first passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence comprises a continuous 19 nucleotide sequence complementary to the TIM-3 mRNA sequence, which is located at 3' (SEQ ID NO: 33) of the open reading frame. The multi-hairpin amiRNA sequence that inhibits TIM-3 further includes a second guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 32, and a second passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting TIM-3 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 32, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting TIM-3 in human immune cells and their respective passenger sequences are SEQ ID NOs: 190 and 494, SEQ ID NOs: 191 and 495, SEQ ID NOs: 192 and 496, SEQ ID NOs: 193 and 497, SEQ ID NOs: 194 and 498, SEQ ID NOs: 195 and 499, SEQ ID NOs: 196 and 500, SEQ ID NOs: 197 and 501, SEQ ID NOs: 198 and 502, and SEQ ID NOs: 199 and 503. Exemplary multi-hairpin amiRNA sequences for inhibiting human TIM-3 are SEQ ID NOs: 767-770.
[0240] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting TIM-3, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting TIM-3 include two hairpins, each hairpin including different sequences of at least 19 consecutive bases complementary to TIM-3 mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0241] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting TIM-3, wherein the polynucleotide is a part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting TIM-3 is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting TIM-3 includes two hairpins, each hairpin includes a different sequence of at least 19 continuous bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flank of the hairpin and the promoter is a reverse end repeat of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0242] Immune cells whose genomes include inhibitory polynucleotides may permanently reduce or eliminate the activity of the TIM-3 gene, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the TIM-3 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within the TIM-3 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in TIM-3 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes include inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the TIM-3 mRNA.
[0243] 5.8.8 NR4A1 (Nur77)
[0244] Nuclear receptor 4A1 (Nur77) is associated with suppression of T cell function in solid tumors (Rao et al 2019. Nature 567, 530-534 "NR4A transcription factors limit CAR T cell function in solid tumors."). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0245] Advantageous gene transfer polynucleotides for inhibiting NUR77 in human immune cells include a multi-hairpin amiRNA sequence that inhibits NUR77. The multi-hairpin amiRNA sequence that inhibits NUR77 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human NUR77 mRNA (SEQ ID NO: 34), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the NUR77 mRNA sequence, which is located at the 3' (SEQ ID NO: 35) of the open reading frame. The multi-hairpin amiRNA sequence that inhibits NUR77 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 34, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting NUR77 can optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 34, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting NUR77 in human immune cells and their respective passenger sequences are SEQ ID NOs: 200 and 504, SEQ ID NOs: 201 and 505, SEQ ID NOs: 202 and 506, SEQ ID NOs: 203 and 507, SEQ ID NOs: 204 and 508, SEQ ID NOs: 205 and 509, SEQ ID NOs: 206 and 510, SEQ ID NOs: 207 and 511, SEQ ID NOs: 208 and 512. Exemplary multiple hairpin amiRNA sequences for inhibiting human NUR77 are SEQ ID NOs: 771-774.
[0246] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NUR77, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNAs can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNAs carried by the lentivirus targeting NUR77 comprise two hairpins, each of which comprises a different sequence of at least 19 consecutive bases complementary to NUR77 mRNA, and each hairpin is operably linked to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpins and the promoter are reverse terminal repeats of the lentivirus.
[0247] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NUR77, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting NUR77 are integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting NUR77 includes two hairpins, each hairpin including a different sequence of at least 19 consecutive bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0248] Immune cells whose genomes contain inhibitory polynucleotides may permanently reduce or eliminate the activity of the NUR77 gene, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the NUR77 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within the NUR77 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in NUR77 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes contain inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the Nur77 mRNA.
[0249] 5.8.9 NR4A2 (Nurr1)
[0250] Nuclear receptor 4A2 (Nurrl) is associated with the suppression of T cell function in solid tumors (Rao et al 2019. Nature 567, 530-534 "NR4A transcription factors limit CAR T cell function in solid tumors."). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0251] Advantageous gene transfer polynucleotides for inhibiting NURR1 in human immune cells include a multi-hairpin amiRNA sequence that inhibits NURR1. The multi-hairpin amiRNA sequence that inhibits NURR1 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human NURR1 mRNA (SEQ ID NO: 36), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the NURR1 mRNA sequence, which is located 3' of the open reading frame (SEQ ID NO: 37). The multi-hairpin amiRNA sequence that inhibits NURR1 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 36, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multiple hairpin amiRNA sequence for inhibiting NURR1 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 36, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complement of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting NURR1 in human immune cells are SEQ ID NOs: 209 and 513, SEQ ID NOs: 210 and 514, SEQ ID NOs: 211 and 515, SEQ ID NOs: 212 and 516, SEQ ID NOs: 213 and 517, SEQ ID NOs: 214 and 518, SEQ ID NOs: 215 and 519, SEQ ID NOs: 216 and 520. Exemplary multiple hairpin amiRNA sequences for inhibiting human NURR1 are SEQ ID NOs: 775-778.
[0252] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NURR1, wherein the polynucleotides are part of a lentiviral vector. Lentiviral vectors comprising multiple hairpin amiRNAs can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. Immune cells modified by multiple hairpin amiRNAs carried by a lentivirus targeting NURR1 include two hairpins, each of which comprises a different sequence of at least 19 consecutive bases complementary to NURR1 mRNA, and each hairpin is operably linked to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpins and the promoter are reverse terminal repeats of the lentivirus.
[0253] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NURR1, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting NURR1 are integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting NURR1 includes two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0254] Immune cells whose genomes contain inhibitory polynucleotides may permanently reduce or eliminate the activity of the NURR1 gene, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the NURR1 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within the NURR1 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. Reducing NURR1 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes contain inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the NUUR1 mRNA.
[0255] 5.8.10 NR4A3 (NOR1)
[0256] Nuclear receptor 4A3 (NOR1) is associated with the suppression of T cell function in solid tumors (Rao et al 2019. Nature 567, 530-534 "NR4A transcription factors limit CAR T cell function in solid tumors."). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0257] Advantageous gene transfer polynucleotides for inhibiting NOR1 in human immune cells include a multi-hairpin amiRNA sequence that inhibits NOR1. The multi-hairpin amiRNA sequence that inhibits NOR1 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human NOR1 mRNA (SEQ ID NO: 38), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the sequence of NOR1 mRNA located at the 3' end of the open reading frame (SEQ ID NO: 39). The multi-hairpin amiRNA sequence that inhibits NOR1 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 38, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting NOR1 can optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO:38, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting NOR1 in human immune cells and their respective passenger sequences are SEQ ID NOs:217 and 521, SEQ ID NOs:218 and 522, SEQ ID NOs:219 and 523, SEQ ID NOs:220 and 524, SEQ ID NOs:221 and 525, SEQ ID NOs:222 and 526, SEQ ID NOs:223 and 527, SEQ ID NOs:224 and 528, and SEQ ID NOs:225 and 529. Exemplary multiple hairpin amiRNA sequences for inhibiting human NOR1 are SEQ ID NOs: 779-782.
[0258] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NOR1, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNAs can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNAs carried by the lentivirus targeting NOR1 include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to NOR1 mRNA, wherein the flanks of the hairpins and the promoter are reverse terminal repeats of the lentivirus.
[0259] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting NOR1, wherein the polynucleotide is part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting NOR1 is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting NOR1 includes two hairpins, each hairpin comprising different sequences of at least 19 continuous bases complementary to the target mRNA, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a SleepingBeauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0260] Immune cells whose genomes include inhibitory polynucleotides may have permanently reduced or eliminated NOR1 gene activity, wherein the multiple hairpin amiRNA includes two guide sequences complementary to two different sequences within NOR1 mRNA. Alternatively, the multiple hairpin amiRNA including two guide sequences complementary to two different sequences within NOR1 mRNA is operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in NOR1 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes include inhibitory polynucleotides may have improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within NOR1 mRNA.
[0261] 5.8.11 NR4A1 (Nur77) and NR4A2 (Nurr1) and NR4A3 (NOR1)
[0262] Nuclear receptors 4A1, 2, and 3 (Nur77, Nurr1, and NOR1) may be involved in suppressing T cell function in solid tumors (Rao et al 2019. Nature 567, 530-534 "NR4A transcription factors limit CAR T cell function in solid tumors."). Therefore, it is advantageous to use multi-hairpin amiRNA to simultaneously inhibit the expression of these two genes in T cells.
[0263] The advantageous gene transfer polynucleotide for inhibiting Nur77, NOR1 and Nuur1 in human immune cells includes a multi-hairpin amiRNA sequence having a guide complementary to the mRNAs of all three genes. The multi-hairpin amiRNA sequence for inhibiting Nur77 / NOR1 / Nuur1 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human Nur77 mRNA (SEQ ID NO: 34), and a first passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the first guide sequence. The multi-hairpin amiRNA sequence for inhibiting Nur77 / NOR1 / Nuur1 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 34, and a second passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multiple hairpin amiRNA sequence for inhibiting Nur77 / NOR1 / Nuur1 further comprises a third guide sequence comprising a 19-nucleotide sequence complementary to a sequence of human Nuur1 mRNA (SEQ ID NO: 36), and a third passenger sequence comprising a 19-nucleotide sequence complementary to the reverse complement of the third guide sequence by at least 78%. The multiple hairpin amiRNA sequence for inhibiting Nur77 / Nuur1 further comprises a fourth guide sequence comprising a 19-nucleotide sequence complementary to SEQ ID NO: 36, and a fourth passenger sequence comprising a 19-nucleotide sequence complementary to the reverse complement of the fourth guide sequence by at least 78%, and wherein the third and fourth guide sequences are different from each other. The multiple hairpin amiRNA sequence for inhibiting Nur77 / NOR1 / Nuur1 further comprises a fifth guide sequence comprising a 19-nucleotide sequence complementary to a sequence of human NOR1 mRNA (SEQ ID NO: 38), and a fifth passenger sequence comprising a 19-nucleotide sequence complementary to the reverse complement of the fifth guide sequence by at least 78%. The multi-hairpin amiRNA sequence that inhibits Nur77 / NOR1 / Nuur1 further includes a sixth guide sequence comprising a 19-contiguous nucleotide sequence complementary to SEQ ID NO:38, and a sixth passenger sequence comprising a 19-contiguous nucleotide sequence that is at least 78% identical to the reverse complement of the sixth guide sequence, and wherein the fifth and sixth guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. The hairpins can appear in any order in the inhibitory gene transfer polynucleotide. For example, two hairpins comprising guides complementary to Nur77 can be adjacent to each other, or they can be separated from each other by one or more hairpins comprising guides complementary to Nuur1 or NOR1.Exemplary multiple hairpin amiRNA sequences for inhibiting human Nur77, Nuur1 and NOR1 are SEQ ID NOs: 783-788. Other exemplary multiple hairpin amiRNA sequences for inhibiting Nur77, Nuur1 and NOR1 can be obtained by selecting a sequence selected from SEQ ID NOs: 771-774, a sequence selected from SEQ ID NOs: 775-778, and a sequence selected from SEQ ID NOs: 779-782 and connecting the three sequences together. The order of the three sequences is not important.
[0264] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting Nur77, NOR1, and Nuur1, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNAs can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by multiple hairpin amiRNAs carried by the lentivirus targeting Nur77, NOR1, and Nuur1 include six hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases, two of which are complementary to Nur77 mRNA, two of which are complementary to NOR1 mRNA, two of which are complementary to Nuur1 mRNA, and each hairpin is operably linked to a heterologous promoter active in human immune cells, wherein the flanks of the hairpins and the promoter are reverse terminal repeats of the lentivirus.
[0265] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting Nur77 and Nuurl, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNAs targeting Nur77, NOR1 and Nuur1 are integrated into the genome of the immune cell. The immune cells modified by the multiple hairpin amiRNAs carried by the transposon targeting Nur77, NOR1 and Nuur1 include six hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases, two of which are complementary to Nur77 mRNA, two of which are complementary to NOR1 mRNA, and two of which are complementary to Nuur1 mRNA, and each hairpin is operably connected to a heterologous promoter active in human immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (eg, a CD4 T cell, a CD8 T cell or a natural killer (NK) T cell, or a B cell.
[0266] An immune cell, whose genome comprises an inhibitory polynucleotide, the inhibitory polynucleotide comprising a multiple hairpin amiRNA containing six guide sequences, wherein two guide sequences are complementary to two different sequences within Nur77 mRNA, two guide sequences are complementary to two different sequences within Nuur1 mRNA, and two guide sequences are complementary to two different sequences within NOR1 mRNA, which may permanently reduce or eliminate the activity of Nur77, NOR1 and Nuur1 genes. Alternatively, the multiple hairpin amiRNA comprises six guide sequences, wherein two guide sequences are complementary to two different sequences within Nur77 mRNA, two guide sequences are complementary to two different sequences within Nuur1 mRNA, and two guide sequences are complementary to two different sequences within NOR1 mRNA, and the NOR1 mRNA is operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in Nur77 and Nuur1 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion.
[0267] 5.8.9 NFAT
[0268] The transcription factor nuclear factor of activated T cells (NFAT) is associated with promoting CD8 T cell exhaustion (Martinez et al., 2015. Immunity 42, 265-278. "The transcription factor NFAT promotes exhaustion of activated CD8+T cells"). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of this gene in T cells.
[0269] The advantageous gene transfer polynucleotide for inhibiting NFAT in human immune cells includes a multi-hairpin amiRNA sequence that inhibits NFAT. The multi-hairpin amiRNA sequence that inhibits NFAT includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human NFAT mRNA (SEQ ID NO: 40), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the NFAT mRNA sequence, which is located at the 3' end of the open reading frame (SEQ ID NO: 41). The multi-hairpin amiRNA sequence that inhibits NFAT further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 40, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence that inhibits NFAT can optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 40, and a third passenger sequence comprising a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are all different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting NFAT in human immune cells are SEQ ID NOs: 226 and 530, SEQ ID NOs: 227 and 531, SEQ ID NOs: 228 and 532, SEQ ID NOs: 229 and 533, SEQ ID NOs: 230 and 534, SEQ ID NOs: 231 and 535, SEQ ID NOs: 232 and 536, SEQ ID NOs: 233 and 537, SEQ ID NOs: 234 and 538, SEQ ID NOs: 235 and 539, and SEQ ID NOs: 236 and 540. Exemplary multi-hairpin amiRNA sequences for inhibiting human NFAT are SEQ ID NOs: 789-792.
[0270] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting NFAT, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting NFAT include two hairpins, each hairpin comprising different sequences of at least 19 continuous bases complementary to NFAT mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of lentivirus.
[0271] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNAs targeting NFAT, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into immune cells and the immune cells express corresponding transposases, the multiple hairpin amiRNAs targeting NFAT are integrated into the genome of the immune cells. The immune cells modified by the multiple hairpin amiRNAs carried by the transposon targeting NFAT include two hairpins, each hairpin comprising different sequences of at least 19 continuous bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse end repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0272] The immunocyte of genome comprises inhibitory polynucleotide and may have the NFAT gene activity that is permanently reduced or eliminated, and this inhibitory polynucleotide comprises multiple hairpin amiRNA, and this multiple hairpin amiRNA comprises two guide sequences complementary to two different sequences in NFAT mRNA.Alternatively, multiple hairpin amiRNA comprising two guide sequences complementary to two different sequences in NFAT mRNA is operably connected with the promoter identical with the gene encoding chimeric antigen receptor.The reduction of NFAT expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion.The T cell of genome comprises inhibitory polynucleotide and may have the ability of improved killing tumor cell, and this inhibitory polynucleotide comprises multiple hairpin amiRNA, and this multiple hairpin amiRNA comprises two guide sequences complementary to two different sequences in NFAT mRNA.
[0273] 5.8.12 FAS (CD95)
[0274] The antigen-independent tonic signal of the chimeric antigen receptor (CAR) can increase the differentiation and exhaustion of T cells, thereby limiting their effectiveness. The addition of 4-1BB co-stimulation to CARs may enable T cells to resist this functional exhaustion. This tonic CAR-derived 4-1BB signal can produce toxicity in T cells by enhancing FAS-dependent cell death (Gomes-Silvaet.al., 2017. Cell Rep.21, 17-26. "Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector Dependent"). Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of FAS in T cells.
[0275] Advantageous gene transfer polynucleotides for inhibiting FAS in human immune cells include a multi-hairpin amiRNA sequence that inhibits FAS. The multi-hairpin amiRNA sequence that inhibits FAS includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human FAS mRNA (SEQ ID NO: 42), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the FAS mRNA sequence, which is located 3' to the open reading frame (SEQ ID NO: 43). The multi-hairpin amiRNA sequence that inhibits FAS further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 42, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multiple hairpin amiRNA sequence for inhibiting FAS may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 42, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences and their respective passenger sequences for inhibiting FAS in human immune cells are SEQ ID NOs: 237 and 541, SEQ ID NOs: 238 and 542, SEQ ID NOs: 239 and 543, SEQ ID NOs: 240 and 544, SEQ ID NOs: 241 and 545, SEQ ID NOs: 242 and 546, SEQ ID NOs: 243 and 547, SEQ ID NOs: 244 and 548. Exemplary multiple hairpin amiRNA sequences for inhibiting human FAS are SEQ ID NOs: 793-796.
[0276] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting FAS, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting FAS include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to FAS mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0277] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting FAS, wherein the polynucleotide is a part of a transposon. The transposon includes a transposon end, so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting FAS is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting FAS includes two hairpins, each hairpin comprising a different sequence of at least 19 continuous bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flank of the hairpin and the promoter is a reverse terminal repeat of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a Sleeping Beauty transposon. The immune cell is preferably a T cell (e.g., a CD4 T cell, a CD8 T cell, or a natural killer (NK) T cell, or a B cell.
[0278] Immune cells whose genomes include inhibitory polynucleotides may have permanently reduced or eliminated FAS gene activity, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the FAS mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within the FAS mRNA are operably connected to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in FAS expression can alleviate the phenotype of tumor infiltrating lymphocyte depletion. T cells whose genomes include inhibitory polynucleotides may have an improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within the FAS mRNA.
[0279] 5.8.13 Caspase 3
[0280] Caspase 3 expression is activated during the induction of T cell anergy. Blocking Caspase 3 expression using siRNA attenuates the induction of anergy. Therefore, it is advantageous to inhibit Caspase 3 expression in T cells using multi-hairpin amiRNA.
[0281] Advantageous gene transfer polynucleotides for inhibiting caspase 3 in human immune cells include a multi-hairpin amiRNA sequence that inhibits caspase 3. The multi-hairpin amiRNA sequence that inhibits caspase 3 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human caspase 3 mRNA (SEQ ID NO: 44), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the caspase 3 mRNA sequence, which is located at the 3' end of the open reading frame (SEQ ID NO: 45). The multi-hairpin amiRNA sequence that inhibits caspase 3 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 44, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting caspase 3 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 44, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting caspase 3 in human immune cells and their respective passenger sequences are SEQ ID NOs: 245 and 549, SEQ ID NOs: 246 and 550, SEQ ID NOs: 247 and 551, SEQ ID NOs: 248 and 552, SEQ ID NOs: 249 and 553, SEQ ID NOs: 250 and 554, SEQ ID NOs: 251 and 555, SEQ ID NOs: 252 and 556. Exemplary multi-hairpin amiRNA sequences for inhibiting human caspase 3 are SEQ ID NOs: 797-800.
[0282] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting caspas 3, wherein the polynucleotide is part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting caspase 3 include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to caspase 3 mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0283] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting caspase 3, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into immune cells and the immune cells express corresponding transposases, the multiple hairpin amiRNA targeting caspase 3 is integrated into the genome of the immune cells. The immune cells modified by the multiple hairpin amiRNA carried by the transposon targeting caspase 3 include two hairpins, each hairpin comprising at least 19 different sequences of continuous bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse end repeats of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a SleepingBeauty transposon. The immune cells are preferably T cells (such as CD4 T cells, CD8 T cells or natural killer (NK) T cells, or B cells.
[0284] Immune cells whose genomes include inhibitory polynucleotides may have permanently reduced or eliminated caspase 3 gene activity, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within caspase 3 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within caspase 3 mRNA are operably connected to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in caspase 3 expression can alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes include inhibitory polynucleotides may have improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within caspase 3 mRNA.
[0285] 5.8.14 Caspase 7
[0286] Mice lacking the caspase 7 gene are protected from endotoxin-induced lymphocyte apoptosis (Lamkanfiet.at.2009.Blood 113,2742-2745.“Caspase-7 deficiency protects from endotoxin-induced lymphocyte apoptosis and improves survival”). Reducing lymphocyte apoptosis may be beneficial in many immune cell therapies. Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of caspase 7 in T cells.
[0287] Advantageous gene transfer polynucleotides for inhibiting caspase 7 in human immune cells include a multi-hairpin amiRNA sequence that inhibits caspase 7. The multi-hairpin amiRNA sequence that inhibits caspase 7 includes a first guide sequence comprising a continuous 19 nucleotide sequence complementary to the sequence of human caspase 7 mRNA (SEQ ID NO: 46), and a first passenger sequence comprising a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence comprises a continuous 19 nucleotide sequence complementary to the caspase 7 mRNA sequence, and the 19 nucleotide sequence is located at the 3' of the open reading frame (SEQ ID NO: 47). The multi-hairpin amiRNA sequence that inhibits caspase 7 further includes a second guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 46, and a second passenger sequence comprising a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting caspase 7 may optionally include a third guide sequence comprising a continuous 19 nucleotide sequence complementary to SEQ ID NO: 46, and a third passenger sequence comprising a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are all different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting caspase 7 in human immune cells and their respective passenger sequences are SEQ ID NOs: 253 and 557, SEQ ID NOs: 254 and 558, SEQ ID NOs: 255 and 559, SEQ ID NOs: 256 and 560, SEQ ID NOs: 257 and 561, SEQ ID NOs: 258 and 562, SEQ ID NOs: 259 and 563, SEQ ID NOs: 260 and 564. Exemplary multi-hairpin amiRNA sequences for inhibiting human caspase 7 are SEQ ID NOs: 801-804.
[0288] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting caspase 7, wherein the polynucleotides are part of a lentiviral vector. The lentiviral vector comprising multiple hairpin amiRNA can be packaged and used to infect immune cells. The immune cells are preferably T cells (e.g., CD4 T cells, CD8 T cells, or natural killer (NK) T cells, or B cells. The immune cells modified by the multiple hairpin amiRNA carried by the lentivirus targeting caspase 7 include two hairpins, each hairpin comprising a different sequence of at least 19 consecutive bases complementary to caspase 7 mRNA, and each hairpin is operably connected to a heterologous promoter active in mammalian immune cells, wherein the flanks of the hairpin and the promoter are reverse terminal repeats of the lentivirus.
[0289] Preferred embodiments include polynucleotides comprising multiple hairpin amiRNA targeting caspase 7, wherein the polynucleotides are part of a transposon. The transposon includes transposon ends so that when the transposon is introduced into an immune cell and the immune cell expresses the corresponding transposase, the multiple hairpin amiRNA targeting caspase 7 is integrated into the genome of the immune cell. The immune cell modified by the multiple hairpin amiRNA carried by the transposon targeting caspase 7 includes two hairpins, each hairpin comprising at least 19 different sequences of continuous bases complementary to the target mRNA, and each hairpin is operably connected to a heterologous promoter active in a mammalian immune cell, wherein the flank of the hairpin and the promoter is the reverse end repeat of the transposon. The transposon can be a piggyBac-like transposon or a Mariner transposon, such as a SleepingBeauty transposon. The immune cell is preferably a T cell (such as a CD4 T cell, a CD8 T cell or a natural killer (NK) T cell, or a B cell.
[0290] Immune cells whose genomes include inhibitory polynucleotides may have permanently reduced or eliminated caspase 7 gene activity, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the multiple hairpin amiRNAs include two guide sequences complementary to two different sequences within caspase 7 mRNA. Alternatively, the multiple hairpin amiRNAs including two guide sequences complementary to two different sequences within caspase 7 mRNA are operably linked to the same promoter as the gene encoding the chimeric antigen receptor. The reduction in caspase 7 expression may alleviate the phenotype of tumor infiltrating lymphocyte exhaustion. T cells whose genomes include inhibitory polynucleotides may have improved ability to kill tumor cells, wherein the inhibitory polynucleotides include multiple hairpin amiRNAs, wherein the amiRNAs include two guide sequences complementary to two different sequences within caspase 7 mRNA.
[0291] 5.8.15 Caspase 8
[0292] Fas and other T cell inhibitory receptors act through the caspase 8 gene (Murali et al., 2011. J. Clin. Cell Immunol. Suppl 3:2. doi: 10.4172 / 2155-9899. S3-002. "Apoptosis-an Ubiquitous T cell Immunomodulator"). In many immune cell therapies, reducing lymphocyte apoptosis may be beneficial. Therefore, it is advantageous to use multi-hairpin amiRNA to inhibit the expression of caspase 8 in T cells.
[0293] Advantageous gene transfer polynucleotides for inhibiting caspase 8 in human immune cells include a multi-hairpin amiRNA sequence that inhibits caspase 8. The multi-hairpin amiRNA sequence that inhibits caspase 8 includes a first guide sequence containing a continuous 19 nucleotide sequence complementary to the sequence of human caspase 8 mRNA (SEQ ID NO: 48), and a first passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the first guide sequence. More preferably, the first guide sequence includes a continuous 19 nucleotide sequence complementary to the sequence of caspase 8 mRNA, which is located 3' to the open reading frame (SEQ ID NO: 49). The multi-hairpin amiRNA sequence that inhibits caspase 8 further includes a second guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 48, and a second passenger sequence containing a continuous 19 nucleotide sequence that is at least 78% identical to the reverse complementary sequence of the second guide sequence, and wherein the first and second guide sequences are different from each other. The multi-hairpin amiRNA sequence for inhibiting caspase 8 may optionally include a third guide sequence containing a continuous 19 nucleotide sequence complementary to SEQ ID NO: 48, and a third passenger sequence containing a continuous 19 nucleotide sequence at least 78% identical to the reverse complementary sequence of the third guide sequence, and wherein the first, second and third guide sequences are different from each other. Each guide sequence is separated from its respective passenger sequence by 5 to 35 bases. Exemplary guide sequences for inhibiting caspase 8 in human immune cells...
Claims
1. A polynucleotide, include: a) a fragment encoding a multiple hairpin amiRNA sequence, wherein the fragment comprises SEQ ID NO: 741; and b) a eukaryotic promoter active in mammalian cells and transcribed by RNA polymerase II or RNA polymerase III, which is operably linked to a fragment encoding the amiRNA sequence, wherein the amiRNA sequence can be expressed and folded into multiple hairpins.
2. The polynucleotide according to claim 1, further comprising two transposon ends flanking the fragment and the promoter, wherein the fragment and the promoter can be transposed by a corresponding transposase.
3. The polynucleotide of claim 2, wherein each transposon end comprises a sequence selected from the group consisting of SEQ ID NOs: 1004 and 1005, or SEQ ID NOs: 1010 and 1011, or SEQ ID NOs: 1014 and 1015, or SEQ ID NOs: 1016 and 1017, or SEQ ID NOs: 1022 and 1023, or SEQ ID NOs: 1026 and 1027, or SEQ ID NOs: 1030 and 1031, or SEQ ID NOs: 1036 and 1037, or SEQ ID NOs: 1040 and 1041, or SEQ ID NOs: 1044 and 1045, or SEQ ID NOs: 1112 and 1113.
4. A mammalian cell comprising the polynucleotide of claim 1 integrated into its genome.
5. The mammalian cell of claim 4, wherein the multi-hairpin amiRNA sequence is expressed and suppresses expression of the native cellular mRNA, whereby the cell requires exogenous supply of glutamine for growth.
6. A mammalian cell, include: (a) the polynucleotide of claim 1 integrated into its genome, wherein the multiple hairpin amiRNA sequence is expressed and inhibits the expression of the native cellular mRNA, and (b) a second polynucleotide comprising a gene encoding a glutamine synthetase that can be expressed in the mammalian cell, wherein the expression of the gene compensates for the inhibition of the expression of the native cell mRNA, thereby allowing the cell to grow in the absence of exogenous glutamine supply.
7. The mammalian cell of claim 6, wherein the second polynucleotide further comprises a second gene expressible in the mammalian cell.
8. A method for selectively integrating a nucleic acid encoding a target protein into a cell genome, include: a) culturing the mammalian cell population according to claim 5 in the presence of glutamine required for the growth of said cells due to the inhibition of expression of said native cellular mRNA by said multiple hairpin amiRNA sequence; b) transfecting the cell population with a second polynucleotide comprising a gene encoding a glutamine synthetase expressible in the mammalian cells and a second gene encoding the target protein, wherein the expression of the glutamine synthetase compensates for the inhibition of the native cell mRNA expression, thereby restoring the ability to grow in the absence of glutamine; and c) culturing the transfected cells in the presence of a reduced concentration or in the absence of glutamine, The transfected cells which survive in culture have integrated the second polynucleotide into their genome and can thus express the target protein.
9. The method of claim 8, wherein the transfected cells are cultured under a downward gradual decrease of the glutamine.
